-DOCSTART- -X- O O

Clinical JJ B-INTV
hypnosis NN I-INTV
versus NN I-INTV
cognitive JJ I-INTV
behavioral JJ I-INTV
training NN I-INTV
for IN O
pain NN B-OC
management NN I-OC
with IN O
pediatric JJ B-POPU
cancer NN I-POPU
patients NNS I-POPU
undergoing VBG I-POPU
bone NN I-POPU
marrow NN I-POPU
aspirations NNS I-POPU
. . O

A DT O
randomized JJ O
controlled JJ O
trial NN O
was VBD O
conducted VBN O
to TO O
compare VB O
the DT O
efficacy NN O
of IN O
clinical JJ B-INTV
hypnosis NN I-INTV
versus NN I-INTV
cognitive JJ I-INTV
behavioral NN I-INTV
( ( I-INTV
CB NNP I-INTV
) ) I-INTV
coping VBG I-INTV
skills NNS I-INTV
training VBG I-INTV
in IN O
alleviating VBG O
the DT O
pain NN B-OC
and CC I-OC
distress NN I-OC
of IN O
30 CD B-POPU
pediatric JJ I-POPU
cancer NN I-POPU
patients NNS I-POPU
( ( I-POPU
age NN I-POPU
5 CD I-POPU
to TO I-POPU
15 CD I-POPU
years NNS I-POPU
) ) I-POPU
undergoing VBG I-POPU
bone NN I-POPU
marrow NN I-POPU
aspirations NNS I-POPU
. . O

Patients NNS O
were VBD O
randomized VBN O
to TO O
one CD O
of IN O
three CD O
groups NNS O
: : O
hypnosis NN B-INTV
, , I-INTV
a DT I-INTV
package NN I-INTV
of IN I-INTV
CB NNP I-INTV
coping VBG I-INTV
skills NNS I-INTV
, , I-INTV
and CC I-INTV
no DT I-INTV
intervention NN I-INTV
. . O

Patients NNS O
who WP O
received VBD O
either CC O
hypnosis NN O
or CC O
CB NNP O
reported VBD O
less JJR O
pain NN B-OC
and CC I-OC
pain-related JJ I-OC
anxiety NN I-OC
than IN O
did VBD O
control VB O
patients NNS O
and CC O
less JJR O
pain NN B-OC
and CC I-OC
anxiety NN I-OC
than IN O
at IN O
their PRP$ O
own JJ O
baseline NN O
. . O

Hypnosis NNP O
and CC O
CB NNP O
were VBD O
similarly RB O
effective JJ O
in IN O
the DT O
relief NN B-OC
of IN I-OC
pain NN I-OC
. . O

Results NNP O
also RB O
indicated VBD O
that IN O
children NNS O
reported VBD O
more RBR O
anxiety NN B-OC
and CC O
exhibited VBD O
more RBR O
behavioral JJ B-OC
distress NN I-OC
in IN O
the DT O
CB NNP O
group NN O
than IN O
in IN O
the DT O
hypnosis NN O
group NN O
. . O

It PRP O
is VBZ O
concluded VBN O
that IN O
hypnosis NN O
and CC O
CB NNP O
coping VBG O
skills NNS O
are VBP O
effective JJ B-OC
in IN O
preparing VBG B-OC
pediatric JJ B-POPU
oncology NN I-POPU
patients NNS I-POPU
for IN O
bone NN O
marrow NN O
aspiration NN O
. . O

-DOCSTART- -X- O O

Oral NNP O
and CC O
parenteral JJ O
glutamine NN B-INTV
in IN O
bone NN O
marrow NN O
transplantation NN O
: : O
a DT O
randomized JJ O
, , O
double-blind JJ O
study NN O
. . O

BACKGROUND NNP O
Total NNP B-INTV
parenteral JJ I-INTV
nutrition NN I-INTV
( ( I-INTV
TPN NNP I-INTV
) ) I-INTV
supplemented VBD I-INTV
with IN I-INTV
glutamine NN I-INTV
( ( I-INTV
GLN NNP I-INTV
) ) I-INTV
has VBZ O
been VBN O
reported VBN O
to TO O
be VB O
effective JJ O
for IN O
patients NNS B-POPU
with IN I-POPU
bone NN I-POPU
marrow NN I-POPU
transplantation NN I-POPU
( ( I-POPU
BMT NNP I-POPU
) ) I-POPU
. . O

Our PRP$ O
aim NN O
was VBD O
to TO O
evaluate VB O
enteral JJ O
and CC O
parenteral JJ O
glutamine NN O
in IN O
patients NNS B-POPU
undergoing JJ I-POPU
BMT NNP I-POPU
. . O

METHODS NNP O
For IN O
evaluation NN O
of IN O
GLN NNP O
in IN O
BMT NNP O
, , O
66 CD B-POPU
patients NNS I-POPU
with IN I-POPU
43 CD I-POPU
hematologic NNS I-POPU
and CC I-POPU
23 CD I-POPU
solid JJ I-POPU
malignancies NNS I-POPU
( ( I-POPU
21 CD I-POPU
breast NN I-POPU
carcinomas NN I-POPU
) ) I-POPU
, , O
were VBD O
randomized VBN O
, , O
double-blinded JJ O
, , O
to TO O
either DT O
oral JJ B-INTV
GLN NNP I-INTV
( ( O
n JJ O
= NNP O
35 CD O
) ) O
or CC O
glycine-control NN B-INTV
( ( O
GLY NNP O
) ) O
( ( O
n JJ O
= NNP O
31 CD O
) ) O
, , O
10 CD O
g NN O
three CD O
times NNS O
daily RB O
. . O

When WRB O
TPN NNP B-INTV
became VBD O
necessary JJ O
, , O
patients NNS O
who WP O
received VBD O
GLN NNP B-INTV
orally RB O
were VBD O
given VBN O
TPN NNP B-INTV
with IN I-INTV
GLN NNP I-INTV
( ( O
0.57 CD O
g/kg NN O
) ) O
. . O

Those DT O
who WP O
received VBD O
GLY NNP O
received VBD O
standard JJ O
TPN NNP B-INTV
, , O
isocaloric JJ O
and CC O
isonitrogenous JJ O
. . O

Patients NNS B-POPU
with IN I-POPU
hematologic JJ I-POPU
malignancies NNS I-POPU
received VBD O
high-dose JJ B-INTV
chemotherapy NN I-INTV
, , I-INTV
total JJ I-INTV
body NN I-INTV
irradiation NN I-INTV
, , I-INTV
and CC I-INTV
either DT I-INTV
allogeneic NN I-INTV
( ( I-INTV
ALLO NNP I-INTV
) ) I-INTV
BMT NNP I-INTV
( ( O
n JJ O
= NNP O
18 CD O
) ) O
or CC O
autologous JJ B-INTV
( ( I-INTV
AUTO NNP I-INTV
) ) I-INTV
stem NN I-INTV
cell NN I-INTV
transplantation NN I-INTV
( ( O
n JJ O
= NNP O
25 CD O
) ) O
. . O

Patients NNS B-POPU
with IN I-POPU
solid JJ I-POPU
malignancies NNS I-POPU
( ( I-POPU
n JJ I-POPU
= NNP I-POPU
23 CD I-POPU
) ) I-POPU
received VBD O
AUTO NNP B-INTV
. . O

RESULTS NNP O
There EX O
were VBD O
14 CD B-POPU
in-hospital JJ I-POPU
deaths NNS I-POPU
without IN I-POPU
relationship NN I-POPU
to TO I-POPU
GLN NNP I-POPU
administration NN I-POPU
. . O

For IN O
respective JJ O
comparisons NNS O
of IN O
ALLO NNP O
and CC O
AUTO NNP O
transplants NNS O
in IN O
the DT O
GLN NNP O
and CC O
GLY NNP O
hematologic VBP O
groups NNS O
and CC O
AUTO NNP O
in IN O
the DT O
solid JJ O
tumor NN O
groups NNS O
, , O
there EX O
were VBD O
no DT O
significant JJ O
differences NNS O
in IN O
hospital NN B-OC
stay NN I-OC
, , I-OC
duration NN I-OC
of IN I-OC
stay NN I-OC
after IN I-OC
BMT NNP I-OC
, , I-OC
TPN NNP I-OC
days NNS I-OC
, , I-OC
neutrophil JJ I-OC
recovery NN I-OC
> NN I-OC
500/mm3 CD I-OC
, , I-OC
incidence NN I-OC
of IN I-OC
positive JJ I-OC
blood NN I-OC
cultures NNS I-OC
, , I-OC
sepsis NN I-OC
, , I-OC
mucositis NN I-OC
, , I-OC
and CC I-OC
diarrhea NN I-OC
. . O

Acute NNP B-OC
graft VBD I-OC
us PRP I-OC
host VB I-OC
disease NN I-OC
occurred VBD O
in IN O
1 CD B-POPU
of IN I-POPU
10 CD I-POPU
hematologic JJ I-POPU
patients NNS I-POPU
receiving VBG I-POPU
GLN NNP I-POPU
and CC O
in IN O
3 CD O
of IN O
8 CD O
patients NNS O
receiving VBG O
GLY NNP O
placebo NN O
( ( O
p JJ O
> NNP O
.05 NNP O
) ) O
. . O

Possible JJ O
reduction NN B-OC
in IN I-OC
need NN I-OC
for IN I-OC
TPN NNP I-OC
and CC O
a DT O
suggestion NN O
of IN O
improved JJ B-OC
long-term JJ I-OC
survival NN I-OC
were VBD O
associated VBN O
with IN O
GLN NNP O
. . O

CONCLUSIONS NNP O
Oral NNP O
and CC O
parenteral JJ O
GLN NNP B-INTV
seemed VBD O
to TO O
be VB O
of IN O
limited JJ O
benefit NN O
for IN O
patients NNS O
having VBG O
AUTO NNP O
or CC O
ALLO NNP O
BMT NNP O
for IN O
hematologic NN O
or CC O
solid JJ O
malignancies NNS O
. . O

Further NNP O
study NN O
of IN O
long-term JJ O
effects NNS O
of IN O
GLN NNP O
in IN O
BMT NNP O
seems VBZ O
warranted VBN O
. . O

-DOCSTART- -X- O O

[ JJ O
Efficacy NNP O
of IN O
combination NN O
with IN O
granisetron NN B-INTV
and CC I-INTV
methylprednisolone NN I-INTV
for IN O
nausea NN B-POPU
, , I-POPU
vomiting VBG I-POPU
and CC I-POPU
appetite JJ I-POPU
loss NN I-POPU
in IN I-POPU
remission NN I-POPU
induction NN I-POPU
chemotherapy NN I-POPU
of IN I-POPU
acute JJ I-POPU
myeloid NN I-POPU
leukemia NN I-POPU
-- : I-POPU
a DT I-POPU
randomized JJ O
comparative JJ O
trial NN O
between IN O
granisetron NN B-INTV
alone RB I-INTV
and CC I-INTV
granisetron JJ I-INTV
plus CC I-INTV
methylprednisolone JJ I-INTV
] NN I-INTV
. . O

The DT O
prevention NN O
of IN O
nausea NN B-OC
, , I-OC
vomiting VBG I-OC
and CC I-OC
appetite JJ I-OC
loss NN I-OC
induced VBN O
by IN O
remission NN O
induction NN O
chemotherapy NN O
for IN O
acute JJ B-POPU
myeloid NN I-POPU
leukemia NN I-POPU
was VBD O
compared VBN O
by IN O
randomization NN O
between IN O
granisetron NN B-POPU
alone RB I-POPU
and CC I-POPU
combination NN I-POPU
with IN I-POPU
granisetron NN I-POPU
plus CC I-POPU
methylprednisolone NN I-POPU
. . O

Granisetron NNP B-INTV
was VBD O
administered VBN O
at IN O
40 CD B-INTV
micrograms/kg NN I-INTV
during IN I-INTV
chemotherapy NN I-INTV
, , I-INTV
and CC I-INTV
methylprednisolone NN I-INTV
was VBD O
administered VBN O
concomitantly RB O
at IN O
125 CD O
mg/body NN O
for IN O
3 CD O
days NNS O
or CC O
more JJR O
in IN O
the DT O
combination NN B-POPU
group NN I-POPU
. . O

The DT B-POPU
single JJ I-POPU
and CC I-POPU
combination NN I-POPU
groups NNS I-POPU
comprised VBD I-POPU
14 CD I-POPU
and CC I-POPU
13 CD I-POPU
patients NNS I-POPU
, , I-POPU
respectively RB I-POPU
, , I-POPU
and CC I-POPU
there EX I-POPU
was VBD I-POPU
no DT I-POPU
significant JJ I-POPU
difference NN I-POPU
between IN I-POPU
the DT I-POPU
background NN I-POPU
of IN I-POPU
both DT I-POPU
groups NNS I-POPU
. . O

To TO O
evaluate VB O
the DT O
effect NN O
they PRP O
were VBD O
scored VBN O
according VBG O
to TO O
4 CD O
grades NNS O
, , O
and CC O
evaluated VBD O
every DT O
24 CD O
hours NNS O
from IN O
the DT O
start NN O
of IN O
chemotherapy NN O
to TO O
5 CD O
days NNS O
after IN O
its PRP$ O
completion NN O
. . O

The DT O
complete JJ B-OC
inhibition NN I-OC
rate NN I-OC
of IN I-OC
vomiting VBG I-OC
was VBD O
as RB O
high JJ O
as IN O
71.4 CD O
% NN O
and CC O
92.3 CD O
% NN O
in IN O
the DT O
single JJ O
and CC O
combination NN O
groups NNS O
, , O
respectively RB O
, , O
showing VBG O
no DT O
significant JJ O
difference NN O
. . O

The DT O
grade NN B-OC
of IN I-OC
vomiting VBG I-OC
was VBD O
mild VBN O
in IN O
both DT O
groups NNS O
. . O

Nausea NN B-OC
was VBD O
noted VBN O
in IN O
71.4 CD O
% NN O
and CC O
46.2 CD O
% NN O
, , O
respectively RB O
, , O
and CC O
the DT O
inhibitory JJ O
effect NN O
tended VBD O
to TO O
be VB O
higher JJR O
in IN O
the DT O
combination NN O
group NN O
. . O

Appetite NNP B-OC
loss NN I-OC
developed VBD O
in IN O
92.9 CD O
% NN O
and CC O
41.7 CD O
% NN O
, , O
respectively RB O
, , O
and CC O
the DT O
prevention NN O
effect NN O
was VBD O
clearly RB O
higher JJR O
in IN O
the DT O
combination NN O
group NN O
. . O

The DT O
prevention NN O
effects NNS O
on IN O
nausea NN B-OC
7 CD O
, , O
8 CD O
and CC O
10 CD O
days NNS O
after IN O
the DT O
start NN O
of IN O
chemotherapy NN O
, , O
on IN B-OC
appetite JJ I-OC
loss NN I-OC
2-10 JJ O
days NNS O
after IN O
it PRP O
, , O
and CC O
2-5 JJ O
days NNS O
after IN O
its PRP$ O
completion NN O
, , O
were VBD O
higher JJR O
in IN O
the DT O
combination NN O
group NN O
. . O

Granisetron NNP B-INTV
revealed VBD O
an DT O
excellent JJ O
inhibitory NN B-OC
effect NN I-OC
on IN I-OC
vomiting VBG I-OC
induced VBN O
by IN O
remission NN O
induction NN O
chemotherapy NN O
for IN O
acute JJ O
myeloid NN O
leukemia NN O
, , O
but CC O
combination NN O
with IN O
granisetron NN B-INTV
and CC I-INTV
methylprednisolone NN I-INTV
was VBD O
considered VBN O
useful JJ O
for IN O
nausea NN B-OC
in IN O
the DT O
latter JJ O
half NN O
of IN O
the DT O
treatment NN O
period NN O
and CC O
for IN O
appetite JJ B-OC
loss NN I-OC
during IN O
the DT O
whole JJ O
period NN O
. . O

-DOCSTART- -X- O O

Use NNP O
of IN O
recombinant JJ B-INTV
human JJ I-INTV
granulocyte NN I-INTV
colony-stimulating NN I-INTV
factor NN I-INTV
to TO O
increase VB O
chemotherapy JJ B-INTV
dose-intensity NN O
: : O
a DT O
randomized JJ O
trial NN O
in IN O
very RB B-POPU
high-risk JJ I-POPU
childhood NN I-POPU
acute NN I-POPU
lymphoblastic JJ I-POPU
leukemia NN I-POPU
. . O

PURPOSE NNP O
To TO O
determine VB O
whether IN O
the DT O
use NN O
of IN O
a DT O
recombinant JJ B-INTV
human JJ I-INTV
granulocyte NN I-INTV
colony-stimulating NN I-INTV
factor NN I-INTV
( ( I-INTV
[ JJ I-INTV
G-CSF NNP I-INTV
] NNP I-INTV
lenogastrim NN I-INTV
) ) I-INTV
can MD O
increase VB O
the DT O
chemotherapy JJ O
dose-intensity NN O
( ( O
CDI NNP O
) ) O
delivered VBD O
during IN O
consolidation NN B-INTV
chemotherapy NN I-INTV
of IN O
childhood NN B-POPU
acute NN I-POPU
lymphoblastic JJ I-POPU
leukemia NN I-POPU
( ( I-POPU
ALL DT I-POPU
) ) I-POPU
. . O

PATIENTS NNP O
AND CC O
METHODS NNP O
Sixty-seven NNP B-POPU
children NNS I-POPU
with IN I-POPU
very RB I-POPU
high-risk JJ I-POPU
ALL NNP I-POPU
were VBD O
randomized VBN O
( ( O
slow JJ O
early JJ O
response NN O
to TO O
therapy VB O
, , O
55 CD O
patients NNS O
; : O
translocation NN O
t NN O
( ( O
9 CD O
; : O
22 CD O
) ) O
or CC O
t NN O
( ( O
4 CD O
; : O
11 CD O
) ) O
, , O
12 CD O
patients NNS O
) ) O
. . O

Consolidation NNP O
consisted VBD O
of IN O
six CD O
courses NNS O
of IN O
chemotherapy NN B-INTV
; : I-INTV
the DT O
first JJ O
, , O
third JJ O
, , O
and CC O
fifth JJ O
courses NNS O
were VBD O
a DT O
combination NN B-INTV
of IN I-INTV
high-dose JJ I-INTV
cytarabine NN I-INTV
, , I-INTV
etoposide RB I-INTV
, , I-INTV
and CC I-INTV
dexamethasone NN I-INTV
( ( I-INTV
R3 NNP I-INTV
) ) I-INTV
, , O
whereas VBD O
the DT O
second JJ O
, , O
fourth JJ O
, , O
and CC O
sixth JJ O
courses NNS O
included VBD O
vincristine NN B-INTV
, , I-INTV
prednisone NN I-INTV
, , I-INTV
cyclophosphamide NN I-INTV
, , I-INTV
doxorubicin NN I-INTV
, , I-INTV
and CC I-INTV
methotrexate NN I-INTV
( ( I-INTV
COPADM NNP I-INTV
) ) I-INTV
. . O

G-CSF NNP B-INTV
was VBD O
given VBN O
after IN O
each DT O
course NN O
, , O
and CC O
the DT O
next JJ O
scheduled JJ O
course NN O
was VBD O
started VBN O
as RB O
soon RB O
as IN O
neutrophil JJ O
count NN O
was VBD O
> JJ O
1 CD O
x JJ O
10 CD O
( ( O
9 CD O
) ) O
/L NN O
and CC O
platelet NN O
count NN O
was VBD O
> JJ O
100 CD O
x JJ O
10 CD O
( ( O
9 CD O
) ) O
/L NN O
. . O

CDI NNP B-OC
was VBD O
calculated VBN O
using VBG O
the DT O
interval NN O
from IN O
day NN O
1 CD O
of IN O
the DT O
first JJ O
course NN O
to TO O
hematologic VB O
recovery NN O
after IN O
the DT O
fifth JJ O
course NN O
( ( O
100 CD O
% NN O
CDI NNP O
= NNP O
105-day JJ O
interval NN O
) ) O
. . O

RESULTS NNP O
CDI NNP B-OC
was VBD O
significantly RB O
increased VBN B-OC
in IN O
the DT O
G-CSF NNP B-INTV
group NN O
compared VBN O
with IN O
the DT O
non-G-CSF JJ B-INTV
group NN O
( ( O
mean JJ O
+/- JJ O
95 CD O
% NN O
confidence NN O
interval NN O
, , O
105 CD O
+/- JJ O
5 CD O
% NN O
v JJ O
91 CD O
+/- JJ O
4 CD O
% NN O
; : O
P NNP O
< NNP O
.001 NNP O
) ) O
. . O

This DT O
higher JJR B-OC
intensity NN I-OC
was VBD O
a DT O
result NN O
of IN O
shorter JJR O
post-R3 NN B-OC
intervals NNS I-OC
in IN O
the DT O
G-CSF NNP B-INTV
group NN O
, , O
whereas IN O
the DT O
post-COPADM JJ B-INTV
intervals NNS O
were VBD O
not RB O
statistically RB O
reduced VBN O
. . O

After IN O
the DT O
R3 NNP O
courses NNS O
, , O
the DT O
number NN B-OC
of IN I-OC
days NNS I-OC
with IN I-OC
fever NN I-OC
and CC I-OC
intravenous JJ I-OC
antibiotics NNS I-OC
and CC I-OC
duration NN I-OC
of IN I-OC
hospitalization NN I-OC
were VBD I-OC
significantly RB I-OC
decreased VBN I-OC
by IN O
G-CSF NNP B-INTV
, , O
whereas JJ O
reductions NNS B-OC
observed VBD I-OC
after IN I-OC
COPADM NNP B-INTV
were VBD B-OC
not RB I-OC
statistically RB I-OC
significant JJ I-OC
. . O

Duration NN B-OC
of IN I-OC
granulocytopenia NN I-OC
was VBD I-OC
reduced VBN I-OC
in IN O
the DT O
G-CSF NNP B-INTV
group NN O
, , O
but CC O
thrombocytopenia NN B-OC
was VBD I-OC
prolonged VBN I-OC
, , O
and CC O
the DT O
number NN B-OC
of IN I-OC
platelet NN I-OC
transfusions NNS I-OC
was VBD I-OC
increased VBN I-OC
. . O

Finally RB O
, , O
the DT O
3-year JJ O
probability NN O
of IN O
event-free JJ B-OC
survival NN I-OC
was VBD O
not RB O
different JJ O
between IN O
the DT O
two CD O
groups NNS O
. . O

CONCLUSION NNP O
G-CSF NNP B-INTV
can MD O
increase VB O
CDI NNP O
in IN O
high-risk JJ B-POPU
childhood NN I-POPU
ALL NNP I-POPU
. . O

Its PRP$ O
effects NNS O
depend VBP O
on IN O
the DT O
chemotherapy NN O
regimen NNS O
given VBN O
before IN O
G-CSF NNP B-INTV
administration NN I-INTV
. . O

In IN O
our PRP$ O
study NN O
, , O
a DT O
higher JJR O
CDI NNP O
did VBD O
not RB O
improve VB O
disease NN O
control NN O
. . O

-DOCSTART- -X- O O

Outcome NN O
of IN O
CNS NNP O
disease NN O
at IN O
diagnosis NN O
in IN O
disseminated JJ B-POPU
small JJ I-POPU
noncleaved-cell JJ I-POPU
lymphoma NN I-POPU
and CC I-POPU
B-cell NNP I-POPU
leukemia NN I-POPU
: : I-POPU
a DT O
Children NNP B-POPU
's POS I-POPU
Cancer NNP I-POPU
Group NNP I-POPU
study NN I-POPU
. . O

PURPOSE NNP O
To TO O
examine VB O
the DT O
impact NN O
of IN O
initial JJ O
CNS NNP O
involvement NN O
on IN O
outcome NN O
and CC O
patterns NNS O
of IN O
failure NN O
in IN O
patients NNS B-POPU
with IN I-POPU
disseminated JJ I-POPU
small JJ I-POPU
noncleaved-cell JJ I-POPU
lymphoma NN I-POPU
and CC I-POPU
B-cell NNP I-POPU
leukemia NN I-POPU
who WP I-POPU
were VBD I-POPU
treated VBN I-POPU
in IN I-POPU
four CD I-POPU
successive JJ I-POPU
Children NNP I-POPU
's POS I-POPU
Cancer NNP I-POPU
Group NNP I-POPU
trials NNS I-POPU
. . O

PATIENTS NNP O
AND CC O
METHODS NNP O
Of IN O
462 CD B-POPU
patients NNS I-POPU
with IN I-POPU
disseminated JJ I-POPU
disease NN I-POPU
, , I-POPU
49 CD I-POPU
( ( I-POPU
10.6 CD I-POPU
% NN I-POPU
) ) I-POPU
had VBD I-POPU
CNS NNP I-POPU
disease NN I-POPU
at IN I-POPU
diagnosis NN I-POPU
( ( I-POPU
CNS+ NNP I-POPU
) ) I-POPU
. . O

CNS NNP O
disease NN O
included VBD O
meningeal JJ O
disease NN O
or CC O
CNS NNP O
parenchymal JJ O
masses NNS O
with IN O
or CC O
without IN O
cranial JJ O
neuropathies NNS O
( ( O
CSF+/Mass NNP O
; : O
CNPs NNP O
) ) O
in IN O
36 CD O
patients NNS O
and CC O
isolated JJ O
CNPs NNP O
in IN O
13 CD O
. . O

Of IN B-POPU
the DT I-POPU
CNS+ NNP I-POPU
patients NNS I-POPU
, , I-POPU
28 CD I-POPU
had VBD I-POPU
M2 NNP I-POPU
( ( I-POPU
5 CD I-POPU
% NN I-POPU
to TO I-POPU
25 CD I-POPU
% NN I-POPU
blasts NNS I-POPU
) ) I-POPU
or CC I-POPU
M3 NNP I-POPU
( ( I-POPU
> VB I-POPU
25 CD I-POPU
% NN I-POPU
blasts NNS I-POPU
) ) I-POPU
bone NN I-POPU
marrow JJ I-POPU
involvement NN I-POPU
. . O

All DT B-POPU
patients NNS I-POPU
received VBD I-POPU
protocol-based JJ I-POPU
systemic JJ I-POPU
and CC I-POPU
intrathecal JJ I-POPU
chemotherapy NN I-POPU
. . O

Thirty-six JJ O
patients NNS O
also RB O
received VBD O
CNS NNP B-INTV
irradiation NN I-INTV
. . O

RESULTS NNP O
Relapses NNPS B-OC
occurred VBD O
in IN O
21 CD O
( ( O
43 CD O
% NN O
) ) O
of IN O
49 CD O
patients NNS O
, , O
predominantly RB O
in IN O
the DT O
CNS NNP O
( ( O
71 CD O
% NN O
) ) O
and CC O
bone NN O
marrow NN O
( ( O
52 CD O
% NN O
) ) O
. . O

The DT O
3-year JJ B-OC
event-free JJ I-OC
survival NN I-OC
+/- JJ O
SE NNP O
for IN O
all DT O
patients NNS O
with IN O
CNS+ NNP O
disease NN O
was VBD O
45 CD O
% NN O
+/- JJ O
7 CD O
% NN O
. . O

Patients NNS O
with IN O
CSF+/Mass NNP O
had VBD O
a DT O
nominally RB O
higher JJR B-OC
treatment NN I-OC
failure NN I-OC
rate NN I-OC
compared VBN O
with IN O
patients NNS O
with IN O
CNS- NNP O
after IN O
adjusting VBG O
for IN O
marrow NN O
status NN O
and CC O
lactate VB O
dehydrogenase NN O
( ( O
LDH NNP O
) ) O
diagnosis NN O
, , O
with IN O
a DT O
relative JJ B-OC
failure NN I-OC
rate NN I-OC
( ( I-OC
RFR NNP I-OC
) ) I-OC
of IN O
1.52 CD O
( ( O
95 CD O
% NN O
confidence NN O
interval NN O
[ NNP O
CI NNP O
] NNP O
, , O
0.88 CD O
to TO O
2.6 CD O
; : O
P NNP O
=.15 NNP O
) ) O
. . O

In IN O
comparison NN O
, , O
the DT O
RFRs NNP B-OC
for IN O
patients NNS O
with IN O
M2 NNP O
or CC O
M3 NNP O
marrow NN O
and CC O
for IN O
those DT O
with IN O
LDH NNP O
levels NNS O
greater JJR O
than IN O
500 CD O
IU/L NNP O
after IN O
adjusting VBG O
for IN O
CNS NNP B-OC
disease NN I-OC
were VBD O
1.4 CD O
( ( O
95 CD O
% NN O
CI NNP O
, , O
0.96 CD O
to TO O
2.0 CD O
; : O
P NNP O
=.029 NNP O
) ) O
and CC O
2.2 CD O
( ( O
95 CD O
% NN O
CI NNP O
, , O
1.5 CD O
to TO O
3.0 CD O
; : O
P NNP O
< NNP O
.001 NNP O
) ) O
, , O
respectively RB O
. . O

The DT O
RFR NNP B-OC
for IN O
patients NNS O
with IN O
isolated JJ B-OC
CNPs NNP I-OC
was VBD O
0.87 CD O
( ( O
95 CD O
% NN O
CI NNP O
, , O
0.36 CD O
to TO O
2.1 CD O
; : O
P NNP O
=.76 NNP O
) ) O
. . O

CONCLUSION NNP O
We PRP O
conclude VBP O
that IN O
, , O
with IN O
the DT O
treatments NNS O
used VBN O
during IN O
the DT O
period NN O
covered VBN O
by IN O
these DT O
studies NNS O
, , O
the DT O
presence NN O
of IN O
CSF+/Mass NNP O
CNS NNP O
disease NN O
at IN O
diagnosis NN O
was VBD O
associated VBN O
with IN O
a DT O
nominally RB B-OC
worse JJR I-OC
outcome JJ I-OC
independent JJ O
of IN O
initial JJ O
bone NN O
marrow NN O
status NN O
and CC O
LDH NNP O
level NN O
, , O
but CC O
the DT O
effect NN O
was VBD O
not RB O
statistically RB O
significant JJ O
. . O

-DOCSTART- -X- O O

Analysis NN B-OC
of IN I-OC
treatment NN I-OC
in IN O
childhood NN B-POPU
leukaemia NN I-POPU
. . O

I. NNP O
Predisposition NNP O
to TO O
methotrexate-induced JJ O
neutropenia NN O
after IN B-POPU
craniospinal JJ I-POPU
irradiation NN I-POPU
. . O

Report NNP O
to TO O
the DT O
Medical NNP O
Research NNP O
Council NNP O
of IN O
the DT O
Working NNP O
Party NNP O
on IN O
Leukaemia NNP B-POPU
in IN I-POPU
Childhood NNP I-POPU
. . O

The DT O
degree NN O
of IN O
drug-induced JJ O
neutropenia NNS B-OC
resulting VBG O
from IN O
a DT O
controlled VBN O
trial NN O
( ( O
UKALL NNP O
I PRP O
) ) O
of IN O
treatment NN O
in IN O
acute JJ B-POPU
lymphoblastic JJ I-POPU
leukaemia NN I-POPU
was VBD O
analysed VBN O
. . O

The DT O
main JJ O
agent NN O
associated VBN O
with IN O
severe JJ B-OC
neutropenia NN I-OC
was VBD O
methotrexate NN B-INTV
, , O
and CC O
methotrexate-induced JJ B-OC
neutropenia NN I-OC
was VBD O
significantly RB O
greater JJR O
in IN O
patients NNS B-POPU
who WP I-POPU
had VBD I-POPU
received VBN I-POPU
craniospinal JJ I-POPU
irradiation NN I-POPU
. . O

The DT O
synergistic JJ B-OC
toxic NN I-OC
effect NN I-OC
of IN I-OC
irradiation NN I-OC
followed VBN O
by IN O
methotrexate NN O
treatment NN O
seems VBZ O
to TO O
have VB O
contributed VBN O
to TO O
three CD O
of IN O
the DT O
five CD O
deaths NNS B-OC
which WDT O
occurred VBD O
in IN O
complete JJ O
remission NN B-OC
in IN O
this DT O
trial NN O
; : O
all DT O
deaths NNS O
in IN O
remission NN O
occurred VBD O
in IN O
patients NNS O
who WP O
had VBD O
received VBN O
central JJ O
nervous JJ O
system NN O
prophylaxis NN O
. . O

Analysis NN O
of IN O
patients NNS O
who WP O
subsequently RB O
relapsed VBD O
compared VBN O
with IN O
those DT O
still RB O
in IN O
remission NN O
after IN O
18 CD O
months NNS O
of IN O
treatment NN O
indicated VBD O
that IN O
the DT O
former JJ O
, , O
on IN O
average NN O
, , O
had VBD O
slightly RB O
lower JJR O
neutrophil NN B-OC
counts NNS I-OC
. . O

This DT O
suggests VBZ O
that IN O
the DT O
children NNS B-POPU
who WP O
relapsed VBD O
did VBD O
not RB O
receive VB O
any DT O
less RBR O
aggressive JJ O
treatment NN O
than IN O
those DT O
who WP O
remained VBD O
in IN O
remission NN O
. . O

-DOCSTART- -X- O O

Relationships NNS O
between IN O
age NN O
at IN O
diagnosis NN O
, , O
clinical JJ O
features NNS O
, , O
and CC O
outcome NN O
of IN O
therapy NN O
in IN O
children NNS B-POPU
treated VBN I-POPU
in IN I-POPU
the DT I-POPU
Medical NNP I-POPU
Research NNP I-POPU
Council NNP I-POPU
AML NNP I-POPU
10 CD I-POPU
and CC I-POPU
12 CD I-POPU
trials NNS I-POPU
for IN I-POPU
acute JJ I-POPU
myeloid NN I-POPU
leukemia NN I-POPU
. . O

Between NNP B-POPU
May NNP I-POPU
1988 CD I-POPU
and CC I-POPU
June NNP I-POPU
2000 CD I-POPU
, , I-POPU
698 CD I-POPU
children NNS I-POPU
were VBD I-POPU
treated VBN I-POPU
in IN I-POPU
the DT I-POPU
Medical NNP I-POPU
Research NNP I-POPU
Council NNP I-POPU
acute VBZ I-POPU
myeloid JJ I-POPU
leukemia NN I-POPU
10 CD I-POPU
and CC I-POPU
12 CD I-POPU
trials NNS I-POPU
. . O

The DT O
presenting NN O
features NNS B-INTV
and CC I-INTV
outcomes NNS I-INTV
of IN I-INTV
therapy NN I-INTV
in IN I-INTV
these DT I-INTV
children NNS I-INTV
were VBD I-INTV
compared VBN I-INTV
by IN I-INTV
age NN I-INTV
. . O

Although IN O
there EX O
was VBD O
no DT O
single JJ O
cutoff NN O
in IN O
age NN O
, , O
younger JJR O
children NNS O
were VBD O
more RBR O
likely JJ O
to TO O
have VB O
intermediate JJ O
risk NN O
and CC O
less RBR O
likely JJ O
to TO O
have VB O
favorable JJ B-OC
cytogenetics NNS I-OC
( ( O
P NNP O
< NNP O
.001 NNP O
) ) O
, , O
and CC O
they PRP O
had VBD O
a DT O
higher JJR O
incidence NN B-OC
of IN I-OC
translocations NNS I-OC
involving VBG I-OC
chromosome NN I-OC
11q23 CD I-OC
( ( O
P NNP O
< NNP O
.001 NNP O
) ) O
. . O

The DT O
distribution NN O
of IN O
French-American-British NNP O
( ( O
FAB NNP O
) ) O
types NNS O
also RB O
varied VBD O
with IN O
age NN O
; : O
FAB NNP B-OC
types VBZ I-OC
M5 NNP I-OC
( ( O
P NNP O
< NNP O
.001 NNP O
) ) O
and CC O
M7 NNP B-OC
( ( O
P NNP O
< NNP O
.001 NNP O
) ) O
were VBD O
more JJR O
common JJ O
in IN O
early JJ O
childhood NN O
, , O
whereas IN O
older JJR O
children NNS O
were VBD O
more RBR O
likely JJ O
to TO O
have VB O
FAB NNP B-OC
types NNS I-OC
M0 NNP I-OC
( ( O
P NNP O
=.03 NNP O
) ) O
, , O
M1 NNP O
( ( O
P NNP O
=.04 NNP O
) ) O
, , O
M2 NNP B-OC
( ( O
P NNP O
=.005 NNP O
) ) O
, , O
and CC O
M3 NNP B-OC
( ( O
P NNP O
< NNP O
.001 NNP O
) ) O
. . O

Involvement NN B-OC
of IN I-OC
the DT I-OC
central JJ I-OC
nervous JJ I-OC
system NN I-OC
at IN O
diagnosis NN O
was VBD O
also RB O
more JJR O
common JJ O
in IN O
the DT O
youngest JJS O
children NNS O
( ( O
P NNP O
=.01 NNP O
) ) O
. . O

Younger JJR O
children NNS O
had VBD O
more RBR O
severe JJ B-OC
diarrhea NN I-OC
( ( O
P NNP O
=.002 NNP O
) ) O
, , O
whereas JJ O
older JJR O
children NNS O
had VBD O
worse JJR O
nausea NN B-OC
and CC I-OC
vomiting NN I-OC
( ( O
P NNP O
=.01 NNP O
) ) O
after IN O
chemotherapy NN O
. . O

When WRB O
adjusted VBN O
for IN O
other JJ O
important JJ O
factors NNS O
, , O
complete JJ B-OC
remission NN I-OC
rates NNS I-OC
were VBD O
similar JJ O
( ( O
P NNP O
=.5 NNP O
) ) O
and CC O
although IN O
there EX O
was VBD O
less RBR O
resistant JJ O
disease NN O
in IN O
younger JJR O
children NNS O
( ( O
P NNP O
=.003 NNP O
) ) O
, , O
this DT O
was VBD O
partially RB O
balanced VBN O
by IN O
a DT O
slight JJ O
increase NN O
in IN O
deaths NNS B-OC
during IN O
induction NN O
therapy NN O
in IN O
younger JJR O
patients NNS O
( ( O
P NNP O
=.06 NNP O
) ) O
. . O

On IN O
multivariate NN O
analysis NN O
overall JJ B-OC
survival NN I-OC
( ( O
P NNP O
=.02 NNP O
) ) O
, , O
event-free JJ B-OC
survival NN I-OC
( ( O
P NNP O
=.02 NNP O
) ) O
, , O
and CC O
disease-free JJ B-OC
survival NN I-OC
were VBD O
better JJR O
( ( O
P NNP O
=.06 NNP O
) ) O
in IN O
younger JJR O
children NNS O
due JJ O
to TO O
a DT O
lower JJR O
relapse NN B-OC
rate NN I-OC
( ( O
P NNP O
=.02 NNP O
) ) O
especially RB O
in IN O
the DT O
bone NN O
marrow NN O
( ( O
P NNP O
=.02 NNP O
) ) O
. . O

-DOCSTART- -X- O O

Overexpression NN O
of IN O
vascular JJ O
endothelial JJ O
growth NN O
factor NN O
( ( O
VEGF NNP O
) ) O
and CC O
its PRP$ O
cellular JJ O
receptor NN O
KDR NNP O
( ( O
VEGFR-2 NNP O
) ) O
in IN O
the DT O
bone NN B-POPU
marrow NN I-POPU
of IN I-POPU
patients NNS I-POPU
with IN I-POPU
acute JJ I-POPU
myeloid NN I-POPU
leukemia NN I-POPU
. . O

Vascular JJ O
endothelial JJ O
growth NN O
factor NN O
( ( O
VEGF NNP O
) ) O
and CC O
its PRP$ O
cellular JJ O
receptor NN O
VEGFR-2 NNP O
have VBP O
been VBN O
implicated VBN O
as IN O
the DT O
main JJ O
endothelial JJ O
pathway NN O
required VBN O
for IN O
tumor NN O
neovascularization NN O
. . O

However RB O
, , O
the DT O
importance NN O
of IN O
the DT O
VEGF/VEGFR-2 NNP O
system NN O
for IN O
angiogenesis NN O
in IN O
hematologic JJ O
malignancies NNS O
such JJ O
as IN O
AML NNP O
remains VBZ O
to TO O
be VB O
elucidated VBN O
. . O

In IN B-POPU
32 CD I-POPU
patients NNS I-POPU
with IN I-POPU
newly RB I-POPU
diagnosed VBN I-POPU
untreated JJ I-POPU
AML NNP I-POPU
, , O
we PRP O
observed VBD O
by IN O
immunohistochemical JJ B-INTV
analysis NN I-INTV
of IN I-INTV
bone NN I-INTV
marrow NN I-INTV
biopsies NNS I-INTV
significantly RB O
higher JJR O
levels NNS O
of IN O
VEGF NNP O
and CC O
VEGFR-2 NNP O
expression NN O
than IN O
in IN O
10 CD B-POPU
control NN I-POPU
patients NNS I-POPU
( ( O
P NNP O
< NNP O
0.001 CD O
) ) O
. . O

In IN O
contrast NN O
, , O
VEGFR-1 NNP O
staining NN O
levels NNS O
in IN O
AML NNP O
patients NNS O
were VBD O
in IN O
the DT O
same JJ O
range NN O
as IN O
in IN O
the DT O
controls NNS O
. . O

Expression NN B-OC
of IN I-OC
VEGF NNP I-OC
and CC I-OC
VEGFR-2 NNP I-OC
was VBD O
significantly RB O
higher JJR O
in IN O
patients NNS O
with IN O
a DT O
high JJ O
degree NN O
of IN O
microvessel NN O
density NN O
compared VBN O
to TO O
those DT O
with IN O
a DT O
low JJ O
degree NN O
( ( O
VEGF NNP O
: : O
P NNP O
=0.024 NNP O
; : O
VEGFR-2 JJ O
: : O
P NNP O
=0.040 NNP O
) ) O
and CC O
correlated VBN O
well RB O
with IN O
bone NN O
marrow NN O
microvessel NN O
density NN O
( ( O
r NN O
( ( O
s PRP O
) ) O
=0.566 NN O
and CC O
0.609 CD O
, , O
respectively RB O
; : O
P NNP O
< NNP O
0.001 CD O
) ) O
. . O

Furthermore UH O
, , O
in IN O
patients NNS O
who WP O
achieved VBD O
a DT O
complete JJ O
remission NN B-OC
following VBG O
induction NN B-INTV
chemotherapy VBD I-INTV
VEGFR-2 NNP B-OC
staining NN I-OC
levels NNS I-OC
decreased VBN O
into IN O
the DT O
normal JJ O
range NN O
. . O

In IN O
conclusion NN O
, , O
our PRP$ O
results NNS O
provide VBP O
evidence NN O
for IN O
increased JJ O
expression NN O
of IN O
VEGF/VEGFR-2 NNP B-OC
of IN I-OC
leukemic JJ I-OC
blasts NNS I-OC
and CC O
correlation NN O
with IN O
angiogenesis NN O
in IN O
the DT O
bone NN O
marrow NN O
of IN O
AML NNP O
patients NNS O
. . O

Thus RB O
, , O
VEGF/VEGFR-2 NNP O
might MD O
constitute VB O
promising VBG O
targets NNS O
for IN O
antiangiogenic JJ B-INTV
and CC O
antileukemic JJ B-INTV
treatment NN I-INTV
strategies NNS O
in IN O
AML NNP O
. . O

-DOCSTART- -X- O O

Cyclosporine NNP B-INTV
inhibition NN O
of IN O
P-glycoprotein NNP O
in IN O
chronic JJ B-POPU
myeloid NN I-POPU
leukemia NN I-POPU
blast NN I-POPU
phase NN I-POPU
. . O

Chronic NNP O
myeloid NN O
leukemia NN O
blast NN O
phase NN O
( ( O
CML-BP NNP O
) ) O
cells NNS O
commonly RB O
express VBP O
the DT O
multidrug NN O
transporter NN O
, , O
P-glycoprotein NNP O
( ( O
Pgp NNP O
) ) O
. . O

To TO O
determine VB O
whether IN O
Pgp NNP O
inhibition NN O
improves VBZ O
treatment NN O
outcome NN O
in IN O
CML-BP NNP O
, , O
the DT O
Southwest NNP O
Oncology NNP O
Group NNP O
performed VBD O
a DT O
randomized VBN B-INTV
, , I-INTV
controlled VBN I-INTV
trial NN I-INTV
testing VBG I-INTV
the DT I-INTV
benefit NN I-INTV
of IN I-INTV
the DT I-INTV
Pgp NNP I-INTV
modulator NN I-INTV
, , I-INTV
cyclosporin VB I-INTV
A NNP I-INTV
( ( I-INTV
CsA NNP I-INTV
) ) I-INTV
. . O

Seventy-three JJ B-POPU
eligible JJ I-POPU
patients NNS I-POPU
were VBD O
assigned VBN B-INTV
to TO I-INTV
treatment NN I-INTV
with IN I-INTV
cytarabine NN I-INTV
and CC I-INTV
infusional JJ I-INTV
daunorubicin NN I-INTV
with IN I-INTV
or CC I-INTV
without IN I-INTV
intravenous JJ I-INTV
CsA NNP I-INTV
. . O

Treatment NN O
with IN O
CsA NNP O
yielded VBD O
no DT B-OC
improvement NN I-OC
in IN O
treatment NN O
outcome NN O
as IN O
measured VBN O
by IN O
the DT O
frequency NN B-OC
of IN I-OC
induction NN I-OC
resistance NN I-OC
( ( O
68 CD O
% NN O
vs JJ O
53 CD O
% NN O
) ) O
, , O
rate NN B-OC
of IN I-OC
complete JJ I-OC
remission NN I-OC
or CC I-OC
restored VBN I-OC
chronic JJ I-OC
phase NN I-OC
( ( O
CR/CP NNP O
, , O
8 CD O
% NN O
vs JJ O
30 CD O
% NN O
) ) O
, , O
and CC O
survival NN B-OC
( ( O
3 CD O
vs RB O
5 CD O
months NNS O
) ) O
. . O

Blast NNP B-OC
expression NN I-OC
of IN I-OC
Pgp NNP I-OC
( ( O
63 CD O
% NN O
) ) O
and CC O
LRP NNP B-OC
( ( O
71 CD O
% NN O
) ) O
was VBD O
common JJ O
, , O
whereas IN O
only RB O
Pgp NNP O
adversely RB O
impacted VBD O
the DT O
rate NN B-OC
of IN I-OC
CR/CP NNP I-OC
( ( O
P NNP O
=.025 NNP O
) ) O
. . O

We PRP O
conclude VBP O
that DT O
Pgp NNP O
has VBZ O
prognostic JJ O
relevance NN O
in IN O
CML-BP NNP O
but CC O
that IN O
the DT O
modulation NN O
of IN O
Pgp NNP O
function NN O
with IN O
CsA NNP O
as IN O
applied VBN O
in IN O
this DT O
trial NN O
is VBZ O
ineffective JJ O
. . O

-DOCSTART- -X- O O

Combined VBN O
therapy NN O
in IN O
the DT O
treatment NN O
of IN O
primary JJ B-POPU
mediastinal JJ I-POPU
B-cell NNP I-POPU
lymphoma NN I-POPU
: : I-POPU
conventional JJ O
versus NN O
escalated VBD O
chemotherapy NN O
. . O

Treatment NN O
of IN O
patients NNS B-POPU
with IN I-POPU
primary JJ I-POPU
mediastinal JJ I-POPU
B-cell NNP I-POPU
lymphoma NN I-POPU
( ( I-POPU
PMBCL NNP I-POPU
) ) I-POPU
remains VBZ O
controversial JJ O
. . O

We PRP O
started VBD O
a DT O
controlled JJ O
clinical JJ O
trial NN O
to TO O
evaluate VB O
the DT O
efficacy NN B-OC
and CC I-OC
toxicity NN I-OC
of IN O
a DT O
conventional JJ O
versus NN O
more RBR O
intensive JJ O
regimen NNS O
of IN O
combined JJ O
chemotherapy NN O
followed VBN O
by IN O
radiotherapy NN O
to TO O
the DT O
mediastinum NN O
with IN O
the DT O
mantle NN O
technique NN O
. . O

From IN B-POPU
1989 CD I-POPU
to TO I-POPU
1997 CD I-POPU
, , I-POPU
68 CD I-POPU
patients NNS I-POPU
diagnosed VBN I-POPU
with IN I-POPU
previously RB I-POPU
untreated VBN I-POPU
PMBCL NNP I-POPU
, , I-POPU
aged VBD I-POPU
18-65 CD I-POPU
years NNS I-POPU
and CC I-POPU
negative JJ I-POPU
for IN I-POPU
immunodeficiency NN I-POPU
virus NN I-POPU
test NN I-POPU
, , O
were VBD O
considered VBN O
candidates NNS O
to TO O
receive VB O
either DT B-INTV
conventional JJ I-INTV
chemotherapy NN I-INTV
with IN I-INTV
CEOP-Bleo NNP I-INTV
( ( I-INTV
cyclophosphamide VB I-INTV
750 CD I-INTV
mg/m NN I-INTV
( ( I-INTV
2 CD I-INTV
) ) I-INTV
, , I-INTV
vincristine JJ I-INTV
1.4 CD I-INTV
mg/m NN I-INTV
( ( I-INTV
2 CD I-INTV
) ) I-INTV
, , I-INTV
prednisone RB I-INTV
40 CD I-INTV
mg/m NN I-INTV
( ( I-INTV
2 CD I-INTV
) ) I-INTV
, , I-INTV
epirubicin $ I-INTV
70 CD I-INTV
mg/m NN I-INTV
( ( I-INTV
2 CD I-INTV
) ) I-INTV
, , I-INTV
and CC I-INTV
bleomycin $ I-INTV
10 CD I-INTV
mg/m NN I-INTV
( ( I-INTV
2 CD I-INTV
) ) I-INTV
) ) I-INTV
or CC I-INTV
mega JJ I-INTV
CEOP-Bleo NNP I-INTV
( ( I-INTV
cyclophosphamide JJ I-INTV
1000 CD I-INTV
mg/m NN I-INTV
( ( I-INTV
2 CD I-INTV
) ) I-INTV
, , I-INTV
epirubicin $ I-INTV
120 CD I-INTV
mg/m NN I-INTV
( ( I-INTV
2 CD I-INTV
) ) I-INTV
, , I-INTV
vincristine NN I-INTV
, , I-INTV
prednisone NN I-INTV
, , I-INTV
and CC I-INTV
bleomycin NN I-INTV
at IN I-INTV
the DT I-INTV
same JJ I-INTV
doses NNS I-INTV
) ) I-INTV
every DT I-INTV
21 CD I-INTV
days NNS I-INTV
for IN I-INTV
six CD I-INTV
cycles NNS I-INTV
, , I-INTV
followed VBN I-INTV
by IN I-INTV
radiotherapy NN I-INTV
to TO I-INTV
the DT I-INTV
mediastinum NN I-INTV
with IN I-INTV
the DT I-INTV
mantle NN I-INTV
technique NN I-INTV
( ( I-INTV
35-45 JJ I-INTV
Gy NNP I-INTV
, , I-INTV
mean VBP I-INTV
38 CD I-INTV
Gy NNP I-INTV
) ) I-INTV
. . O

Complete JJ B-OC
response NN I-OC
( ( I-OC
CR NNP I-OC
) ) I-OC
rates NNS I-OC
were VBD O
not RB O
statistically RB O
different JJ O
: : O
64 CD O
% NN O
[ CC O
95 CD O
percent NN O
confidence NN B-OC
interval NN I-OC
( ( I-OC
CI NNP I-OC
) ) I-OC
: : I-OC
58 CD O
percent NN O
to TO O
70 CD O
percent NN O
] NN O
for IN O
conventional JJ O
arm NN O
vs NN O
81 CD O
percent NN O
( ( O
95 CD O
CI NN O
: : O
77-86 JJ O
percent NN O
) ) O
in IN O
the DT O
intensive JJ O
group NN O
( ( O
p=0.2 NN O
) ) O
. . O

However RB O
, , O
failure-free JJ B-OC
survival NN I-OC
( ( I-OC
FFS NNP I-OC
) ) I-OC
and CC I-OC
overall JJ I-OC
survival NN I-OC
( ( I-OC
OS NNP I-OC
) ) I-OC
had VBD I-OC
statistical JJ I-OC
differences NNS I-OC
. . O

At IN O
5 CD O
years NNS O
, , O
actuarial JJ B-OC
FFS NNP I-OC
for IN O
patients NNS O
treated VBN O
with IN O
conventional JJ O
chemotherapy NN O
was VBD O
51 CD O
percent NN O
( ( O
95 CD O
percent NN O
CI NN O
: : O
44-59 JJ O
percent NN O
) ) O
compared VBN O
to TO O
70 CD O
percent NN O
( ( O
95 CD O
percent NN O
CI NN O
: : O
65-76 JJ O
percent NN O
) ) O
in IN O
the DT O
intensive JJ O
arm NN O
( ( O
p JJ O
> NNP O
0.01 CD O
) ) O
. . O

OS CC B-OC
rates NNS I-OC
were VBD O
also RB O
different JJ O
: : O
54 CD O
percent NN O
( ( O
95 CD O
percent NN O
CI NN O
: : O
48-57 JJ O
percent NN O
) ) O
vs VBZ O
70 CD O
percent NN O
( ( O
95 CD O
percent NN O
CI NN O
: : O
65-76 JJ O
percent NN O
) ) O
, , O
respectively RB O
( ( O
p JJ O
< NNP O
0.01 CD O
) ) O
. . O

Toxicity NN B-OC
was VBD O
mild JJ O
and CC O
no DT O
therapy-related JJ B-OC
deaths NNS I-OC
were VBD O
observed VBN O
. . O

At IN O
a DT O
median JJ O
follow-up NN O
of IN O
7.3 CD O
years NNS O
, , O
no DT O
second JJ O
neoplasia NN B-OC
or CC I-OC
acute NN I-OC
leukemia NN I-OC
has VBZ O
been VBN O
observed VBN O
. . O

The DT B-OC
international JJ I-OC
prognostic JJ I-OC
index NN I-OC
was VBD O
not RB O
useful JJ O
to TO O
define VB O
clinical JJ O
risk NN O
in IN O
this DT O
selected VBN O
group NN O
of IN O
patients NNS O
. . O

Multivariate NNP O
analysis NN O
identified VBN O
pleural JJ B-OC
and CC I-OC
pericardial JJ I-OC
effusion NN I-OC
and CC I-OC
chemotherapy NN I-OC
regimen NNS I-OC
as IN O
prognostic JJ O
factors NNS O
influencing VBG O
FFS NNP B-OC
and CC I-OC
OS NNP I-OC
. . O

We PRP O
feel VBP O
that IN O
patients NNS B-POPU
with IN I-POPU
PMBCL NNP I-POPU
should MD O
be VB O
treated VBN O
with IN O
more RBR O
intensive JJ O
, , O
but CC O
not RB O
myeloablative JJ O
chemotherapy NN O
, , O
followed VBN O
by IN O
adjuvant JJ O
radiotherapy NN O
to TO O
achieve VB O
an DT O
improvement NN O
in IN O
outcome NN O
in IN O
this DT O
setting NN O
of IN O
patients NNS O
. . O

Patients NNS O
with IN O
pleural JJ O
or CC O
pericardial JJ O
effusion NN O
are VBP O
considered VBN O
at IN O
high JJ O
risk NN O
for IN O
failure NN O
with IN O
the DT O
actual JJ O
programs NNS O
of IN O
treatment NN O
and CC O
probably RB O
will MD O
be VB O
considered VBN O
for IN O
experimental JJ O
therapeutic JJ O
approaches NNS O
. . O

-DOCSTART- -X- O O

Local JJ O
warming NN O
and CC O
insertion NN O
of IN O
peripheral JJ O
venous JJ O
cannulas NNS O
: : O
single JJ O
blinded VBD O
prospective JJ O
randomised VBN O
controlled VBN O
trial NN O
and CC O
single JJ O
blinded VBD O
randomised VBN O
crossover RB O
trial NN O
. . O

OBJECTIVE NN O
To TO O
determine VB O
whether IN O
local JJ O
warming NN O
of IN O
the DT O
lower JJR O
arm NN O
and CC O
hand NN O
facilitates NNS O
peripheral VBP B-OC
venous JJ I-OC
cannulation NN I-OC
. . O

DESIGN NNP O
Single NNP O
blinded VBD O
prospective JJ O
randomised VBN O
controlled VBN O
trial NN O
and CC O
single JJ O
blinded VBD O
randomised VBN O
crossover RB O
trial NN O
. . O

SETTING NNP O
Neurosurgical JJ B-POPU
unit NN I-POPU
and CC I-POPU
haematology NN I-POPU
ward NN I-POPU
of IN I-POPU
university NN I-POPU
hospital NN I-POPU
. . O

PARTICIPANTS CC O
100 CD B-POPU
neurosurgical JJ I-POPU
patients NNS I-POPU
and CC I-POPU
40 CD I-POPU
patients NNS I-POPU
with IN I-POPU
leukaemia NNS I-POPU
who WP I-POPU
required VBD I-POPU
chemotherapy NN I-POPU
. . O

INTERVENTIONS NNP O
Neurosurgical JJ O
patients NNS O
' POS O
hands NNS B-INTV
and CC I-INTV
forearms NNS I-INTV
were VBD I-INTV
covered VBN I-INTV
for IN I-INTV
15 CD I-INTV
minutes NNS I-INTV
with IN I-INTV
a DT I-INTV
carbon NN I-INTV
fibre NN I-INTV
heating VBG I-INTV
mitt NN I-INTV
. . O

Patients NNS O
were VBD O
assigned VBN O
randomly RB O
to TO O
active JJ B-INTV
warming NN I-INTV
at IN I-INTV
52 CD I-INTV
degrees NNS I-INTV
C NNP I-INTV
or CC I-INTV
passive JJ I-INTV
insulation NN I-INTV
( ( O
heater NN O
not RB O
activated VBN O
) ) O
. . O

The DT O
same JJ O
warming NN O
system NN O
was VBD O
used VBN O
for IN O
10 CD O
minutes NNS O
in IN O
patients NNS O
with IN O
leukaemia NN O
. . O

They PRP O
were VBD O
assigned VBN O
randomly RB O
to TO O
active JJ O
warming NN O
or CC O
passive JJ O
insulation NN O
on IN O
day NN O
1 CD O
and CC O
given VBN O
alternative JJ O
treatment NN O
during IN O
the DT O
subsequent JJ O
visit NN O
. . O

MAIN NNP O
OUTCOME NNP O
MEASURES NNP O
PRIMARY NNP O
: : O
success NN B-OC
rate NN I-OC
for IN I-OC
insertion NN I-OC
of IN I-OC
18 CD I-OC
gauge NN I-OC
cannula NN I-OC
into IN I-OC
vein NN I-OC
on IN I-OC
back NN I-OC
of IN I-OC
hand NN I-OC
. . O

SECONDARY NN O
: : O
time NN B-OC
required VBN I-OC
for IN I-OC
successful JJ I-OC
cannulation NN I-OC
. . O

RESULTS NNP O
In IN O
neurosurgical JJ O
patients NNS O
, , O
it PRP O
took VBD O
36 CD O
seconds NNS O
( ( O
95 CD O
% NN O
confidence NN O
interval NN O
31 CD O
to TO O
40 CD O
seconds NNS O
) ) O
to TO O
insert VB B-OC
a DT I-OC
cannula NN I-OC
in IN O
the DT O
active JJ O
warming NN O
group NN O
and CC O
62 CD O
( ( O
50 CD O
to TO O
74 CD O
) ) O
seconds NNS O
in IN O
the DT O
passive JJ O
insulation NN O
group NN O
( ( O
P=0.002 NNP O
) ) O
. . O

Three NNP O
( ( O
6 CD O
% NN O
) ) O
first RB O
attempts VBZ O
failed VBN B-OC
in IN O
the DT O
active JJ O
warming VBG O
group NN O
compared VBN O
with IN O
14 CD O
( ( O
28 CD O
% NN O
) ) O
in IN O
the DT O
passive JJ O
insulation NN O
group NN O
( ( O
P=0.008 NNP O
) ) O
. . O

The DT O
crossover NN O
study NN O
in IN O
patients NNS O
with IN O
leukaemia NN O
showed VBD O
that IN O
insertion NN B-OC
time NN I-OC
was VBD O
reduced VBN O
by IN O
20 CD O
seconds NNS O
( ( O
8 CD O
to TO O
32 CD O
, , O
P=0.013 NNP O
) ) O
with IN O
active JJ O
warming NN O
and CC O
that IN O
failure NN B-OC
rates NNS I-OC
at IN I-OC
first JJ I-OC
attempt NN I-OC
were VBD O
6 CD O
% NN O
with IN O
warming VBG O
and CC O
30 CD O
% NN O
with IN O
passive JJ O
insulation NN O
( ( O
P NNP O
< NNP O
0.001 CD O
) ) O
. . O

CONCLUSIONS NNP O
Local NNP O
warming VBG O
facilitates VBZ O
the DT O
insertion NN B-OC
of IN I-OC
peripheral JJ I-OC
venous JJ I-OC
cannulas NNS I-OC
, , O
reducing VBG O
both DT O
time NN B-OC
and CC I-OC
number NN I-OC
of IN I-OC
attempts NNS I-OC
required VBN I-OC
. . O

This DT O
may MD O
decrease VB O
the DT O
time NN B-OC
staff NN O
spend VBP O
inserting VBG B-OC
cannulas NN I-OC
, , O
reduce VB O
supply NN B-OC
costs NNS I-OC
, , O
and CC O
improve VB O
patient JJ O
satisfaction NN O
. . O

-DOCSTART- -X- O O

Dexamethasone NNP B-INTV
versus NN I-INTV
prednisone NN I-INTV
and CC O
daily JJ O
oral JJ O
versus NN O
weekly RB O
intravenous JJ B-INTV
mercaptopurine NN I-INTV
for IN O
patients NNS B-POPU
with IN I-POPU
standard-risk JJ I-POPU
acute JJ I-POPU
lymphoblastic JJ I-POPU
leukemia NN I-POPU
: : I-POPU
a DT O
report NN O
from IN O
the DT O
Children NNP O
's POS O
Cancer NNP O
Group NNP O
. . O

Conventional NNP B-INTV
therapy NN I-INTV
for IN O
childhood NN B-POPU
acute NN I-POPU
lymphoblastic JJ I-POPU
leukemia NN I-POPU
( ( I-POPU
ALL DT I-POPU
) ) I-POPU
includes VBZ O
prednisone NN B-INTV
and CC I-INTV
oral JJ I-INTV
6-mercaptopurine JJ I-INTV
. . O

Prior JJ O
observations NNS O
suggested VBD O
potential JJ O
advantages NNS O
for IN O
dexamethasone NN B-INTV
over IN I-INTV
prednisone NN I-INTV
and CC I-INTV
for IN I-INTV
intravenous JJ I-INTV
( ( I-INTV
IV NNP I-INTV
) ) I-INTV
over IN I-INTV
oral JJ I-INTV
6-mercaptopurine CD I-INTV
, , O
which WDT O
remain VBP O
to TO O
be VB O
validated VBN O
. . O

We PRP O
report VBP O
the DT O
results NNS O
of IN O
a DT O
randomized JJ O
trial NN O
of IN O
more JJR B-POPU
than IN I-POPU
1000 CD I-POPU
subjects NNS I-POPU
that WDT O
examined VBD O
the DT O
efficacy NN B-OC
of IN O
dexamethasone NN B-INTV
and CC I-INTV
IV NNP I-INTV
6-mercaptopurine JJ I-INTV
. . O

Children NNP B-POPU
with IN I-POPU
National NNP I-POPU
Cancer NNP I-POPU
Institute NNP I-POPU
standard-risk NN I-POPU
ALL NNP I-POPU
were VBD O
randomly RB O
assigned VBN O
in IN O
a DT O
2 CD O
x NN O
2 CD O
factorial JJ O
design NN O
to TO O
receive VB O
dexamethasone NN B-INTV
( ( O
6 CD O
mg/m NN O
( ( O
2 CD O
) ) O
/d NN O
) ) O
for IN O
28 CD O
days NNS O
in IN O
induction NN O
, , O
plus CC B-INTV
taper NN I-INTV
, , O
compared VBN O
with IN O
prednisone NN B-INTV
( ( O
40 CD O
mg/m NN O
( ( O
2 CD O
) ) O
/d NN O
) ) O
. . O

The DT O
second JJ O
randomized JJ O
assignment NN O
was VBD O
for IN O
daily JJ O
oral JJ O
or CC O
weekly JJ O
IV NNP B-INTV
6-mercaptopurine NN I-INTV
during IN O
consolidation NN O
. . O

During IN O
maintenance NN O
, , O
5 CD O
days NNS O
of IN O
the DT O
randomized JJ O
steroid NN O
was VBD O
given VBN O
monthly RB O
, , O
at IN O
the DT O
same JJ O
dose NN O
, , O
and CC O
all DT O
patients NNS O
received VBD O
daily JJ O
oral JJ B-INTV
6-mercaptopurine JJ I-INTV
. . O

During IN O
delayed JJ O
intensification NN O
, , O
all DT O
patients NNS O
received VBD O
a DT O
dexamethasone JJ B-INTV
dosage NN O
of IN O
10 CD O
mg/m NN O
( ( O
2 CD O
) ) O
/d NN O
for IN O
21 CD O
days NNS O
, , O
with IN B-INTV
taper NN I-INTV
. . O

Intrathecal NNP B-INTV
( ( I-INTV
IT NNP I-INTV
) ) I-INTV
methotrexate NN I-INTV
was VBD O
the DT O
sole JJ O
central JJ O
nervous JJ O
system-directed JJ O
therapy NN O
. . O

Patients NNS O
randomly RB O
assigned VBN O
to TO O
receive VB O
dexamethasone NN B-INTV
had VBD O
a DT O
6-year JJ B-OC
isolated JJ I-OC
central JJ I-OC
nervous JJ I-OC
system-relapse JJ I-OC
rate NN I-OC
of IN O
3.7 CD O
% NN O
+/- JJ O
0.8 CD O
% NN O
, , O
compared VBN O
with IN O
7.1 CD O
% NN O
+/- JJ O
1.1 CD O
% NN O
for IN O
prednisone NN B-INTV
( ( O
P NNP O
=.01 NNP O
) ) O
. . O

There EX O
was VBD O
also RB O
a DT O
trend NN O
toward IN O
fewer JJR O
isolated JJ B-OC
bone NN I-OC
marrow NN I-OC
relapses VBZ I-OC
with IN O
dexamethasone NN B-INTV
. . O

The DT O
6-year JJ B-OC
event-free JJ I-OC
survival NN I-OC
( ( I-OC
EFS NNP I-OC
) ) I-OC
was VBD O
85 CD O
% NN O
+/- JJ O
2 CD O
% NN O
for IN O
dexamethasone NN B-INTV
and CC O
77 CD O
% NN O
+/- JJ O
2 CD O
% NN O
for IN O
prednisone NN B-INTV
( ( O
P NNP O
=.002 NNP O
) ) O
. . O

EFS NNP O
was VBD O
similar JJ O
with IN O
oral JJ B-INTV
or CC I-INTV
IV JJ I-INTV
6-mercaptopurine JJ I-INTV
; : I-INTV
however RB O
, , O
patients NNS O
assigned VBD O
to TO O
IV NNP B-INTV
6-mercaptopurine JJ I-INTV
had VBD O
decreased VBN O
survival NN B-OC
after IN I-OC
relapse NN I-OC
. . O

-DOCSTART- -X- O O

Short-term JJ O
effects NNS O
of IN O
prednisolone NN B-INTV
and CC I-INTV
dexamethasone NN I-INTV
on IN O
circulating VBG B-OC
concentrations NNS I-OC
of IN I-OC
leptin NN I-OC
and CC I-OC
sex NN I-OC
hormone-binding JJ I-OC
globulin NN I-OC
in IN O
children NNS B-POPU
being VBG I-POPU
treated VBN I-POPU
for IN I-POPU
acute JJ I-POPU
lymphoblastic JJ I-POPU
leukaemia NN I-POPU
. . O

OBJECTIVE NNP O
Disturbances NNPS O
in IN O
body NN O
weight JJ O
regulation NN O
are VBP O
often RB O
encountered VBN O
during IN O
glucocorticoid JJ B-INTV
treatment NN I-INTV
and CC O
are VBP O
associated VBN O
with IN O
increased JJ O
insulin NN O
resistance NN O
and CC O
truncal JJ O
fat NN O
accumulation NN O
. . O

Children NNP B-POPU
were VBD I-POPU
investigated VBN I-POPU
who WP I-POPU
were VBD I-POPU
receiving VBG I-POPU
glucocorticoid JJ I-POPU
treatment NN I-POPU
for IN I-POPU
acute JJ I-POPU
lymphoblastic JJ I-POPU
leukaemia NN I-POPU
( ( I-POPU
ALL DT I-POPU
) ) I-POPU
. . O

They PRP O
were VBD O
randomized VBN O
to TO O
receive VB O
either CC O
prednisolone VB B-INTV
or CC I-INTV
dexamethasone VB I-INTV
as IN O
part NN O
of IN O
induction NN O
of IN O
remission NN O
. . O

This DT O
randomization NN O
process NN O
provided VBD O
a DT O
suitable JJ O
opportunity NN O
to TO O
compare VB O
the DT O
effects NNS O
of IN O
these DT O
two CD O
administered VBD O
steroid NN O
on IN O
surrogate JJ O
markers NNS O
of IN O
adipocyte NN O
activity NN O
( ( O
leptin NN O
) ) O
and CC O
hyperinsulinaemia/insulin JJ O
resistance NN O
( ( O
SHBG NNP O
) ) O
. . O

DESIGN NNP O
AND CC O
PATIENTS NNP O
Prospective NNP O
study NN O
over IN O
16 CD O
weeks NNS O
of IN O
children NNS B-POPU
randomized VBN O
to TO O
receive VB O
prednisolone NN B-INTV
( ( I-INTV
40 CD I-INTV
mg/m2 NN I-INTV
) ) I-INTV
or CC I-INTV
dexamethasone NN I-INTV
( ( I-INTV
6.5 CD I-INTV
mg/m2 NN I-INTV
) ) I-INTV
as IN I-INTV
part NN I-INTV
of IN I-INTV
the DT I-INTV
MRC-ALL97/99 NNP I-INTV
induction NN I-INTV
chemotherapy NN I-INTV
for IN I-INTV
ALL NNP I-INTV
. . O

Nineteen NNP B-POPU
children NNS I-POPU
( ( I-POPU
8 CD I-POPU
male NN I-POPU
, , I-POPU
11 CD I-POPU
female NN I-POPU
) ) I-POPU
with IN I-POPU
a DT I-POPU
median JJ I-POPU
age NN I-POPU
5.9 CD I-POPU
years NNS I-POPU
( ( I-POPU
range VB I-POPU
2.6-13 CD I-POPU
years NNS I-POPU
) ) I-POPU
were VBD I-POPU
recruited VBN I-POPU
into IN I-POPU
the DT I-POPU
study NN I-POPU
. . O

Main NNP O
outcome JJ O
measures NNS O
were VBD O
body JJ B-OC
mass NN I-OC
index NN I-OC
( ( I-OC
BMI NNP I-OC
) ) I-OC
, , I-OC
serum JJ I-OC
leptin NN I-OC
and CC I-OC
sex NN I-OC
hormone NN I-OC
binding VBG I-OC
globulin NN I-OC
( ( I-OC
SHBG NNP I-OC
) ) I-OC
. . O

RESULTS NNP O
Glucocorticoid NNP O
administration NN O
for IN O
5 CD O
weeks NNS O
resulted VBD O
in IN O
significant JJ O
( ( O
P NNP O
< NNP O
0.05 CD O
) ) O
increases NNS O
in IN O
BMI NNP B-OC
, , I-OC
leptin NN I-OC
( ( I-OC
corrected VBN I-OC
for IN I-OC
BMI NNP I-OC
) ) I-OC
and CC I-OC
the DT I-OC
leptin NN I-OC
: : I-OC
SHBG NNP I-OC
ratio NN I-OC
and CC I-OC
lowering NN I-OC
of IN I-OC
SHBG NNP I-OC
. . O

Dose NNP O
for IN O
dose NN O
, , O
dexamethasone NN B-INTV
was VBD O
significantly RB O
more RBR O
potent JJ O
than IN O
prednisolone NN B-INTV
in IN O
altering VBG O
these DT O
parameters NNS O
. . O

CONCLUSIONS NNP O
Short-term JJ O
glucocorticoid NN O
treatment NN O
has VBZ O
significant JJ O
effects NNS O
on IN O
BMI NNP O
, , O
leptin NN O
and CC O
SHBG NNP O
. . O

The DT O
leptin NN O
: : O
SHBG NNP O
ratio NN O
increase NN O
indicates VBZ O
that IN O
this DT O
may MD O
be VB O
a DT O
novel JJ O
and CC O
sensitive JJ O
biochemical JJ O
marker NN O
of IN O
metabolic JJ O
change NN O
. . O

Our PRP$ O
results NNS O
suggest VBP O
that IN O
glucocorticoid JJ B-INTV
treatment NN I-INTV
regimens NNS I-INTV
should MD O
be VB O
kept VBN O
as RB O
short JJ O
as IN O
possible JJ O
to TO O
avoid VB O
possible JJ O
detrimental JJ O
effects NNS O
associated VBN O
with IN O
increased JJ O
adiposity NN O
and CC O
insulin NN O
resistance NN O
. . O

-DOCSTART- -X- O O

Recombinant JJ B-INTV
human JJ I-INTV
thrombopoietin NN I-INTV
augments NNS O
mobilization NN O
of IN O
peripheral JJ B-OC
blood NN I-OC
progenitor NN I-OC
cells NNS I-OC
for IN O
autologous JJ B-POPU
transplantation NN I-POPU
. . O

This DT O
study NN O
assessed VBD O
the DT O
ability NN O
of IN O
various JJ O
schedules NNS O
of IN O
recombinant JJ B-INTV
human JJ I-INTV
thrombopoietin NN I-INTV
( ( I-INTV
rhTPO NN I-INTV
) ) I-INTV
to TO O
enhance VB O
mobilization NN O
of IN O
peripheral JJ O
blood NN O
progenitor NN O
cells NNS O
( ( O
PBPCs NNP O
) ) O
in IN O
134 CD B-POPU
patients NNS I-POPU
with IN I-POPU
cancer NN I-POPU
undergoing VBG I-POPU
high-dose JJ I-POPU
chemotherapy NN I-POPU
and CC I-POPU
autologous JJ I-POPU
PBPC NNP I-POPU
transplantation NN I-POPU
. . O

Patients NNS O
received VBD O
the DT O
study NN O
drug NN O
on IN O
days NNS O
1 CD O
, , O
3 CD O
, , O
and CC O
5 CD O
before IN O
initiation NN O
of IN O
granulocyte JJ O
colony-stimulating JJ O
factor NN O
( ( O
G-CSF NNP O
) ) O
10 CD O
microg/kg/day NN O
on IN O
day NN O
5 CD O
and CC O
pheresis NN O
starting VBG O
on IN O
day NN O
9 CD O
. . O

Randomly RB O
assigned JJ O
treatments NNS O
on IN O
days NNS O
1 CD O
, , O
3 CD O
, , O
and CC O
5 CD O
were VBD O
: : O
group NN O
1 CD O
( ( O
n=27 NN O
) ) O
placebo NN B-INTV
, , I-INTV
placebo NN I-INTV
, , I-INTV
rhTPO VBZ I-INTV
1.5 CD O
microg/kg NN O
; : O
group NN O
2 CD O
( ( O
n=27 NN O
) ) O
rhTPO VBZ O
1.5 CD O
microg/kg NN O
, , O
placebo NN O
, , O
placebo NN O
; : O
groups NNS O
3 CD O
( ( O
n=28 NN O
) ) O
and CC O
4 CD O
( ( O
n=22 NN O
) ) O
rhTPO VBZ O
0.5 CD O
microg/kg NN O
on IN O
all DT O
3 CD O
treatment NN O
days NNS O
; : O
and CC O
group NN O
5 CD O
( ( O
n=30 NN O
) ) O
placebo NN O
on IN O
all DT O
3 CD O
treatment NN O
days NNS O
. . O

After IN O
high-dose JJ B-INTV
chemotherapy NN I-INTV
and CC I-INTV
PBPC NNP I-INTV
transplantation NN I-INTV
, , O
groups NNS O
1 CD O
through IN O
4 CD O
received VBD O
rhTPO NN O
1.5 CD O
microg/kg NN O
days NNS O
0 CD O
, , O
+2 NNP O
, , O
+4 NNP O
, , O
and CC O
+6 VBZ O
with IN O
either DT O
G-CSF NNP O
5 CD O
microg/kg/day NN O
( ( O
groups NNS O
1-3 CD O
) ) O
or CC O
granulocyte-macrophage JJ O
colony-stimulating JJ O
factor NN O
250 CD O
microg/m NN O
( ( O
2 CD O
) ) O
/day NN O
( ( O
group NN O
4 CD O
) ) O
. . O

Group NNP O
5 CD O
received VBD O
placebo JJ B-INTV
plus CC O
G-CSF JJ O
5 CD O
microg/kg/day NN O
. . O

The DT O
addition NN O
of IN O
rhTPO NN B-INTV
to TO O
G-CSF NNP O
increased JJ O
median JJ B-OC
CD34+ NNP I-OC
cell NN I-OC
yield/pheresis NN I-OC
in IN O
cohorts NNS O
in IN O
which WDT O
rhTPO NN B-INTV
was VBD O
started VBN O
before IN O
day NN O
5 CD O
, , O
with IN O
higher JJR O
yields NNS O
in IN O
groups NNS O
2 CD O
( ( O
2.67 CD O
x RB O
10 CD O
( ( O
6 CD O
) ) O
/kg NN O
) ) O
and CC O
groups NNS O
3 CD O
and CC O
4 CD O
( ( O
3.10 CD O
x RB O
10 CD O
( ( O
6 CD O
) ) O
/kg NN O
) ) O
than IN O
in IN O
group NN O
1 CD O
( ( O
1.86 CD O
x RB O
10 CD O
( ( O
6 CD O
) ) O
/kg NN O
) ) O
or CC O
group NN O
5 CD O
( ( O
1.65 CD O
x RB O
10 CD O
( ( O
6 CD O
) ) O
/kg NN O
) ) O
( ( O
P=.006 NNP O
across IN O
groups NNS O
) ) O
. . O

Comparing VBG O
rhTPO NN B-INTV
to TO O
placebo VB B-INTV
, , O
higher JJR O
percentages NNS O
of IN O
patients NNS O
achieved VBN O
the DT O
minimum JJ B-OC
yield NN I-OC
of IN I-OC
CD34+ NNP I-OC
> NNP O
or CC O
=2 NNP O
x VBP O
10 CD O
( ( O
6 CD O
) ) O
/kg NN O
( ( O
92 CD O
% NN O
v JJ O
75 CD O
% NN O
; : O
P=.050 NNP O
) ) O
as RB O
well RB O
as IN O
the DT O
target NN O
yield NN O
of IN O
CD34+ NNP O
> NNP O
or CC O
=5 NNP O
x VBP O
10 CD O
( ( O
6 CD O
) ) O
/kg NN O
( ( O
73 CD O
% NN O
v JJ O
46 CD O
% NN O
; : O
P= NNP O
.041 NNP O
) ) O
. . O

rhTPO-treated JJ B-INTV
patients NNS O
required VBN O
fewer JJR O
phereses NNS O
to TO O
achieve VB O
minimum NN O
( ( O
P= NNP O
.011 NNP O
) ) O
and CC O
target NN O
( ( O
P= NNP O
.015 NNP O
) ) O
CD34+ NNP B-OC
cell NN I-OC
values NNS I-OC
. . O

rhTPO VB B-INTV
given VBN O
after IN O
transplantation NN O
did VBD O
not RB O
speed VB O
platelet NN B-OC
recovery NN I-OC
. . O

No UH O
neutralizing JJ O
antibodies NNS O
were VBD O
observed VBN O
. . O

We PRP O
conclude VBP O
that IN O
rhTPO NN B-INTV
can MD O
safely RB O
enhance VB O
mobilization NN O
of IN O
PBPC NNP B-OC
, , O
reduce VB O
the DT O
number NN O
of IN O
leukapheresis NN B-OC
, , O
and CC O
allow VB O
more JJR O
patients NNS O
to TO O
meet VB O
minimal JJ O
cell NN O
yield NN O
requirements NNS O
to TO O
receive VB O
high-dose JJ O
chemotherapy NN B-INTV
with IN O
PBPC NNP B-INTV
transplantation NN I-INTV
. . O

-DOCSTART- -X- O O

Randomized NNP O
comparison NN O
of IN O
interferon NN B-INTV
alpha NN I-INTV
and CC I-INTV
hydroxyurea NN I-INTV
with IN O
hydroxyurea JJ O
monotherapy NN O
in IN O
chronic JJ O
myeloid NN O
leukemia NN O
( ( O
CML-study NNP O
II NNP O
) ) O
: : O
prolongation NN O
of IN O
survival NN O
by IN O
the DT O
combination NN O
of IN O
interferon NN O
alpha NN O
and CC O
hydroxyurea NN O
. . O

The DT O
optimum JJ O
treatment NN O
conditions NNS O
of IN O
interferon NN B-INTV
( ( I-INTV
IFN NNP I-INTV
) ) I-INTV
alpha VBP I-INTV
therapy NN I-INTV
in IN O
chronic JJ O
myeloid NN O
leukemia NN O
( ( O
CML NNP O
) ) O
are VBP O
still RB O
controversial JJ O
. . O

To TO O
evaluate VB O
the DT O
role NN O
of IN O
hydroxyurea NN B-INTV
( ( I-INTV
HU NNP I-INTV
) ) I-INTV
for IN O
the DT O
outcome NN O
of IN O
IFN NNP B-INTV
therapy NN I-INTV
, , O
we PRP O
conducted VBD O
a DT O
randomized JJ O
trial NN O
to TO O
compare VB B-INTV
the DT I-INTV
combination NN I-INTV
of IN I-INTV
IFN NNP I-INTV
and CC I-INTV
HU NNP I-INTV
vs VBP I-INTV
HU NNP I-INTV
monotherapy NN I-INTV
( ( I-INTV
CML-study NNP I-INTV
II NNP I-INTV
) ) I-INTV
. . O

From IN B-POPU
February NNP I-POPU
1991 CD I-POPU
to TO I-POPU
December NNP I-POPU
1994 CD I-POPU
, , I-POPU
376 CD I-POPU
patients NNS I-POPU
with IN I-POPU
newly RB I-POPU
diagnosed VBN I-POPU
CML NNP I-POPU
in IN I-POPU
chronic JJ I-POPU
phase NN I-POPU
were VBD O
randomized VBN O
. . O

In IN O
all DT O
, , O
340 CD B-POPU
patients NNS I-POPU
were VBD I-POPU
Ph/BCR-ABL NNP I-POPU
positive JJ I-POPU
and CC I-POPU
evaluable JJ I-POPU
. . O

Randomization NN O
was VBD O
unbalanced JJ O
1:2 CD O
in IN O
favor NN O
of IN O
the DT O
combination NN O
therapy NN O
, , O
since IN O
study NN O
conditions NNS O
were VBD O
identical JJ O
to TO O
the DT O
previous JJ O
CML-study NNP O
I PRP O
and CC O
it PRP O
had VBD O
been VBN O
planned VBN O
in IN O
advance NN O
to TO O
add VB O
the DT O
HU NNP O
patients NNS O
of IN O
study NN O
I PRP O
( ( O
n=194 RB O
) ) O
to TO O
the DT O
HU NNP O
control NN O
group NN O
. . O

Therefore RB O
, , O
a DT B-POPU
total NN I-POPU
of IN I-POPU
534 CD I-POPU
patients NNS I-POPU
were VBD I-POPU
evaluable JJ I-POPU
( ( I-POPU
226 CD I-POPU
patients NNS I-POPU
with IN I-POPU
IFN/HU NNP I-POPU
and CC I-POPU
308 CD I-POPU
patients NNS I-POPU
with IN I-POPU
HU NNP I-POPU
) ) I-POPU
. . O

Analyses NNS O
were VBD O
according VBG O
to TO O
intention-to-treat NN O
. . O

Median JJ O
observation NN O
time NN O
of IN O
nontransplanted JJ B-POPU
living NN I-POPU
patients NNS I-POPU
was VBD O
7.6 CD O
years NNS O
( ( O
7.9 CD O
years NNS O
for IN O
IFN/HU NNP O
and CC O
7.3 CD O
years NNS O
for IN O
HU NNP O
) ) O
. . O

The DT O
risk NN O
profile NN O
( ( O
new JJ O
CML NNP O
score NN O
) ) O
was VBD O
available JJ O
for IN O
532 CD O
patients NNS O
: : O
200 CD O
patients NNS O
( ( O
38 CD O
% NN O
) ) O
were VBD O
low JJ O
, , O
239 CD O
patients NNS O
( ( O
45 CD O
% NN O
) ) O
intermediate NN O
, , O
and CC O
93 CD O
patients NNS O
( ( O
17 CD O
% NN O
) ) O
high JJ O
risk NN O
. . O

Complete NNP B-OC
hematologic JJ I-OC
response NN I-OC
rates NNS I-OC
were VBD O
higher JJR O
in IN O
IFN/HU-treated JJ O
patients NNS O
( ( O
59 CD O
vs RB O
32 CD O
% NN O
) ) O
. . O

Of IN O
169 CD O
evaluable JJ O
IFN/HU-treated JJ O
patients NNS O
( ( O
75 CD O
% NN O
) ) O
, , O
104 CD O
patients NNS O
( ( O
62 CD O
% NN O
) ) O
achieved VBD O
a DT O
cytogenetic JJ B-OC
response NN I-OC
that WDT O
was VBD O
complete JJ O
in IN O
12 CD O
% NN O
( ( O
n=21 JJ O
) ) O
, , O
major JJ O
in IN O
14 CD O
% NN O
( ( O
n=24 JJ O
) ) O
, , O
and CC O
at IN O
least JJS O
minimal JJ O
in IN O
35 CD O
% NN O
( ( O
n=59 JJ O
) ) O
. . O

Of IN O
the DT O
534 CD B-POPU
patients NNS I-POPU
, , O
105 CD O
( ( O
20 CD O
% NN O
) ) O
underwent NN O
allogeneic JJ O
stem NN O
cell NN O
transplantation NN O
in IN O
first JJ O
chronic JJ O
phase NN O
. . O

In IN O
the DT O
low-risk JJ O
group NN O
, , O
65 CD O
of IN O
200 CD O
patients NNS O
were VBD O
transplanted VBN O
( ( O
33 CD O
% NN O
) ) O
, , O
30 CD O
( ( O
13 CD O
% NN O
) ) O
in IN O
the DT O
intermediate-risk JJ O
group NN O
, , O
and CC O
nine CD O
( ( O
10 CD O
% NN O
) ) O
in IN O
the DT O
high-risk JJ O
group NN O
. . O

Duration NN B-OC
of IN I-OC
chronic JJ I-OC
phase NN I-OC
was VBD O
55 CD O
months NNS O
for IN O
IFN/HU NNP O
and CC O
41 CD O
months NNS O
for IN O
HU NNP O
( ( O
P NNP O
< NNP O
0.0001 CD O
) ) O
. . O

Median JJ B-OC
survival NN I-OC
was VBD O
64 CD O
months NNS O
for IN O
IFN/HU NNP O
and CC O
53 CD O
months NNS O
for IN O
HU-treated JJ O
patients NNS O
( ( O
P=0.0063 NNP O
) ) O
. . O

We PRP O
conclude VBP O
that DT O
IFN NNP O
in IN O
combination NN O
with IN O
HU NNP O
achieves VBZ O
a DT O
significant JJ O
long-term JJ O
survival NN O
advantage NN O
over IN O
HU NNP O
monotherapy NN O
. . O

In IN O
view NN O
of IN O
the DT O
data NNS O
of IN O
CML-study NNP O
I PRP O
, , O
these DT O
results NNS O
suggest VBP O
that IN O
IFN/HU NNP O
is VBZ O
also RB O
superior JJ O
to TO O
IFN NNP O
alone RB O
. . O

HU NNP O
should MD O
be VB O
combined VBN O
with IN O
IFN NNP O
in IN O
IFN-based JJ O
therapies NNS O
and CC O
for IN O
comparisons NNS O
with IN O
new JJ O
therapies NNS O
. . O

-DOCSTART- -X- O O

Prospective NNP O
randomised VBD O
study NN O
of IN O
double JJ O
hemi-body JJ B-INTV
irradiation NN I-INTV
with IN O
and CC O
without IN O
subsequent JJ O
maintenance NN O
recombinant NN B-INTV
alpha VBD I-INTV
2b CD I-INTV
interferon NN I-INTV
on IN O
survival NN B-OC
in IN O
patients NNS B-POPU
with IN I-POPU
relapsed JJ I-POPU
multiple JJ I-POPU
myeloma NN I-POPU
. . O

Immediately RB O
before IN O
first JJ O
hemi-body NN O
irradiation NN O
, , O
59 CD B-POPU
patients NNS I-POPU
with IN I-POPU
relapsed JJ I-POPU
multiple JJ I-POPU
myeloma NN I-POPU
were VBD O
randomised VBN O
to TO O
receive VB O
or CC O
not RB O
to TO O
receive VB O
subsequent JJ O
alpha-2b JJ B-INTV
interferon NN I-INTV
maintenance NN I-INTV
. . O

13 CD O
patients NNS O
( ( O
22 CD O
% NN O
) ) O
[ VBZ O
8 CD O
of IN O
31 CD O
( ( O
26 CD O
% NN O
) ) O
controls VBZ O
, , O
5 CD O
of IN O
28 CD O
( ( O
18 CD O
% NN O
) ) O
in IN O
the DT O
interferon NN O
arm NN O
] NN O
received VBD O
single JJ B-INTV
hemi-body JJ I-INTV
irradiation NN I-INTV
alone RB I-INTV
due JJ O
to TO O
progressive JJ O
disease NN O
and/or JJ O
persistent JJ B-INTV
cytopoenias NN I-INTV
following VBG O
the DT O
initial JJ O
procedure NN O
. . O

Mean JJ O
time NN O
between IN O
upper JJ O
and CC O
lower JJR O
hemi-body NN O
irradiation NN O
was VBD O
69 CD O
days NNS O
( ( O
range VB O
35-294 NNP O
) ) O
. . O

Of IN O
23 CD O
patients NNS O
randomised VBN O
to TO O
receive VB O
interferon NN O
and CC O
completing VBG O
double JJ O
hemi-body JJ O
irradiation NN O
, , O
15 CD O
( ( O
65 CD O
% NN O
) ) O
achieved VBD O
peripheral JJ B-OC
blood NN I-OC
counts NNS I-OC
adequate VBP O
to TO O
allow VB O
interferon JJ O
administration NN O
as IN O
per IN O
study NN O
criteria NNS O
commencing VBG O
at IN O
a DT O
mean JJ O
116 CD O
days NNS O
( ( O
61-241 JJ O
) ) O
from IN O
time NN O
of IN O
study NN O
entry NN O
. . O

The DT O
mean JJ O
period NN O
of IN O
interferon NN B-INTV
therapy NN I-INTV
, , O
starting VBG O
at IN O
a DT O
mean JJ O
65 CD O
days NNS O
( ( O
26-160 JJ O
) ) O
post NN O
second JJ O
hemi-body NN O
irradiation NN O
, , O
is VBZ O
16.4 CD O
months NNS O
( ( O
2-33.5 JJ O
) ) O
. . O

There EX O
was VBD O
no DT O
significant JJ O
difference NN O
in IN O
median JJ B-OC
survival NN I-OC
durations NNS I-OC
( ( O
10 CD O
months NNS O
) ) O
from IN O
time NN O
of IN O
initial JJ O
radiotherapy NN O
between IN O
control NN B-POPU
and CC I-POPU
interferon NN I-POPU
patients NNS I-POPU
. . O

-DOCSTART- -X- O O

Predicting VBG O
the DT O
costs NNS B-OC
of IN O
allogeneic JJ B-POPU
sibling VBG I-POPU
stem-cell JJ I-POPU
transplantation NN I-POPU
: : I-POPU
results NNS O
from IN O
a DT O
prospective JJ O
, , O
multicenter NN O
, , O
French JJ B-POPU
study NN I-POPU
. . O

BACKGROUND NNP O
Allogeneic NNP B-INTV
hematopoietic JJ I-INTV
stem-cell NN I-INTV
transplantation NN I-INTV
is VBZ O
a DT O
widely RB O
used VBN O
, , O
cost-intensive JJ O
procedure NN O
. . O

Our PRP$ O
purpose NN O
was VBD O
to TO O
estimate VB O
costs NNS B-OC
and CC O
determine VB O
cost NN B-OC
predictors NNS I-OC
. . O

METHODS NNP O
We PRP O
used VBD O
data NNS B-INTV
from IN I-INTV
a DT I-INTV
prospective JJ B-POPU
French JJ I-POPU
study NN I-POPU
comparing VBG I-POPU
four CD I-POPU
doses NNS I-POPU
of IN I-POPU
immunoglobulins NNS I-POPU
. . O

Resource NNP O
use NN O
of IN O
hematopoietic JJ B-POPU
stem-cell NN I-POPU
transplant NN I-POPU
recipients NNS I-POPU
during IN O
the DT O
first JJ O
6 CD O
months NNS O
posttransplant JJ O
, , O
both DT O
inpatient NN O
and CC O
ambulatory NN O
costs NNS O
, , O
in IN O
85 CD B-POPU
patients NNS I-POPU
from IN I-POPU
five CD I-POPU
centers NNS I-POPU
were VBD I-POPU
collected VBN I-POPU
prospectively RB I-POPU
and CC I-POPU
costed VBN I-POPU
. . O

Baseline NNP O
data NN O
and CC O
clinical JJ O
events NNS O
were VBD O
retrieved VBN O
. . O

Protocol-driven JJ O
costs NNS O
were VBD O
excluded VBN O
. . O

Multivariable JJ B-OC
analysis NN I-OC
evaluated VBD O
the DT O
association NN O
between IN O
costs NNS B-OC
and CC I-OC
patient NN B-POPU
's POS I-POPU
pretransplant JJ I-POPU
status NN I-POPU
and CC I-POPU
transplant-related JJ I-POPU
complications NNS I-POPU
. . O

Because IN O
of IN O
the DT O
absence NN O
of IN O
differences NNS O
in IN O
outcome NN O
among IN O
the DT O
four CD O
randomization NN O
groups NNS O
, , O
cost NN B-OC
data NNS I-OC
for IN O
all DT O
patients NNS O
were VBD O
pooled VBN O
. . O

RESULTS NNP O
Total JJ B-OC
costs NNS I-OC
per IN O
patient NN O
were VBD O
the DT O
following JJ O
: : O
mean JJ O
76,237 CD O
Euros NNP O
; : O
standard JJ O
deviation NN O
32,565 CD O
Euros NNP O
; : O
median JJ O
69,516 CD O
Euros NNPS O
; : O
range VB O
183,758 CD O
to TO O
14,761Euros CD O
. . O

The DT O
major JJ O
cost NN O
driver NN O
was VBD O
hospital JJ O
days NNS O
. . O

No DT O
association NN O
was VBD O
found VBN O
between IN O
costs NNS B-OC
and CC I-OC
baseline NN I-OC
status NN I-OC
. . O

The DT O
" JJ O
predictors NNS O
" CD O
of IN O
higher JJR O
costs NNS O
( ( O
adding VBG O
an DT O
average JJ O
20,000 CD O
Euros/patient NN O
) ) O
were VBD O
the DT O
occurrence NN O
of IN O
transplant-related JJ B-OC
complications NNS I-OC
: : I-OC
graft-versus-host JJ O
disease NN O
and CC O
repeated VBD B-OC
infections NNS I-OC
that WDT O
were VBD O
unpredictable JJ O
before RB O
transplant NN O
in IN O
this DT O
homogeneous JJ B-POPU
group NN I-POPU
of IN I-POPU
patients NNS I-POPU
. . O

CONCLUSION NNP O
Our PRP$ O
data NNS O
highlight VBD O
the DT O
discrepancy NN O
between IN O
the DT O
Diagnosis NNP O
Related NNP O
Group NNP O
prospective JJ O
payment NN O
system NN O
and CC O
actual JJ B-OC
costs NNS I-OC
. . O

The DT O
actual JJ B-OC
cost NN I-OC
of IN O
geno-identical JJ O
stem-cell JJ O
transplantation NN O
results NNS O
from IN O
posttransplant JJ O
complications NNS O
that WDT O
can MD O
not RB O
be VB O
predicted VBN O
prospectively RB O
and CC O
require VB O
ex NN O
post NN O
cost NN O
adjustment NN O
. . O

-DOCSTART- -X- O O

Low-dose JJ B-INTV
oral JJ I-INTV
etoposide-based JJ I-INTV
induction NN O
regimen NNS O
for IN O
children NNS B-POPU
with IN I-POPU
acute JJ I-POPU
lymphoblastic JJ I-POPU
leukemia NN I-POPU
in IN I-POPU
first JJ I-POPU
bone NN I-POPU
marrow NN I-POPU
relapse NN I-POPU
. . O

We PRP O
evaluated VBD O
the DT O
clinical JJ B-OC
response NN I-OC
to TO O
low-dose JJ B-INTV
etoposide NN I-INTV
in IN O
relapsed JJ B-POPU
acute NN I-POPU
lymphoblastic JJ I-POPU
leukemia NN I-POPU
( ( I-POPU
ALL DT I-POPU
) ) I-POPU
. . O

Of IN O
the DT O
45 CD B-POPU
patients NNS I-POPU
with IN I-POPU
ALL NNP I-POPU
in IN I-POPU
first JJ I-POPU
bone NN I-POPU
marrow NN I-POPU
relapse NN I-POPU
enrolled VBD I-POPU
on IN O
the DT O
ALL NNP O
R15 NNP O
protocol NN O
, , O
44 CD O
had VBD O
received VBN O
epipodophyllotoxins NNS B-INTV
during IN I-INTV
frontline JJ I-INTV
therapy NN I-INTV
. . O

In IN O
the DT O
first JJ O
week NN O
of IN O
remission NN O
induction NN O
therapy NN O
, , O
patients NNS B-INTV
received VBD I-INTV
etoposide RB I-INTV
( ( I-INTV
50 CD I-INTV
mg/m NN I-INTV
( ( I-INTV
2 CD I-INTV
) ) I-INTV
per IN I-INTV
day NN I-INTV
) ) I-INTV
administered VBD I-INTV
orally RB I-INTV
as IN I-INTV
a DT I-INTV
single JJ I-INTV
agent NN I-INTV
once RB I-INTV
or CC I-INTV
twice RB I-INTV
daily RB I-INTV
. . O

On IN O
Day NNP O
8 CD O
, , O
patients NNS O
started VBD O
to TO O
receive VB O
dexamethasone NN B-INTV
, , I-INTV
vincristine NN I-INTV
, , I-INTV
and CC I-INTV
L-asparaginase NNP I-INTV
. . O

Etoposide NNP B-INTV
was VBD I-INTV
administered VBN I-INTV
until IN I-INTV
Day NNP I-INTV
22 CD I-INTV
. . O

Two CD B-INTV
courses NNS I-INTV
of IN I-INTV
consolidation NN I-INTV
therapy NN I-INTV
were VBD I-INTV
followed VBN I-INTV
by IN I-INTV
continuation NN I-INTV
therapy NN I-INTV
or CC I-INTV
hematopoietic JJ I-INTV
stem NN I-INTV
cell NN I-INTV
transplantation NN I-INTV
. . O

After IN O
7 CD O
days NNS O
of IN O
single-agent JJ O
etoposide NN O
treatment NN O
, , O
peripheral JJ B-OC
blast NN I-OC
cell NN I-OC
counts NNS I-OC
( ( O
P=0.013 NNP O
) ) O
and CC O
percentages NNS B-OC
of IN I-OC
bone NN I-OC
marrow NN I-OC
blasts NNS I-OC
( ( O
P=0.016 NNP O
) ) O
were VBD O
significantly RB O
reduced VBN O
. . O

In IN O
all DT O
, , O
38 CD O
( ( O
84.4 CD O
% NN O
) ) O
attained VBD O
second JJ B-OC
remission NN I-OC
. . O

Only RB O
time NN B-OC
to TO I-OC
relapse VB I-OC
was VBD O
significantly RB O
associated VBN O
with IN O
outcome NN O
( ( O
P=0.025 NNP O
) ) O
: : O
the DT O
5-year JJ B-OC
event-free JJ I-OC
survival NN I-OC
estimates NNS O
( ( O
+/-se JJ O
) ) O
were VBD O
52.0+/-9.6 JJ O
% NN O
for IN O
those DT O
with IN O
late JJ O
relapse NN O
and CC O
20.0+/-8.0 JJ O
% NN O
for IN O
those DT O
with IN O
early JJ O
relapse NN O
. . O

We PRP O
conclude VBP O
that IN O
low-dose JJ B-INTV
etoposide NN I-INTV
administered VBN O
orally RB O
has VBZ O
a DT O
cytoreductive JJ O
effect NN O
in IN O
relapsed VBN O
ALL NNP O
. . O

-DOCSTART- -X- O O

Long-term JJ O
follow-up NN O
of IN O
a DT O
randomized JJ O
trial NN O
of IN O
fludarabine-mitoxantrone NN B-INTV
, , O
compared VBN O
with IN O
cyclophosphamide NN B-INTV
, , I-INTV
doxorubicin NN I-INTV
, , I-INTV
vindesine NN I-INTV
, , I-INTV
prednisone NN I-INTV
( ( I-INTV
CHVP NNP I-INTV
) ) I-INTV
, , O
as IN O
first-line JJ O
treatment NN O
of IN O
elderly JJ B-POPU
patients NNS I-POPU
with IN I-POPU
advanced JJ I-POPU
, , I-POPU
low-grade JJ I-POPU
non-Hodgkin NN I-POPU
's POS I-POPU
lymphoma NN I-POPU
before IN I-POPU
the DT I-POPU
era NN I-POPU
of IN I-POPU
monoclonal JJ I-POPU
antibodies NNS I-POPU
. . O

BACKGROUND NNP O
This DT O
randomized VBN O
study NN O
compared VBN O
the DT O
efficacy NN B-OC
and CC I-OC
safety NN I-OC
of IN O
fludarabine-mitoxantrone NN B-INTV
( ( I-INTV
FM NNP I-INTV
) ) I-INTV
with IN I-INTV
mini-CHVP NN I-INTV
( ( I-INTV
cyclophosphamide NN I-INTV
, , I-INTV
doxorubicin NN I-INTV
, , I-INTV
vindesine NN I-INTV
, , I-INTV
prednisone NN I-INTV
) ) I-INTV
in IN O
elderly JJ B-POPU
patients NNS I-POPU
with IN I-POPU
advanced JJ I-POPU
, , I-POPU
low-grade JJ I-POPU
non-Hodgkin NN I-POPU
's POS I-POPU
lymphoma NN I-POPU
. . O

PATIENTS NNP O
AND CC O
METHODS NNP O
End NNP O
points NNS O
were VBD O
remission JJ B-OC
rates NNS I-OC
[ VBP I-OC
overall JJ I-OC
response NN I-OC
( ( I-OC
OR NNP I-OC
) ) I-OC
and CC I-OC
complete JJ I-OC
response NN I-OC
( ( I-OC
CR NNP I-OC
) ) I-OC
] NN I-OC
, , I-OC
failure-free JJ I-OC
survival NN I-OC
( ( I-OC
FFS NNP I-OC
) ) I-OC
, , I-OC
survival JJ I-OC
and CC I-OC
toxicity NN I-OC
. . O

One CD B-POPU
hundred CD I-POPU
and CC I-POPU
fifty-five JJ I-POPU
patients NNS I-POPU
were VBD I-POPU
randomized VBN I-POPU
, , I-POPU
144 CD I-POPU
were VBD I-POPU
evaluable JJ I-POPU
for IN I-POPU
safety NN I-POPU
and CC I-POPU
142 CD I-POPU
for IN I-POPU
response NN I-POPU
. . O

Each DT O
treatment NN O
arm NN O
was VBD O
given VBN O
as IN O
six CD O
monthly JJ O
cycles NNS O
, , O
followed VBN O
by IN O
three CD O
bimonthly JJ O
cycles NNS O
. . O

FM NNP O
comprised VBD O
fludarabine NN B-INTV
( ( O
20 CD O
mg/m NN O
( ( O
2 CD O
) ) O
i.v NN O
. . O

) ) O
, , O
days NNS O
1-5 CD O
, , O
plus CC O
mitoxantrone NN B-INTV
( ( O
10 CD O
mg/m NN O
( ( O
2 CD O
) ) O
i.v NN O
. . O

) ) O
, , O
day NN O
1 CD O
. . O

CHVP NNP O
cycles NNS O
comprised VBD O
cyclophosphamide NN B-INTV
( ( O
750 CD O
mg/m NN O
( ( O
2 CD O
) ) O
i.v NN O
. . O

infusion NN O
) ) O
, , O
doxorubicin NN B-INTV
( ( O
25 CD O
mg/m NN O
( ( O
2 CD O
) ) O
i.v NN O
. . O

) ) O
and CC O
vindesine NN B-INTV
( ( O
3 CD O
mg/m NN O
( ( O
2 CD O
) ) O
i.v NN O
. . O

) ) O
on IN O
day NN O
1 CD O
, , O
and CC O
prednisone NN B-INTV
( ( O
50 CD O
mg/m NN O
( ( O
2 CD O
) ) O
) ) O
on IN O
days NNS O
1-5 JJ O
. . O

RESULTS NNP O
FM NNP B-INTV
therapy NN O
resulted VBD O
in IN O
superior JJ O
remission NN B-OC
rates NNS I-OC
( ( O
OR CC O
81 CD O
% NN O
versus IN O
64 CD O
% NN O
, , O
CR NNP O
49 CD O
% NN O
versus IN O
17 CD O
% NN O
; : O
P NNP O
= NNP O
0.0004 CD O
) ) O
. . O

Median JJ B-OC
FFS NNP I-OC
for IN O
FM NNP B-INTV
patients NNS O
was VBD O
36 CD O
months NNS O
, , O
compared VBN O
with IN O
19 CD O
months NNS O
for IN O
CHVP NNP O
patients NNS O
, , O
and CC O
has VBZ O
not RB O
yet RB O
been VBN O
reached VBN O
for IN O
early JJ O
CR NNP O
patients NNS O
at IN O
53 CD O
months NNS O
. . O

Treatment NNP O
arm NN O
was VBD O
the DT O
major JJ O
risk NN O
factor NN O
influencing VBG O
survival NN B-OC
. . O

Both DT O
treatments NNS O
were VBD O
well RB O
tolerated VBN B-OC
, , O
with IN O
only RB O
few JJ O
infectious JJ B-OC
complications NNS I-OC
. . O

CONCLUSION NNP O
FM NNP B-INTV
was VBD O
more RBR O
effective JJ B-OC
than IN O
CHVP NNP O
in IN O
achieving VBG O
OR NNP B-OC
and CC I-OC
CR NNP I-OC
, , O
and CC O
favorably RB O
affected VBD O
the DT O
outcome NN O
. . O

-DOCSTART- -X- O O

Prospective JJ O
randomised VBD O
trial NN O
of IN O
amifostine JJ B-INTV
cytoprotection NN I-INTV
in IN O
myeloma NN B-POPU
patients NNS I-POPU
undergoing VBG I-POPU
high-dose JJ I-POPU
melphalan NN I-POPU
conditioned VBN I-POPU
autologous JJ I-POPU
stem NN I-POPU
cell NN I-POPU
transplantation NN I-POPU
. . O

In IN O
this DT O
prospective JJ O
multicentre NN O
trial NN O
, , O
90 CD B-POPU
patients NNS I-POPU
undergoing VBG I-POPU
autologous JJ I-POPU
stem NN I-POPU
cell NN I-POPU
transplantation NN I-POPU
( ( I-POPU
ASCT NNP I-POPU
) ) I-POPU
were VBD I-POPU
randomised VBN I-POPU
to TO O
receive VB O
( ( O
n=43 NN O
) ) O
or CC O
not RB O
receive JJ O
( ( O
n=47 JJ O
) ) O
amifostine VBP B-INTV
910 CD I-INTV
mg/m NN I-INTV
( ( I-INTV
2 CD I-INTV
) ) I-INTV
prior RB I-INTV
to TO I-INTV
melphalan VB I-INTV
200 CD I-INTV
mg/m NN I-INTV
( ( I-INTV
2 CD I-INTV
) ) I-INTV
. . O

Patients NNS O
were VBD O
monitored VBN O
for IN O
regimen-related JJ B-OC
toxicity NN I-OC
, , I-OC
engraftment NN I-OC
, , I-OC
supportive JJ I-OC
care NN I-OC
, , I-OC
response NN I-OC
and CC I-OC
survival NN I-OC
. . O

Both DT B-POPU
groups NNS I-POPU
underwent VBD O
ASCT NNP B-INTV
at IN O
a DT O
median NN O
of IN O
8 CD O
months NNS O
from IN O
diagnosis NN O
and CC O
were VBD O
matched VBN O
for IN O
disease NN O
characteristics NNS O
, , O
prior JJ O
therapy NN O
and CC O
pre-ASCT JJ O
disease NN O
responsiveness NN O
. . O

Amifostine NNP B-INTV
infusional JJ O
side-effects NNS O
were VBD O
frequent JJ O
, , O
occurring VBG O
in IN O
65 CD O
% NN O
of IN O
patients NNS O
, , O
but CC O
of IN O
mild JJ O
severity NN O
. . O

Amifostine NNP B-INTV
use NN O
was VBD O
associated VBN O
with IN O
a DT O
reduction NN B-OC
in IN O
the DT O
median JJ B-OC
grade NN I-OC
of IN I-OC
oral JJ I-OC
mucositis NN I-OC
( ( O
1 CD O
vs NN O
2 CD O
, , O
P=0.01 NNP O
) ) O
and CC O
the DT O
frequency NN B-OC
of IN I-OC
severe JJ I-OC
( ( I-OC
WHO NNP I-OC
grades VBZ I-OC
3 CD I-OC
or CC I-OC
4 CD I-OC
) ) I-OC
mucositis NN I-OC
( ( O
12 CD O
vs RB O
33 CD O
% NN O
, , O
P=0.02 NNP O
) ) O
, , O
but CC O
no DT O
reduction NN O
in IN O
the DT O
requirement NN O
for IN O
parenteral JJ O
nutrition NN O
or CC O
analgesic JJ O
use NN O
. . O

Conversion NN O
to TO O
complete VB O
remission NN O
post-ASCT NN B-OC
occurred VBD O
in IN O
30 CD O
and CC O
14 CD O
% NN O
of IN O
the DT O
amifostine NN B-INTV
and CC O
control NN O
groups NNS O
, , O
respectively RB O
( ( O
P=0.09 NNP O
) ) O
. . O

With IN O
a DT O
median JJ O
follow-up NN O
of IN O
35 CD O
months NNS O
, , O
there EX O
was VBD O
no DT O
statistically RB O
significant JJ O
difference NN O
between IN O
the DT O
median JJ B-OC
progression-free NN I-OC
or CC I-OC
overall JJ I-OC
survival NN I-OC
times NNS I-OC
for IN O
the DT O
two CD O
groups NNS O
. . O

We PRP O
conclude VBP O
that IN O
amifostine NN B-INTV
can MD O
be VB O
safely RB O
administered VBN O
prior RB O
to TO O
high-dose JJ O
melphalan NN O
and CC O
significantly RB O
reduces VBZ O
the DT O
frequency NN B-OC
and CC I-OC
severity NN I-OC
of IN I-OC
therapy-induced JJ I-OC
oral JJ I-OC
mucositis NN I-OC
. . O

-DOCSTART- -X- O O

DNA NN O
as IN O
a DT O
carrier NN O
for IN O
anthracyclines NNS B-INTV
in IN O
the DT O
treatment NN B-POPU
of IN I-POPU
acute JJ I-POPU
myelocytic JJ I-POPU
leukemia NN I-POPU
( ( I-POPU
AML NNP I-POPU
) ) I-POPU
. . O

-DOCSTART- -X- O O

POG JJ O
8625 CD O
: : O
a DT O
randomized JJ O
trial NN O
comparing VBG O
chemotherapy NN B-INTV
with IN O
chemoradiotherapy NN B-POPU
for IN I-POPU
children NNS I-POPU
and CC I-POPU
adolescents NNS I-POPU
with IN I-POPU
Stages NNP I-POPU
I PRP I-POPU
, , I-POPU
IIA NNP I-POPU
, , I-POPU
IIIA1 NNP I-POPU
Hodgkin NNP I-POPU
Disease NNP I-POPU
: : I-POPU
a DT O
report NN O
from IN O
the DT O
Children NNP O
's POS O
Oncology NNP O
Group NNP O
. . O

To TO O
determine VB O
if IN O
6 CD O
courses NNS O
of IN O
chemotherapy NN B-INTV
alone RB O
could MD O
achieve VB O
the DT O
same JJ O
or CC O
better JJR O
outcome NN O
than IN O
4 CD O
courses NNS O
of IN O
chemotherapy NN B-INTV
followed VBN I-INTV
by IN I-INTV
radiation NN I-INTV
therapy NN I-INTV
( ( I-INTV
chemoradiotherapy NN I-INTV
) ) I-INTV
in IN O
pediatric JJ B-POPU
and CC I-POPU
adolescent JJ I-POPU
patients NNS I-POPU
with IN I-POPU
Hodgkin NNP I-POPU
disease NN I-POPU
. . O

Children NNP B-POPU
< VBD I-POPU
or CC I-POPU
=21 CD I-POPU
years NNS I-POPU
old JJ I-POPU
with IN I-POPU
biopsy-proven JJ I-POPU
, , I-POPU
pathologically RB I-POPU
staged VBD I-POPU
I PRP I-POPU
, , I-POPU
IIA NNP I-POPU
, , I-POPU
or CC I-POPU
IIIA1 NNP I-POPU
Hodgkin NNP I-POPU
disease NN I-POPU
were VBD O
randomly RB O
assigned VBN O
6 CD O
courses NNS O
of IN O
alternating VBG B-INTV
nitrogen JJ I-INTV
mustard NN I-INTV
, , I-INTV
oncovin NN I-INTV
, , I-INTV
prednisone NN I-INTV
, , I-INTV
and CC I-INTV
procarbazine/doxorubicin NN I-INTV
, , I-INTV
bleomycin NN I-INTV
, , I-INTV
vinblastine NN I-INTV
, , I-INTV
and CC I-INTV
dacarbazine NN I-INTV
( ( I-INTV
treatment NN I-INTV
1 CD I-INTV
) ) I-INTV
or CC O
4 CD B-INTV
courses NNS I-INTV
of IN I-INTV
alternating VBG I-INTV
nitrogen JJ I-INTV
mustard NN I-INTV
, , I-INTV
oncovin NN I-INTV
, , I-INTV
prednisone NN I-INTV
, , I-INTV
and CC I-INTV
procarbazine/doxorubicin NN I-INTV
, , I-INTV
bleomycin NN I-INTV
, , I-INTV
vinblastine NN I-INTV
, , I-INTV
and CC I-INTV
dacarbazine VB I-INTV
+2550 JJ I-INTV
cGy JJ I-INTV
involved-field JJ I-INTV
radiotherapy NN I-INTV
( ( I-INTV
treatment NN I-INTV
2 CD I-INTV
) ) I-INTV
. . O

The DT O
complete JJ O
response NN O
rate NN O
was VBD O
89 CD O
% NN O
, , O
with IN O
a DT O
complete JJ O
response NN O
and CC O
partial JJ O
response NN O
rate NN O
of IN O
99.4 CD O
% NN O
. . O

There EX O
was VBD O
no DT O
statistically RB O
significant JJ O
difference NN O
in IN O
event-free JJ B-OC
survival NN I-OC
( ( I-OC
EFS NNP I-OC
) ) I-OC
or CC I-OC
overall JJ I-OC
survival NN I-OC
between IN O
arms NNS O
. . O

The DT O
EFS NNP B-OC
for IN O
those DT O
who WP O
achieved VBD O
an DT O
early JJ O
complete JJ B-OC
response NN I-OC
was VBD O
significantly RB O
higher JJR O
than IN O
for IN O
those DT O
who WP O
did VBD O
not RB O
. . O

For IN O
pediatric JJ B-POPU
patients NNS I-POPU
with IN I-POPU
asymptomatic JJ I-POPU
low-stage NN I-POPU
and CC I-POPU
intermediate-stage NN I-POPU
Hodgkin NNP I-POPU
disease NN I-POPU
, , O
chemotherapy NN B-INTV
and CC O
chemoradiotherapy VB B-INTV
both DT O
resulted VBN O
in IN O
3-year JJ B-OC
EFS NNP I-OC
of IN O
approximately RB O
90 CD O
% NN O
and CC O
statistically RB O
indistinguishable JJ O
8-year JJ B-OC
EFS NNP I-OC
and CC O
overall JJ B-OC
survival NN I-OC
, , O
without IN O
significant JJ O
long-term JJ B-OC
toxicity NN I-OC
. . O

Early JJ O
response NN B-OC
to TO I-OC
therapy NN I-OC
was VBD O
associated VBN O
with IN O
higher JJR O
EFS NNP B-OC
, , O
a DT O
concept NN O
that WDT O
has VBZ O
led VBN O
to TO O
the DT O
Children NNP O
's POS O
Oncology NNP O
Group NNP O
paradigm NN O
of IN O
response-based JJ O
risk-adapted JJ O
therapy NN O
for IN O
pediatric JJ O
Hodgkin NNP O
disease NN O
. . O

-DOCSTART- -X- O O

Long-term JJ B-OC
results NNS I-OC
of IN O
the DT O
MRC NNP B-POPU
AML10 NNP I-POPU
trial NN I-POPU
. . O

-DOCSTART- -X- O O

Toxicity NN B-OC
and CC I-OC
efficacy NN I-OC
of IN O
6-thioguanine JJ B-INTV
versus NN I-INTV
6-mercaptopurine JJ I-INTV
in IN O
childhood NN B-POPU
lymphoblastic JJ I-POPU
leukaemia NN I-POPU
: : I-POPU
a DT O
randomised JJ O
trial NN O
. . O

BACKGROUND NNP O
6-mercaptopurine JJ B-INTV
has VBZ O
been VBN O
a DT O
standard JJ O
component NN O
of IN O
long-term JJ O
continuing VBG O
treatment NN O
for IN O
childhood NN B-POPU
lymphoblastic JJ I-POPU
leukaemia NN I-POPU
, , O
whereas JJ O
6-thioguanine NN B-INTV
has VBZ O
been VBN O
mainly RB O
used VBN O
for IN O
intensification NN O
courses NNS O
. . O

Since IN O
preliminary JJ O
data NNS O
have VBP O
shown VBN O
that IN O
6-thioguanine JJ B-INTV
is VBZ O
more RBR O
effective JJ O
than IN O
6-mercaptopurine JJ B-INTV
, , O
we PRP O
compared VBN O
the DT O
efficacy NN B-OC
and CC I-OC
toxicity NN I-OC
of IN O
the DT O
two CD O
drugs NNS O
for IN O
childhood NN B-POPU
lymphoblastic JJ I-POPU
leukaemia NN I-POPU
. . O

METHODS NNP O
Consecutive JJ B-POPU
children NNS I-POPU
with IN I-POPU
lymphoblastic JJ I-POPU
leukaemia NN I-POPU
diagnosed VBN I-POPU
in IN I-POPU
the DT I-POPU
UK NNP I-POPU
and CC I-POPU
Ireland NNP I-POPU
between IN I-POPU
April NNP I-POPU
, , I-POPU
1997 CD I-POPU
, , I-POPU
and CC I-POPU
June NNP I-POPU
, , I-POPU
2002 CD I-POPU
, , O
were VBD O
randomly RB O
assigned VBN O
either CC O
6-thioguanine JJ B-INTV
( ( I-INTV
750 CD I-INTV
patients NNS O
) ) O
or CC O
6-mercaptopurine JJ B-INTV
( ( O
748 CD O
patients NNS O
) ) O
during IN O
interim JJ O
maintenance NN O
and CC O
continuing VBG O
therapy NN O
. . O

All DT O
patients NNS O
received VBD O
6-thioguanine JJ B-INTV
during IN O
intensification NN O
courses NNS O
. . O

We PRP O
analysed VBD O
event-free JJ B-OC
and CC I-OC
overall JJ I-OC
survival NN I-OC
on IN O
an DT O
intention-to-treat JJ O
basis NN O
. . O

We PRP O
obtained VBD O
toxicity NN B-OC
data NNS O
using VBG O
an DT O
adverse-event JJ O
reporting NN O
system NN O
, , O
with IN O
follow-up JJ O
questionnaires NNS O
to TO O
seek VB O
detailed JJ O
information NN O
for IN O
specific JJ O
toxicities NNS O
. . O

This DT O
trial NN O
is VBZ O
registered VBN O
with IN O
the DT O
International NNP O
Standard NNP O
Randomised VBD O
Controlled NNP O
Number NNP O
26727615 CD O
with IN O
the DT O
name NN O
ALL97 NNP O
. . O

FINDINGS NNP O
After IN O
a DT O
median JJ O
follow NN O
up IN O
of IN O
6 CD O
years NNS O
, , O
there EX O
was VBD O
no DT O
difference NN O
in IN O
event-free JJ B-OC
or CC I-OC
overall JJ I-OC
survival NN I-OC
between IN O
the DT O
two CD O
treatment NN O
groups NNS O
. . O

Although IN O
6-thioguanine JJ B-INTV
conferred VBD O
a DT O
significantly RB O
lower JJR O
risk NN O
of IN O
isolated JJ O
CNS NNP B-OC
relapse NN I-OC
than IN O
did VBD O
6-mercaptopurine JJ B-INTV
( ( O
odds NNS O
ratio VBP O
[ CD O
OR NNP O
] $ O
0.53 CD O
, , O
95 CD O
% NN O
CI NNP O
0.30-0.92 CD O
, , O
p=0.02 NN O
) ) O
, , O
the DT O
benefit NN O
was VBD O
offset VBN O
by IN O
an DT O
increased VBN O
risk NN B-OC
of IN I-OC
death NN I-OC
in IN O
remission NN O
( ( O
2.22 CD O
, , O
1.20-4.14 CD O
, , O
p=0.01 NN O
) ) O
, , O
mainly RB O
due JJ O
to TO O
infections NNS O
during IN O
continuing VBG O
therapy NN O
. . O

Additionally RB O
, , O
95 CD O
patients NNS O
developed VBD O
veno-occlusive JJ B-OC
disease NN I-OC
of IN I-OC
the DT I-OC
liver NN I-OC
. . O

Of IN O
these DT O
, , O
82 CD O
were VBD O
randomly RB O
assigned VBN O
6-thioguanine JJ B-INTV
, , O
representing VBG O
11 CD O
% NN O
of IN O
all DT O
6-thioguanine JJ B-INTV
recipients NNS O
. . O

On IN O
long-term JJ O
follow-up NN O
, , O
about RB O
5 CD O
% NN O
of IN O
6-thioguanine JJ B-INTV
recipients NNS O
have VBP O
evidence NN O
of IN O
non-cirrhotic JJ B-OC
portal JJ I-OC
hypertension NN I-OC
due JJ O
to TO O
periportal JJ O
liver JJ O
fibrosis NN O
or CC O
nodular JJ O
regenerative JJ O
hyperplasia NN O
. . O

INTERPRETATION NNP O
Compared VBD O
with IN O
6-mercaptopurine JJ B-INTV
, , I-INTV
6-thioguanine JJ I-INTV
causes NNS O
excess JJ O
toxicity NN B-OC
without IN O
an DT O
overall JJ B-OC
benefit NN I-OC
. . O

6-mercaptopurine JJ B-INTV
should MD O
remain VB O
the DT O
thiopurine NN O
of IN O
choice NN O
for IN O
continuing VBG O
therapy NN O
of IN O
childhood NN O
lymphoblastic JJ O
leukaemia NN O
. . O

-DOCSTART- -X- O O

Evolution NN O
of IN O
neuropathy JJ O
and CC O
myopathy JJ O
during IN O
intensive JJ O
vincristine/corticosteroid NNS B-INTV
chemotherapy NN I-INTV
for IN O
non-Hodgkin NN O
's POS O
lymphoma NN O
. . O

Neuropathy NNP O
and CC O
myopathy NN O
are VBP O
common JJ O
sequelae NN O
of IN O
intensive JJ B-INTV
chemotherapy NN I-INTV
protocols NNS I-INTV
that WDT I-INTV
contain VBP I-INTV
vincristine JJ I-INTV
and CC I-INTV
corticosteroids NNS I-INTV
. . O

The DT O
authors NNS O
prospectively RB O
monitored VBD O
the DT O
evolution NN O
of IN O
neuropathy JJ O
and CC O
myopathy JJ O
during IN O
an DT O
intensive JJ O
12-week JJ O
chemotherapy NN B-INTV
program NN O
for IN O
patients NNS B-POPU
with IN I-POPU
intermediate JJ I-POPU
and CC I-POPU
high-grade JJ I-POPU
non-Hodgkin NN I-POPU
's POS I-POPU
lymphoma NN I-POPU
. . O

In IN O
this DT O
study NN O
, , O
vincristine NN B-INTV
was VBD O
administered VBN O
by IN O
bolus NN B-INTV
injection NN O
followed VBN O
by IN O
a DT O
3-day JJ O
continuous JJ O
intravenous JJ O
( ( O
IV NNP O
) ) O
infusion NN O
( ( O
total JJ O
dose NN O
of IN O
2.0 CD O
mg/m2 NNS O
every DT O
other JJ O
week NN O
) ) O
; : O
the DT O
maximum JJ O
dose NN O
of IN O
vincristine NN B-INTV
was VBD O
not RB O
arbitrarily RB O
limited VBN O
. . O

Cronassial NNP B-INTV
, , I-INTV
a DT I-INTV
mixture NN I-INTV
of IN I-INTV
four CD I-INTV
naturally RB I-INTV
occurring VBG I-INTV
gangliosides NNS I-INTV
, , O
was VBD O
administered VBN O
in IN O
a DT O
randomized JJ O
double-blind JJ O
test NN O
to TO O
evaluate VB O
whether IN O
this DT O
agent NN O
could MD O
prevent VB O
vincristine-induced JJ B-INTV
neuropathy NN O
. . O

High JJ O
doses NNS O
of IN O
dexamethasone NN B-INTV
( ( O
50 CD O
mg/d NN O
for IN O
3 CD O
days NNS O
weekly RB O
or CC O
every DT O
other JJ O
week NN O
) ) O
were VBD O
also RB O
prescribed VBN O
. . O

Patients NNS O
were VBD O
monitored VBN O
every DT O
4 CD O
weeks NNS O
with IN O
comprehensive JJ O
physical JJ O
and CC O
neurologic JJ O
examinations NNS O
and CC O
electrophysiologic JJ O
studies NNS O
of IN O
peripheral JJ O
nerve NN O
function NN O
. . O

Twenty-seven JJ B-POPU
patients NNS I-POPU
were VBD I-POPU
fully RB I-POPU
evaluable JJ I-POPU
. . O

Weakness NNP B-OC
was VBD O
a DT O
prominent JJ O
adverse JJ O
reaction NN O
in IN O
this DT O
study NN O
, , O
and CC O
all DT O
patients NNS O
had VBD O
moderate JJ B-OC
to TO I-OC
severe VB I-OC
signs NNS I-OC
and CC I-OC
symptoms NNS I-OC
of IN I-OC
neuropathy JJ I-OC
and CC I-OC
myopathy JJ I-OC
. . O

Cronassial NNP B-INTV
( ( O
100 CD O
mg NN O
) ) O
administered VBN O
by IN O
intramuscular NN O
( ( O
IM NNP O
) ) O
injection NN O
daily RB O
provided VBD O
no DT O
protection NN O
against IN O
the DT O
development NN B-OC
of IN I-OC
neuropathic JJ I-OC
symptoms NNS I-OC
. . O

Vincristine NNP B-INTV
typically RB O
impaired VBD O
fine-motor JJ B-OC
coordination NN I-OC
initially RB O
, , O
whereas JJ O
corticosteroids NNS B-INTV
were VBD O
associated VBN O
with IN O
delayed JJ O
development NN B-OC
of IN I-OC
proximal JJ I-OC
muscle NN I-OC
weakness NN I-OC
. . O

Results NNS O
of IN O
electrodiagnostic JJ O
studies NNS O
did VBD O
not RB O
add VB O
to TO O
the DT O
clinical JJ O
examination NN O
results NNS O
. . O

The DT O
authors NNS O
conclude VBP O
that IN O
symptomatic JJ B-OC
weakness NN I-OC
due JJ O
to TO O
neuropathy JJ O
or CC O
myopathy JJ O
appears VBZ O
in IN O
a DT O
predictable JJ O
manner NN O
during IN O
intensive JJ O
vincristine/corticosteroid-based JJ B-INTV
treatment NN I-INTV
protocols NNS O
. . O

Simple JJ O
clinical JJ O
tests NNS O
can MD O
be VB O
used VBN O
to TO O
rapidly RB O
distinguish VB O
between IN O
toxic JJ O
effects NNS O
due JJ O
either RB O
to TO O
vincristine VB B-INTV
or CC I-INTV
corticosteroids NNS I-INTV
, , O
and CC O
routine JJ O
implementation NN O
of IN O
these DT O
tests NNS O
can MD O
prevent VB O
inappropriate JJ O
dose JJ O
attenuation NN O
of IN O
these DT O
agents NNS O
. . O

-DOCSTART- -X- O O

Effect NN O
of IN O
daily JJ O
etidronate NN B-INTV
on IN O
the DT O
osteolysis NN O
of IN O
multiple JJ O
myeloma NN O
. . O

Progressive NNP O
bone NN O
disease NN O
in IN O
multiple JJ O
myeloma NN O
frequently RB O
leads VBZ O
to TO O
osteolysis VB O
, , O
bone NN O
resorption NN O
, , O
pathologic JJ O
fractures NNS O
, , O
vertebral JJ O
compression NN O
, , O
and CC O
hypercalcemia NN O
. . O

We PRP O
conducted VBD O
a DT O
double-blind NN O
study NN O
in IN O
173 CD B-POPU
newly RB I-POPU
diagnosed VBN I-POPU
multiple JJ I-POPU
myeloma NN I-POPU
patients NNS I-POPU
of IN I-POPU
etidronate JJ I-POPU
disodium NN I-POPU
( ( I-POPU
EHDP NNP I-POPU
) ) I-POPU
, , I-POPU
a DT I-POPU
diphosphonate NN I-POPU
compound NN I-POPU
that WDT I-POPU
reduces VBZ I-POPU
bone NN I-POPU
resorption NN I-POPU
by IN I-POPU
inhibiting VBG I-POPU
osteoclastic JJ I-POPU
activity NN I-POPU
. . O

The DT O
patients NNS O
were VBD O
randomly RB O
assigned VBN O
to TO O
receive VB O
oral JJ B-INTV
EHDP NNP I-INTV
5 CD I-INTV
mg/kg/d NN I-INTV
or CC I-INTV
placebo NN I-INTV
until IN O
death NN O
or CC O
discontinuation NN O
due JJ O
to TO O
intolerance VB O
or CC O
refusal VB O
. . O

The DT O
extent NN O
of IN O
vertebral JJ O
deformity NN O
was VBD O
measured VBN O
by IN O
a DT O
vertebral JJ O
index NN O
as RB O
well RB O
as IN O
height NN O
. . O

The DT O
frequency NN B-OC
of IN I-OC
pathologic JJ I-OC
fractures NNS I-OC
, , I-OC
hypercalcemia NN I-OC
, , I-OC
and CC I-OC
bone NN I-OC
pain NN I-OC
was VBD O
regularly RB O
assessed VBN O
, , O
as RB O
well RB O
as IN O
size NN O
and CC O
number NN O
of IN O
osteolytic JJ O
lesions NNS O
. . O

All DT O
patients NNS O
received VBD O
melphalan JJ B-INTV
and CC O
prednisone JJ B-INTV
daily JJ O
for IN O
4 CD O
days NNS O
every DT O
4 CD O
weeks NNS O
as IN O
the DT O
primary JJ O
chemotherapy NN O
for IN O
their PRP$ O
disease NN O
. . O

Although IN O
the DT O
repeated JJ O
measures NNS O
analysis NN O
showed VBD O
a DT O
significant JJ O
height JJ B-OC
loss NN I-OC
, , O
there EX O
was VBD O
no DT O
difference NN O
between IN O
treatment NN O
arms NNS O
( ( O
P NNP O
= NNP O
.98 NNP O
) ) O
. . O

There EX O
was VBD O
no DT O
significant JJ O
difference NN O
in IN O
bone NN B-OC
pain NN I-OC
, , I-OC
episodes NNS I-OC
of IN I-OC
hypercalcemia NN I-OC
, , I-OC
or CC I-OC
development NN I-OC
of IN I-OC
pathologic JJ I-OC
fractures NNS I-OC
. . O

Patients NNS B-POPU
on IN I-POPU
EHDP NNP I-POPU
showed VBD O
less JJR O
deterioration NN B-OC
in IN I-OC
their PRP$ I-OC
vertebral JJ I-OC
index NN I-OC
, , O
but CC O
this DT O
difference NN O
only RB O
approached VBD O
statistical JJ O
significance NN O
( ( O
P NNP O
= NNP O
.07 NNP O
) ) O
. . O

We PRP O
conclude VBP O
that IN O
EHDP NNP B-INTV
therapy NN O
used VBN O
in IN O
this DT O
dosage NN O
schedule NN O
does VBZ O
not RB O
have VB O
a DT O
clinically RB O
significant JJ O
impact NN O
in IN O
multiple JJ O
myeloma NN O
. . O

-DOCSTART- -X- O O

Granulocyte-macrophage JJ B-INTV
colony-stimulating JJ I-INTV
factor NN I-INTV
( ( I-INTV
GM-CSF NNP I-INTV
) ) I-INTV
as IN O
adjunct JJ O
therapy NN O
in IN O
relapsed JJ B-POPU
Hodgkin NNP I-POPU
disease NN I-POPU
. . O

OBJECTIVE UH O
To TO O
determine VB O
the DT O
clinical JJ O
and CC O
economic JJ O
effects NNS O
of IN O
granulocyte JJ B-INTV
macrophage NN I-INTV
colony-stimulating JJ I-INTV
factor NN I-INTV
( ( I-INTV
GM-CSF NNP I-INTV
) ) I-INTV
as IN O
adjunct JJ O
therapy NN O
in IN O
relapsed JJ B-POPU
or CC I-POPU
refractory JJ I-POPU
Hodgkin NNP I-POPU
disease NN I-POPU
. . O

DESIGN VB O
A DT O
randomized JJ O
, , O
double-blind JJ O
, , O
phase JJ O
III NNP O
clinical JJ O
trial NN O
. . O

SETTING VB O
A DT O
tertiary JJ B-POPU
referral NN I-POPU
center NN I-POPU
. . O

PATIENTS VB O
Twenty-four JJ B-POPU
patients NNS I-POPU
( ( I-POPU
twelve NN I-POPU
of IN I-POPU
whom WP I-POPU
were VBD I-POPU
controls NNS I-POPU
) ) I-POPU
treated VBN I-POPU
with IN I-POPU
high-dose JJ I-POPU
chemotherapy NN I-POPU
and CC I-POPU
autologous JJ I-POPU
bone NN I-POPU
marrow NN I-POPU
transplantation NN I-POPU
. . O

MAIN NNP O
RESULTS VBD O
The DT O
12 CD O
patients NNS O
treated VBN O
with IN O
GM-CSF NNP B-INTV
, , O
when WRB O
compared VBN O
with IN O
placebo NN B-INTV
recipients NNS O
, , O
had VBD O
shorter JJR O
periods NNS B-OC
of IN I-OC
neutropenia NN I-OC
( ( O
median JJ O
duration NN O
of IN O
an DT O
absolute JJ O
neutrophil NN O
count NN O
of IN O
less JJR O
than IN O
1000 CD O
cells/mm3 NN O
, , O
16 CD O
days NNS O
compared VBN O
with IN O
27 CD O
days NNS O
; : O
P NNP O
= NNP O
0.02 CD O
) ) O
, , O
shorter JJR B-OC
periods NNS I-OC
of IN I-OC
platelet-transfusion NN I-OC
dependency NN I-OC
( ( O
median JJ O
duration NN O
, , O
13.5 CD O
days NNS O
compared VBN O
with IN O
21 CD O
days NNS O
; : O
P NNP O
= NNP O
0.03 CD O
) ) O
, , O
and CC O
shorter JJR B-OC
hospitalizations NNS I-OC
( ( O
median JJ O
hospital NN O
stay NN O
, , O
32 CD O
days NNS O
compared VBN O
with IN O
40.5 CD O
days NNS O
; : O
P NNP O
= NNP O
0.004 CD O
) ) O
. . O

Other JJ O
clinical JJ O
outcomes NNS O
, , O
such JJ O
as IN O
frequency NN B-OC
and CC I-OC
severity NN I-OC
of IN I-OC
toxicities NNS I-OC
, , I-OC
development NN I-OC
of IN I-OC
pneumonia NN I-OC
or CC I-OC
infection NN I-OC
, , I-OC
in-hospital JJ I-OC
death NN I-OC
, , I-OC
and CC I-OC
response NN I-OC
rate NN I-OC
were VBD O
similar JJ O
in IN O
the DT O
two CD O
groups NNS O
. . O

Actuarial JJ O
long-term JJ B-OC
disease-free JJ I-OC
survival NN I-OC
was VBD O
64 CD O
% NN O
for IN O
patients NNS O
treated VBN O
with IN O
GM-CSF NNP B-INTV
and CC O
58 CD O
% NN O
for IN O
patients NNS O
who WP O
received VBD O
placebo NN B-INTV
after IN O
32 CD O
months NNS O
of IN O
follow-up NN O
( ( O
P NNP O
= NNP O
0.15 CD O
) ) O
. . O

The DT O
group NN O
treated VBD O
with IN O
GM-CSF NNP B-INTV
had VBD O
lower JJR B-OC
total NN I-OC
charges NNS I-OC
after IN I-OC
infusion NN I-OC
of IN I-OC
autologous JJ I-OC
marrow NN I-OC
than IN O
the DT O
placebo NN B-INTV
group NN O
( ( O
median JJ O
in-hospital NN O
charges NNS O
, , O
$ $ O
39,800 CD O
compared VBN O
with IN O
$ $ O
62,500 CD O
; : O
P NNP O
= NNP O
0.005 CD O
) ) O
because IN O
of IN O
lower JJR B-OC
post-infusion NN I-OC
charges NNS I-OC
for IN O
room NN O
and CC O
board NN O
, , O
antibiotic JJ O
therapy NN O
, , O
transfusions NNS O
, , O
laboratory NN O
tests NNS O
, , O
and CC O
physical JJ O
therapy NN O
visits NNS O
. . O

CONCLUSIONS NNP O
Administration NNP O
of IN O
GM-CSF NNP B-INTV
was VBD O
associated VBN O
with IN O
acceleration NN B-OC
of IN I-OC
myeloid NN I-OC
and CC I-OC
platelet NN I-OC
recovery NN I-OC
and CC O
was VBD O
cost VBN B-OC
effective JJ I-OC
in IN O
the DT O
treatment NN O
of IN O
patients NNS B-POPU
with IN I-POPU
relapsed JJ I-POPU
Hodgkin NNP I-POPU
disease NN I-POPU
who WP I-POPU
received VBD I-POPU
intensive JJ I-POPU
chemotherapy NN I-POPU
. . O

-DOCSTART- -X- O O

Stage NN B-POPU
II NNP I-POPU
carcinoma NN I-POPU
of IN I-POPU
the DT I-POPU
ovary JJ I-POPU
: : I-POPU
an DT O
analysis NN O
of IN O
survival NN B-OC
after IN O
comprehensive JJ O
surgical JJ B-INTV
staging NN I-INTV
and CC O
adjuvant JJ B-INTV
therapy NN I-INTV
. . O

Ninety-three JJ B-POPU
women NNS I-POPU
with IN I-POPU
FIGO NNP I-POPU
stage NN I-POPU
II NNP I-POPU
epithelial JJ I-POPU
ovarian JJ I-POPU
carcinoma NN I-POPU
underwent JJ O
comprehensive JJ O
surgical JJ O
staging NN O
and CC O
were VBD O
randomized VBN O
prospectively RB O
to TO O
therapy VB O
consisting NN O
of IN O
either DT O
intraperitoneal JJ B-INTV
radioactive JJ I-INTV
phosphorus NN I-INTV
or CC I-INTV
oral JJ I-INTV
melphalan NN I-INTV
. . O

No DT O
patient NN O
had VBD O
gross JJ O
residual JJ O
disease NN O
at IN O
the DT O
time NN O
of IN O
randomization NN O
. . O

Ten CD O
of IN O
the DT O
forty-five JJ B-POPU
women NNS I-POPU
treated VBN I-POPU
with IN I-POPU
melphalan NN I-POPU
experienced VBN O
severe JJ B-OC
bone NN I-OC
marrow NN I-OC
depression NN I-OC
at IN O
some DT O
time NN O
during IN O
therapy NN O
and CC O
two CD O
women NNS O
expired VBD B-OC
from IN I-OC
leukemia NN I-OC
. . O

Four CD O
of IN O
the DT O
forty-eight JJ B-POPU
women NNS I-POPU
treated VBN I-POPU
with IN I-POPU
intraperitoneal JJ I-POPU
phosphorus NN I-POPU
required VBN O
surgical JJ B-OC
reexploration NN I-OC
for IN I-OC
intestinal JJ I-OC
obstruction NN I-OC
or CC I-OC
bowel NN I-OC
injury NN I-OC
. . O

Twenty-one JJ O
women NNS O
died VBD B-OC
of IN O
their PRP$ O
disease NN O
. . O

Survival NNP B-OC
was VBD O
not RB O
statistically RB O
different JJ O
between IN O
the DT O
two CD O
treatment NN O
arms NNS O
. . O

The DT O
5-year JJ B-OC
actuarial JJ I-OC
survival NN I-OC
was VBD O
78 CD O
% NN O
. . O

-DOCSTART- -X- O O

Randomized VBN O
study NN O
of IN O
chlorambucil NN B-INTV
( ( O
CB NNP O
) ) O
compared VBN O
to TO O
interferon VB B-INTV
( ( O
alfa-2b JJ O
) ) O
combined VBN O
with IN O
CB NNP B-INTV
in IN O
low-grade JJ O
non-Hodgkin NN B-POPU
's POS I-POPU
lymphoma NN I-POPU
: : I-POPU
an DT O
interim JJ O
report NN O
of IN O
a DT O
randomized JJ O
study NN O
. . O

Non-Hodgkin NNP B-POPU
's POS I-POPU
Lymphoma NNP I-POPU
Cooperative NNP I-POPU
Study NNP I-POPU
Group NNP I-POPU
. . O

Alpha NNP B-INTV
interferon NN I-INTV
has VBZ O
shown VBN O
initial JJ O
promise NN O
in IN O
the DT O
treatment NN O
of IN O
low-grade JJ O
non-Hodgkin NN O
's POS O
lymphoma NN O
( ( O
NHL NNP O
) ) O
, , O
especially RB O
with IN O
the DT O
nodular JJ O
form NN O
of IN O
the DT O
disease NN O
. . O

The DT O
present JJ O
study NN O
enrolled VBD O
70 CD B-POPU
NHL NNP I-POPU
patients NNS I-POPU
who WP I-POPU
received VBD I-POPU
either CC I-POPU
chlorambucil NN I-POPU
( ( I-POPU
CB NNP I-POPU
; : I-POPU
10 CD I-POPU
mg/day NN I-POPU
) ) I-POPU
or CC I-POPU
CB NNP I-POPU
plus CC I-POPU
interferon JJ I-POPU
alfa-2b NN I-POPU
( ( I-POPU
5 CD I-POPU
million CD I-POPU
units NNS I-POPU
( ( I-POPU
MU NNP I-POPU
) ) I-POPU
/m2 VBD I-POPU
subcutaneously RB I-POPU
three CD I-POPU
times NNS I-POPU
a DT I-POPU
week NN I-POPU
) ) I-POPU
. . O

Among IN O
63 CD B-POPU
evaluable JJ I-POPU
patients NNS I-POPU
, , O
similar JJ O
response NN O
rates NNS O
( ( O
62.1 CD O
% NN O
and CC O
64.7 CD O
% NN O
respectively RB O
) ) O
were VBD O
recorded VBN O
for IN O
the DT O
treatment NN O
arms NNS O
. . O

In IN O
patients NNS B-POPU
receiving VBG I-POPU
no DT I-POPU
maintenance NN I-POPU
therapy NN I-POPU
, , O
those DT O
who WP O
received VBD O
interferon JJ O
alfa-2b JJ O
during IN O
the DT O
induction NN O
phase NN O
showed VBD O
a DT O
favourable JJ O
trend NN O
in IN O
terms NNS O
of IN O
incidence NN B-OC
of IN I-OC
relapse NN I-OC
compared VBN O
to TO O
those DT O
who WP O
had VBD O
received VBN O
chlorambucil NN O
alone RB O
. . O

During IN O
maintenance NN O
therapy NN O
with IN O
interferon JJ B-INTV
alfa-2b NN I-INTV
, , O
no DT O
significant JJ O
differences NNS O
in IN O
the DT O
occurrence NN B-OC
of IN I-OC
relapse NN I-OC
have VBP O
yet RB O
been VBN O
seen VBN O
compared VBN O
to TO O
patients NNS B-POPU
on IN I-POPU
no DT I-POPU
maintenance NN I-POPU
therapy NN I-POPU
. . O

A NNP O
longer JJR O
observation NN O
period NN O
is VBZ O
needed VBN O
to TO O
make VB O
a DT O
definitive JJ O
conclusion NN O
about IN O
the DT O
usefulness NN O
of IN O
interferon JJ B-INTV
maintenance NN I-INTV
therapy NN I-INTV
and CC O
to TO O
evaluate VB O
further RBR O
the DT O
effects NNS O
of IN O
the DT O
combined JJ O
schedule NN O
of IN O
chlorambucil NN B-INTV
and CC O
interferon NN B-INTV
induction NN O
on IN O
the DT O
duration NN O
of IN O
remission NN O
. . O

-DOCSTART- -X- O O

Randomized VBN O
trial NN O
of IN O
daily JJ O
versus FW O
weekly JJ O
administration NN O
of IN O
2-chlorodeoxyadenosine JJ B-INTV
in IN O
patients NNS B-POPU
with IN I-POPU
hairy JJ I-POPU
cell NN I-POPU
leukemia NN I-POPU
: : I-POPU
a DT I-POPU
multicenter NN I-POPU
phase NN I-POPU
III NNP I-POPU
trial NN I-POPU
( ( I-POPU
SAKK NNP I-POPU
32/98 CD I-POPU
) ) I-POPU
. . O

Daily JJ O
administration NN O
of IN O
2-chlorodeoxyadenosine JJ B-INTV
( ( I-INTV
Cladribine NNP I-INTV
, , I-INTV
CDA NNP I-INTV
) ) I-INTV
is VBZ O
a DT O
standard JJ O
treatment NN O
for IN O
hairy NN O
cell NN O
leukemia NN O
, , O
but CC O
may MD O
cause VB O
severe JJ O
neutropenia NN B-OC
and CC I-OC
neutropenic JJ I-OC
fever NN I-OC
. . O

This DT O
trial NN O
compared VBN O
toxicity NN O
and CC O
efficacy NN O
of IN O
weekly JJ O
versus NN O
daily RB O
CDA NNP B-INTV
administration NN O
. . O

One CD B-POPU
hundred VBD I-POPU
patients NNS I-POPU
were VBD O
randomized VBN O
to TO O
receive VB O
standard NN O
( ( B-INTV
CDA NNP I-INTV
0.14 CD O
mg/kg/day JJ O
day NN O
1-5 JJ O
[ NNP O
Arm NNP O
A NNP O
] NN O
) ) O
or CC O
experimental JJ O
treatment NN O
( ( B-INTV
CDA NNP I-INTV
0.14 CD O
mg/kg/day NN O
once RB O
weekly JJ O
for IN O
5 CD O
weeks NNS O
[ JJ O
Arm NNP O
B NNP O
] NN O
) ) O
. . O

The DT O
primary JJ O
endpoint NN O
was VBD O
average JJ B-OC
leukocyte JJ I-OC
count NN I-OC
within IN O
6 CD O
weeks NNS O
from IN O
randomization NN O
. . O

Secondary JJ O
endpoints NNS O
included VBD O
response NN B-OC
rates NNS I-OC
, , I-OC
other JJ I-OC
acute JJ I-OC
hematotoxicity NN I-OC
, , I-OC
acute JJ I-OC
infection NN I-OC
rate NN I-OC
, , I-OC
hospital NN I-OC
admission NN I-OC
, , I-OC
remission NN I-OC
duration NN I-OC
, , I-OC
event-free JJ I-OC
, , I-OC
and CC I-OC
overall JJ I-OC
survival NN I-OC
. . O

There EX O
was VBD O
no DT O
significant JJ O
difference NN O
in IN O
average JJ B-OC
leukocyte JJ I-OC
count NN I-OC
. . O

Response JJ B-OC
rate NN I-OC
( ( O
complete JJ O
+ NNP O
partial JJ O
remission NN O
) ) O
at IN O
week NN O
10 CD O
was VBD O
78 CD O
% NN O
( ( O
95 CD O
% NN O
confidence NN O
interval NN O
( ( O
CI NNP O
) ) O
64-88 CD O
% NN O
) ) O
in IN O
Arm NNP O
A NNP O
and CC O
68 CD O
% NN O
( ( O
95 CD O
% NN O
CI NNP O
54-80 CD O
% NN O
) ) O
in IN O
Arm NNP O
B NNP O
( ( O
p JJ O
= NNP O
0.13 CD O
) ) O
. . O

Best JJS O
response NN B-OC
rates NNS I-OC
during IN O
follow-up JJ O
were VBD O
identical JJ O
( ( O
86 CD O
% NN O
) ) O
in IN O
both DT O
arms NNS O
. . O

No DT O
significant JJ O
difference NN O
was VBD O
found VBN O
in IN O
the DT O
rate NN O
of IN O
grade NN B-OC
3+4 CD I-OC
leukocytopenia NN I-OC
( ( O
94 CD O
% NN O
vs NN O
. . O

84 CD O
% NN O
) ) O
, , O
grade VBD B-OC
3+4 CD I-OC
neutropenia NN I-OC
( ( O
90 CD O
% NN O
vs NN O
. . O

80 CD O
% NN O
) ) O
, , O
acute JJ B-OC
infection NN I-OC
( ( O
44 CD O
% NN O
vs NN O
. . O

40 CD O
% NN O
) ) O
, , O
hospitalization NN B-OC
( ( O
38 CD O
% NN O
vs NN O
. . O

34 CD O
% NN O
) ) O
, , O
and CC O
erythrocyte JJ B-OC
support NN I-OC
( ( O
22 CD O
% NN O
vs NN O
. . O

30 CD O
% NN O
) ) O
within IN O
10 CD O
weeks NNS O
. . O

Overall JJ O
, , O
these DT O
findings NNS O
indicate VBP O
that IN O
there EX O
are VBP O
no DT O
apparent JJ O
advantages NNS O
in IN O
toxicity NN B-OC
and CC I-OC
efficacy NN I-OC
by IN O
giving VBG O
CDA NNP B-INTV
weekly RB O
rather RB O
than IN O
daily RB O
. . O

-DOCSTART- -X- O O

Comparison NNP O
of IN O
neurocognitive JJ B-OC
functioning NN I-OC
in IN O
children NNS B-POPU
previously RB I-POPU
randomly RB I-POPU
assigned VBN I-POPU
to TO I-POPU
intrathecal JJ I-POPU
methotrexate NN I-POPU
compared VBN O
with IN O
triple JJ B-INTV
intrathecal JJ I-INTV
therapy NN I-INTV
for IN O
the DT O
treatment NN O
of IN O
childhood NN B-POPU
acute NN I-POPU
lymphoblastic JJ I-POPU
leukemia NN I-POPU
. . O

PURPOSE NNP O
For IN O
the DT O
majority NN O
of IN O
children NNS B-POPU
with IN I-POPU
acute JJ I-POPU
lymphoblastic JJ I-POPU
leukemia NN I-POPU
( ( I-POPU
ALL NNP I-POPU
) ) I-POPU
, , I-POPU
CNS NNP I-POPU
prophylaxis NN I-POPU
consists VBZ I-POPU
of IN I-POPU
either DT I-POPU
intrathecal JJ I-POPU
( ( I-POPU
IT NNP I-POPU
) ) I-POPU
methotrexate NN I-POPU
or CC I-POPU
triple VB I-POPU
IT NNP I-POPU
therapy NN I-POPU
( ( I-POPU
ie JJ I-POPU
, , I-POPU
methotrexate NN I-POPU
with IN I-POPU
both DT I-POPU
cytarabine NN I-POPU
and CC I-POPU
hydrocortisone NN I-POPU
) ) I-POPU
. . O

The DT O
long-term JJ O
neurotoxicities NNS O
of IN O
these DT O
two CD O
IT NNP O
strategies NNS O
have VBP O
not RB O
yet RB O
been VBN O
directly RB O
compared VBN O
. . O

PATIENTS NNP O
AND CC O
METHODS NNP O
In IN O
this DT O
multisite NN O
study NN O
, , O
171 CD B-POPU
children NNS I-POPU
with IN I-POPU
standard-risk JJ I-POPU
ALL NNP I-POPU
, , I-POPU
age NN I-POPU
1 CD I-POPU
to TO I-POPU
9.99 CD I-POPU
years NNS I-POPU
at IN I-POPU
diagnosis NN I-POPU
, , I-POPU
previously RB I-POPU
randomly RB I-POPU
assigned VBN I-POPU
to TO I-POPU
IT NNP I-POPU
methotrexate NNP I-POPU
( ( I-POPU
n JJ I-POPU
= NNP I-POPU
82 CD I-POPU
) ) I-POPU
or CC I-POPU
to TO I-POPU
triple VB I-POPU
IT NNP I-POPU
therapy NN I-POPU
( ( I-POPU
n JJ I-POPU
= NNP I-POPU
89 CD I-POPU
) ) I-POPU
on IN I-POPU
CCG NNP I-POPU
1952 CD I-POPU
, , I-POPU
underwent JJ I-POPU
neurocognitive JJ I-POPU
evaluation NN I-POPU
by IN I-POPU
a DT I-POPU
licensed JJ I-POPU
psychologist NN I-POPU
at IN I-POPU
a DT I-POPU
mean NN I-POPU
of IN I-POPU
5.9 CD I-POPU
years NNS I-POPU
after IN I-POPU
random JJ I-POPU
assignment NN I-POPU
. . O

RESULTS JJ O
Patients NNPS B-POPU
who WP I-POPU
received VBD I-POPU
IT NNP I-POPU
methotrexate NNP I-POPU
had VBD O
a DT O
mean JJ B-OC
Processing NNP I-OC
Speed NNP I-OC
Index NNP I-OC
that WDT O
was VBD O
3.6 CD O
points NNS O
lower JJR O
, , O
about IN O
one CD O
fourth JJ O
of IN O
a DT O
standard JJ O
deviation NN O
, , O
than IN O
those DT O
who WP O
received VBD O
triple JJ B-INTV
IT NNP I-INTV
therapy NN I-INTV
( ( O
P NNP O
= NNP O
.04 NNP O
) ) O
after IN O
analysis NN O
was VBD O
adjusted VBN O
for IN O
age NN O
, , O
sex NN O
, , O
and CC O
time NN O
since IN O
diagnosis NN O
. . O

Likewise NNP O
, , O
19.5 CD B-POPU
% NN I-POPU
of IN I-POPU
children NNS I-POPU
in IN I-POPU
the DT I-POPU
IT NNP I-POPU
methotrexate NNP I-POPU
group NN I-POPU
had VBD O
a DT O
Processing NNP B-OC
Speed NNP I-OC
Index NNP I-OC
score NN I-OC
in IN O
the DT O
below-average NN O
range NN O
compared VBN O
with IN O
6.9 CD O
% NN O
in IN O
the DT O
triple NN B-INTV
IT NNP I-INTV
therapy NN I-INTV
group NN I-INTV
( ( O
P NNP O
= NNP O
.02 NNP O
) ) O
. . O

Otherwise UH O
, , O
the DT O
groups NNS O
performed VBD O
similarly RB O
on IN O
tests NNS B-OC
of IN I-OC
full-scale JJ I-OC
intelligence NN I-OC
quotient NN I-OC
, , I-OC
academic JJ I-OC
achievement NN I-OC
, , I-OC
attention/concentration NN I-OC
, , I-OC
memory NN I-OC
, , I-OC
and CC I-OC
visual JJ I-OC
motor NN I-OC
integration NN I-OC
. . O

The DT O
association NN O
of IN O
treatment NN O
with IN O
measures NNS B-OC
of IN I-OC
cognitive JJ I-OC
functioning NN I-OC
was VBD O
not RB O
modified VBN O
by IN O
sex NN B-POPU
or CC I-POPU
age NN I-POPU
at IN I-POPU
diagnosis NN I-POPU
. . O

In IN O
the DT O
post-therapy JJ O
period NN O
, , O
there EX O
were VBD O
no DT O
group NN O
differences VBZ O
in IN O
special JJ B-OC
education NN I-OC
services NNS I-OC
, , I-OC
neurologic JJ I-OC
events NNS I-OC
, , I-OC
or CC I-OC
use NN I-OC
of IN I-OC
psychotropic NN I-OC
medications NNS I-OC
. . O

CONCLUSION NNP O
This DT O
study NN O
did VBD O
not RB O
show VB O
any DT O
clinically RB O
meaningful JJ O
differences NNS O
in IN O
neurocognitive JJ B-OC
functioning NN I-OC
between IN O
patients NNS O
previously RB O
randomly RB O
assigned VBN O
to TO O
IT NNP B-INTV
methotrexate NN I-INTV
or CC O
triple VB B-INTV
IT NNP I-INTV
therapy NN I-INTV
except IN O
for IN O
a DT O
small JJ O
difference NN O
in IN O
processing VBG B-OC
speed NN I-OC
in IN O
the DT O
IT NNP B-INTV
methotrexate NNP I-INTV
group NN I-INTV
. . O

-DOCSTART- -X- O O

The DT O
impact NN O
on IN O
outcome NN O
of IN O
the DT O
addition NN O
of IN O
all-trans NNS B-INTV
retinoic JJ I-INTV
acid NN I-INTV
to TO I-INTV
intensive JJ I-INTV
chemotherapy NN I-INTV
in IN O
younger JJR B-POPU
patients NNS I-POPU
with IN I-POPU
nonacute JJ I-POPU
promyelocytic JJ I-POPU
acute NN I-POPU
myeloid NN I-POPU
leukemia NN I-POPU
: : I-POPU
overall JJ O
results NNS O
and CC O
results NNS O
in IN O
genotypic JJ B-POPU
subgroups NNS I-POPU
defined VBN I-POPU
by IN I-POPU
mutations NNS I-POPU
in IN I-POPU
NPM1 NNP I-POPU
, , I-POPU
FLT3 NNP I-POPU
, , I-POPU
and CC I-POPU
CEBPA NNP I-POPU
. . O

We PRP O
investigated VBD O
the DT O
benefit NN O
of IN O
adding VBG O
all-trans JJ B-INTV
retinoic NN I-INTV
acid NN I-INTV
( ( I-INTV
ATRA NNP I-INTV
) ) I-INTV
to TO O
chemotherapy VB B-POPU
for IN I-POPU
younger JJR I-POPU
patients NNS I-POPU
with IN I-POPU
nonacute JJ I-POPU
promyelocytic JJ I-POPU
acute NN I-POPU
myeloid NN I-POPU
leukemia NN I-POPU
and CC I-POPU
high-risk JJ I-POPU
myelodysplastic JJ I-POPU
syndrome NN I-POPU
, , O
and CC O
considered VBD O
interactions NNS O
between IN O
treatment NN O
and CC O
molecular JJ O
markers NNS O
. . O

Overall NNP O
, , O
1075 CD B-POPU
patients NNS I-POPU
less RBR I-POPU
than IN I-POPU
60 CD I-POPU
years NNS I-POPU
of IN I-POPU
age NN I-POPU
were VBD O
randomized VBN O
to TO O
receive VB O
or CC O
not RB O
receive JJ O
ATRA NNP B-INTV
in IN O
addition NN O
to TO O
daunorubicin/Ara-C/thioguanine JJ B-INTV
chemotherapy NN I-INTV
with IN I-INTV
Ara-C NNP I-INTV
at IN I-INTV
standard NN I-INTV
or CC I-INTV
double JJ I-INTV
standard NN I-INTV
dose NN I-INTV
. . O

There EX O
were VBD O
data NNS O
on IN O
FLT3 NNP O
internal JJ O
tandem NN O
duplications NNS O
and CC O
NPM1 NNP O
mutations NNS O
( ( O
n JJ O
= NNP O
592 CD O
) ) O
, , O
CEBPA NNP O
mutations NNS O
( ( O
n JJ O
= NNP O
423 CD O
) ) O
, , O
and CC O
MN1 NNP O
expression NN O
( ( O
n JJ O
= NNP O
195 CD O
) ) O
. . O

The DT O
complete JJ B-OC
remission NN I-OC
rate NN I-OC
was VBD O
68 CD O
% NN O
with IN O
complete JJ O
remission NN O
with IN O
incomplete JJ O
count NN O
recovery NN O
in IN O
an DT O
additional JJ O
16 CD O
% NN O
; : O
8-year JJ B-OC
overall JJ I-OC
survival NN I-OC
was VBD O
32 CD O
% NN O
. . O

There EX O
was VBD O
no DT O
significant JJ O
treatment NN O
effect NN O
for IN O
any DT O
outcome NN O
, , O
with IN O
no DT O
significant JJ O
interactions NNS O
between IN O
treatment NN O
and CC O
demographics NNS O
, , O
or CC O
cytarabine JJ O
randomization NN O
. . O

Importantly RB O
, , O
there EX O
were VBD O
no DT O
interactions NNS O
by IN O
FLT3/internal NNP B-OC
tandem NN I-OC
duplications NNS I-OC
, , I-OC
NPM1 NNP I-OC
, , I-OC
or CC I-OC
CEBPA NNP I-OC
mutation NN I-OC
. . O

There EX O
was VBD O
a DT O
suggestion NN O
that IN O
ATRA NNP B-INTV
reduced VBD O
relapse NN B-OC
in IN O
patients NNS O
with IN O
lower JJR O
MN1 NNP O
levels NNS O
, , O
but CC O
no DT O
significant JJ O
effect NN O
on IN O
overall JJ B-OC
survival NN I-OC
. . O

Results NNS O
were VBD O
consistent JJ O
when WRB O
restricted VBN O
to TO O
patients NNS O
with IN O
normal JJ O
karyotype NN O
. . O

ATRA NNP B-INTV
has VBZ O
no DT O
overall JJ O
effect NN O
on IN O
treatment NN O
outcomes NNS O
in IN O
this DT O
group NN O
of IN O
patients NNS O
. . O

The DT O
study NN O
did VBD O
not RB O
identify VB O
any DT O
subgroup NN O
of IN O
patients NNS O
likely JJ O
to TO O
derive VB O
a DT O
significant JJ O
survival JJ O
benefit NN O
from IN O
the DT O
addition NN O
of IN O
ATRA NNP B-INTV
to TO I-INTV
chemotherapy VB I-INTV
. . O

-DOCSTART- -X- O O

Phase NNP O
III NNP O
, , O
randomized VBD O
, , O
open-label JJ O
study NN O
of IN O
daily JJ O
imatinib NN B-INTV
mesylate NN I-INTV
400 CD O
mg NN O
versus NN O
800 CD O
mg NN O
in IN O
patients NNS B-POPU
with IN I-POPU
newly RB I-POPU
diagnosed VBN I-POPU
, , I-POPU
previously RB I-POPU
untreated VBN I-POPU
chronic JJ I-POPU
myeloid NN I-POPU
leukemia NN I-POPU
in IN I-POPU
chronic JJ I-POPU
phase NN I-POPU
using VBG O
molecular JJ O
end NN O
points NNS O
: : O
tyrosine NN O
kinase NN O
inhibitor NN O
optimization NN O
and CC O
selectivity NN O
study NN O
. . O

PURPOSE NNP O
To TO O
evaluate VB O
the DT O
safety NN O
and CC O
efficacy NN O
of IN O
initial JJ O
treatment NN O
with IN O
imatinib JJ B-INTV
mesylate NN I-INTV
800 CD O
mg/d NN O
( ( O
400 CD O
mg NN O
twice RB O
daily RB O
) ) O
versus NN O
400 CD O
mg/d NN O
in IN O
patients NNS B-POPU
with IN I-POPU
newly RB I-POPU
diagnosed VBN I-POPU
chronic JJ I-POPU
myeloid NN I-POPU
leukemia NN I-POPU
in IN I-POPU
chronic JJ I-POPU
phase NN I-POPU
. . O

PATIENTS NNP O
AND CC O
METHODS NNP O
A NNP B-POPU
total NN I-POPU
of IN I-POPU
476 CD I-POPU
patients NNS I-POPU
were VBD I-POPU
randomly RB I-POPU
assigned VBN I-POPU
2:1 CD O
to TO O
imatinib VB B-INTV
800 CD I-INTV
mg NN I-INTV
( ( O
n JJ O
= NNP O
319 CD O
) ) O
or CC B-INTV
400 CD I-INTV
mg NN I-INTV
( ( O
n JJ O
= NNP O
157 CD O
) ) O
daily RB O
. . O

The DT O
primary JJ O
end NN O
point NN O
was VBD O
the DT O
major JJ B-OC
molecular JJ I-OC
response NN I-OC
( ( I-OC
MMR NNP I-OC
) ) I-OC
rate NN I-OC
at IN O
12 CD O
months NNS O
. . O

RESULTS NNP O
At IN O
12 CD O
months NNS O
, , O
differences NNS O
in IN O
MMR NNP B-OC
and CC I-OC
complete JJ I-OC
cytogenetic JJ I-OC
response NN I-OC
( ( I-OC
CCyR NNP I-OC
) ) I-OC
rates NNS I-OC
were VBD O
not RB O
statistically RB O
significant JJ O
( ( O
MMR NNP O
, , O
46 CD O
% NN O
v JJ O
40 CD O
% NN O
; : O
P NNP O
= NNP O
.2035 NNP O
; : O
CCyR NNP O
, , O
70 CD O
% NN O
v JJ O
66 CD O
% NN O
; : O
P NNP O
= NNP O
.3470 NNP O
) ) O
. . O

However RB O
, , O
MMR NNP B-OC
occurred VBD O
faster RBR O
among IN O
patients NNS O
randomly RB O
assigned VBN O
to TO O
imatinib VB B-INTV
800 CD O
mg/d NNS O
, , O
who WP O
had VBD O
higher JJR O
rates NNS O
of IN O
MMR NNP B-OC
at IN O
3 CD O
and CC O
6 CD O
months NNS O
compared VBN O
with IN O
those DT O
in IN O
the DT O
imatinib JJ O
400-mg/d JJ O
arm NN O
( ( O
P NNP O
= NNP O
.0035 NNP O
by IN O
log-rank JJ O
test NN O
) ) O
. . O

CCyR NNP B-OC
also RB O
occurred VBD O
faster RBR O
in IN O
the DT O
800-mg/d JJ O
arm NN O
( ( O
CCyR NNP O
at IN O
6 CD O
months NNS O
, , O
57 CD O
% NN O
v JJ O
45 CD O
% NN O
; : O
P NNP O
= NNP O
.0146 NNP O
) ) O
. . O

The DT O
most RBS O
common JJ O
adverse JJ O
events NNS O
were VBD O
edema RB B-OC
, , I-OC
gastrointestinal JJ I-OC
problems NNS I-OC
, , I-OC
and CC I-OC
rash NN I-OC
, , O
and CC O
all DT O
were VBD O
more JJR O
common JJ O
in IN O
patients NNS O
in IN O
the DT O
800-mg/d JJ O
arm NN O
. . O

Grades VBZ B-OC
3 CD I-OC
to TO I-OC
4 CD I-OC
hematologic NN I-OC
toxicity NN I-OC
also RB O
occurred VBD O
more RBR O
frequently RB O
in IN O
patients NNS O
receiving VBG O
imatinib JJ O
800 CD O
mg/d NN O
. . O

CONCLUSION NNP O
MMR NNP O
rates NNS O
at IN O
1 CD O
year NN O
were VBD O
similar JJ O
with IN O
imatinib JJ O
800 CD O
mg/d NN O
and CC O
400 CD O
mg/d NN O
, , O
but CC O
MMR NNP B-OC
and CC I-OC
CCyR NNP I-OC
occurred VBD O
earlier RBR O
in IN O
patients NNS O
treated VBN O
with IN O
800 CD O
mg/d NN O
. . O

Continued VBN O
follow-up NN O
is VBZ O
needed VBN O
to TO O
determine VB O
the DT O
clinical JJ O
significance NN O
of IN O
earlier JJR O
responses NNS O
on IN O
high-dose JJ O
imatinib NN B-INTV
. . O

-DOCSTART- -X- O O

Rituximab NNP B-INTV
plus CC I-INTV
concurrent JJ I-INTV
infusional JJ I-INTV
EPOCH NNP I-INTV
chemotherapy NN I-INTV
is VBZ O
highly RB O
effective JJ O
in IN B-POPU
HIV-associated JJ I-POPU
B-cell NNP I-POPU
non-Hodgkin JJ I-POPU
lymphoma NN I-POPU
. . O

Rituximab NNP O
plus CC O
intravenous JJ O
bolus NN O
chemotherapy NN O
is VBZ O
a DT O
standard JJ O
treatment NN O
for IN O
immunocompetent JJ B-POPU
patients NNS I-POPU
with IN I-POPU
B-cell NNP I-POPU
non-Hodgkin JJ I-POPU
lymphoma NN I-POPU
( ( I-POPU
NHL NNP I-POPU
) ) I-POPU
. . O

Some DT O
studies NNS O
have VBP O
suggested VBN O
that IN O
rituximab NN O
is VBZ O
associated VBN O
with IN O
excessive JJ B-OC
toxicity NN I-OC
in IN O
HIV-associated NNP O
NHL NNP O
, , O
and CC O
that IN O
infusional JJ O
chemotherapy NN O
may MD O
be VB O
more RBR O
effective JJ O
. . O

We PRP O
performed VBD O
a DT O
randomized JJ O
phase NN O
2 CD O
trial NN O
of IN O
rituximab NN B-INTV
( ( I-INTV
375 CD I-INTV
mg/m NN I-INTV
( ( I-INTV
2 CD I-INTV
) ) I-INTV
) ) I-INTV
given VBN I-INTV
either CC I-INTV
concurrently RB I-INTV
before IN I-INTV
each DT I-INTV
infusional JJ I-INTV
etoposide NN I-INTV
, , I-INTV
vincristine NN I-INTV
, , I-INTV
doxorubicin NN I-INTV
, , I-INTV
cyclophosphamide NN I-INTV
, , I-INTV
and CC I-INTV
prednisone NN I-INTV
( ( I-INTV
EPOCH NNP I-INTV
) ) I-INTV
chemotherapy NN I-INTV
cycle NN I-INTV
or CC I-INTV
sequentially RB I-INTV
( ( I-INTV
weekly JJ I-INTV
for IN I-INTV
6 CD I-INTV
weeks NNS I-INTV
) ) I-INTV
after IN I-INTV
completion NN I-INTV
of IN I-INTV
all DT I-INTV
chemotherapy NN I-INTV
in IN I-INTV
HIV-associated NNP B-POPU
NHL NNP I-POPU
. . O

EPOCH NNP B-INTV
consisted VBD O
of IN O
a DT O
96-hour JJ O
intravenous JJ O
infusion NN O
of IN O
etoposide NN B-INTV
, , I-INTV
doxorubicin NN I-INTV
, , I-INTV
and CC I-INTV
vincristine JJ I-INTV
plus CC I-INTV
oral JJ I-INTV
prednisone NN I-INTV
followed VBN O
by IN O
intravenous JJ O
bolus JJ O
cyclophosphamide NN B-INTV
given VBN O
every DT O
21 CD O
days NNS O
for IN O
4 CD O
to TO O
6 CD O
cycles NNS O
. . O

In IN O
the DT O
concurrent NN O
arm NN O
, , O
35 CD O
of IN O
48 CD B-POPU
evaluable JJ I-POPU
patients NNS I-POPU
( ( O
73 CD O
% NN O
; : O
95 CD O
% NN O
confidence NN O
interval NN O
, , O
58 CD O
% NN O
-85 NNP O
% NN O
) ) O
had VBD O
a DT O
complete JJ B-OC
response NN I-OC
. . O

In IN O
the DT O
sequential JJ O
arm NN O
, , O
29 CD O
of IN O
53 CD B-POPU
evaluable JJ I-POPU
patients NNS I-POPU
( ( O
55 CD O
% NN O
; : O
95 CD O
% NN O
confidence NN O
interval NN O
, , O
41 CD O
% NN O
-68 CD O
% NN O
) ) O
had VBD O
a DT O
complete JJ O
response NN O
. . O

The DT O
primary JJ O
efficacy NN O
endpoint NN O
was VBD O
met VBN O
for IN O
the DT O
concurrent NN O
arm NN O
only RB O
. . O

Toxicity NNP B-OC
was VBD O
comparable JJ O
in IN O
the DT O
2 CD O
arms NNS O
, , O
although IN O
patients NNS O
with IN O
a DT O
baseline NN O
CD4 NNP B-OC
count NN O
less JJR O
than IN O
50/microL CD O
had VBD O
a DT O
high JJ O
infectious JJ B-OC
death NN I-OC
rate NN I-OC
in IN O
the DT O
concurrent NN O
arm NN O
. . O

We PRP O
conclude VBP O
that DT O
concurrent NN B-INTV
rituximab NN I-INTV
plus CC I-INTV
infusional JJ I-INTV
EPOCH NNP I-INTV
is VBZ O
an DT O
effective JJ O
regimen NNS O
for IN O
HIV-associated JJ B-POPU
lymphoma NN I-POPU
. . O

-DOCSTART- -X- O O

Oral JJ B-INTV
6-mercaptopurine JJ I-INTV
versus NN O
oral JJ B-INTV
6-thioguanine JJ I-INTV
and CC O
veno-occlusive JJ O
disease NN O
in IN B-POPU
children NNS I-POPU
with IN I-POPU
standard-risk JJ I-POPU
acute JJ I-POPU
lymphoblastic JJ I-POPU
leukemia NN I-POPU
: : I-POPU
report NN O
of IN O
the DT O
Children NNP O
's POS O
Oncology NNP O
Group NNP O
CCG-1952 NNP O
clinical JJ O
trial NN O
. . O

The DT O
Children NNP B-POPU
's POS I-POPU
Cancer NNP I-POPU
Group NNP I-POPU
1952 CD I-POPU
( ( I-POPU
CCG-1952 NNP I-POPU
) ) I-POPU
clinical JJ O
trial NN O
studied VBD O
the DT O
substitution NN B-INTV
of IN I-INTV
oral JJ I-INTV
6-thioguanine JJ I-INTV
( ( I-INTV
TG NNP I-INTV
) ) I-INTV
for IN I-INTV
6-mercaptopurine JJ I-INTV
( ( I-INTV
MP NNP I-INTV
) ) I-INTV
and CC I-INTV
triple JJ I-INTV
intrathecal JJ I-INTV
therapy NN I-INTV
( ( I-INTV
ITT NNP I-INTV
) ) I-INTV
for IN I-INTV
intrathecal JJ I-INTV
methotrexate NN I-INTV
( ( I-INTV
IT-MTX NNP I-INTV
) ) I-INTV
in IN O
the DT O
treatment NN O
of IN O
standard-risk JJ B-POPU
acute JJ I-POPU
lymphoblastic JJ I-POPU
leukemia NN I-POPU
. . O

After IN B-POPU
remission NN I-POPU
induction NN I-POPU
, , I-POPU
2027 CD I-POPU
patients NNS I-POPU
were VBD O
randomized VBN O
to TO O
receive VB O
MP NNP B-INTV
( ( O
n JJ O
= NN O
1010 CD O
) ) O
or CC B-INTV
TG NNP I-INTV
( ( O
n JJ O
= NN O
1017 CD O
) ) O
and CC B-INTV
IT-MTX NNP I-INTV
( ( O
n CD O
= NNP O
1018 CD O
) ) O
or CC B-INTV
ITT NNP I-INTV
( ( O
n JJ O
= NN O
1009 CD O
) ) O
. . O

The DT O
results NNS O
of IN O
the DT O
thiopurine NN O
comparison NN O
are VBP O
as IN O
follows VBZ O
. . O

The DT O
estimated JJ O
7-year JJ O
event-free JJ B-OC
survival NN I-OC
( ( I-OC
EFS NNP I-OC
) ) I-OC
for IN O
subjects NNS O
randomized VBN O
to TO O
TG NNP O
was VBD O
84.1 CD O
% NN O
( ( O
+/- JJ O
1.8 CD O
% NN O
) ) O
and CC O
to TO O
MP NNP O
was VBD O
79.0 CD O
% NN O
( ( O
+/- JJ O
2.1 CD O
% NN O
; : O
P NNP O
= NNP O
.004 NNP O
log NNP O
rank NN O
) ) O
, , O
although IN O
overall JJ B-OC
survival NN I-OC
was VBD O
91.9 CD O
% NN O
( ( O
+/- JJ O
1.4 CD O
% NN O
) ) O
and CC O
91.2 CD O
% NN O
( ( O
+/- JJ O
1.5 CD O
% NN O
) ) O
, , O
respectively RB O
( ( O
P NNP O
= NNP O
.6 NNP O
log NNP O
rank NN O
) ) O
. . O

The DT O
TG NNP O
starting VBG O
dose NN O
was VBD O
reduced VBN O
from IN O
60 CD O
to TO O
50 CD O
mg/m NN O
( ( O
2 CD O
) ) O
per IN O
day NN O
after IN O
recognition NN O
of IN O
hepatic JJ B-OC
veno-occlusive JJ I-OC
disease NN I-OC
( ( I-OC
VOD NNP I-OC
) ) I-OC
. . O

A DT O
total NN O
of IN O
257 CD B-POPU
patients NNS I-POPU
on IN O
TG NNP O
( ( O
25 CD O
% NN O
) ) O
developed VBD O
VOD NNP B-OC
or CC O
disproportionate VB B-OC
thrombocytopenia NN I-OC
and CC O
switched VBD O
to TO O
MP NNP O
. . O

Once NNP O
portal JJ B-OC
hypertension NN I-OC
occurred VBD O
, , O
all DT O
subjects NNS O
on IN O
TG NNP O
were VBD O
changed VBN O
to TO O
MP NNP O
. . O

The DT O
benefit NN O
of IN O
randomization NN O
to TO O
TG NNP O
over IN O
MP NNP O
, , O
as IN O
measured VBN O
by IN O
EFS NNP O
, , O
was VBD O
evident JJ O
primarily RB O
in IN O
boys NNS O
who WP O
began VBD O
TG NNP O
at IN O
60 CD O
mg/m NN O
( ( O
2 CD O
) ) O
( ( O
relative JJ O
hazard NN O
rate NN O
[ NNP O
RHR NNP O
] NNP O
0.65 CD O
, , O
P NNP O
= NNP O
.002 NNP O
) ) O
. . O

The DT O
toxicities NNS O
of IN O
TG NNP O
preclude VBP O
its PRP$ O
protracted JJ O
use NN O
as IN O
given VBN O
in IN O
this DT O
study NN O
. . O

This DT O
study NN O
is VBZ O
registered VBN O
at IN O
http NN O
: : O
//clinicaltrials.gov NN O
as IN O
NCT00002744 NNP O
. . O

-DOCSTART- -X- O O

Allogeneic NNP B-INTV
marrow NN I-INTV
transplantation NN I-INTV
in IN O
patients NNS B-POPU
with IN I-POPU
chronic JJ I-POPU
myeloid NN I-POPU
leukemia NN I-POPU
in IN I-POPU
the DT I-POPU
chronic JJ I-POPU
phase NN I-POPU
: : I-POPU
a DT O
randomized JJ O
trial NN O
of IN O
two CD O
irradiation NN O
regimens NNS O
. . O

A DT O
randomized JJ O
trial NN O
was VBD O
performed VBN O
to TO O
compare VB O
two CD O
regimens NNS O
of IN O
total JJ B-INTV
body NN I-INTV
irradiation NN I-INTV
in IN O
patients NNS B-POPU
with IN I-POPU
chronic JJ I-POPU
myeloid NN I-POPU
leukemia NN I-POPU
treated VBN I-POPU
by IN I-POPU
allogeneic JJ I-POPU
marrow NN I-POPU
transplantation NN I-POPU
while IN I-POPU
in IN I-POPU
the DT I-POPU
chronic JJ I-POPU
phase NN I-POPU
. . O

All DT O
patients NNS O
received VBD O
cyclophosphamide JJ B-INTV
120 CD O
mg/kg NN O
followed VBN O
by IN O
total JJ B-INTV
body NN I-INTV
irradiation NN I-INTV
and CC I-INTV
marrow NN I-INTV
from IN I-INTV
HLA-identical JJ I-INTV
siblings NNS I-INTV
. . O

Cyclosporine NNP B-INTV
and CC I-INTV
methotrexate NN I-INTV
were VBD O
used VBN O
for IN O
prophylaxis NN O
against IN O
acute JJ O
graft-versus-host JJ O
disease NN O
. . O

Fifty-seven JJ B-POPU
patients NNS I-POPU
were VBD O
randomized VBN O
to TO O
receive VB O
2.0 CD O
Gy NNP O
fractions NNS O
of IN O
irradiation NN B-INTV
daily NN O
for IN O
6 CD O
days NNS O
and CC O
59 CD O
were VBD O
randomized VBN O
to TO O
receive VB O
2.25 CD O
Gy NNP O
fractions NNS O
daily RB O
for IN O
7 CD O
days NNS O
. . O

The DT O
probabilities NNS B-OC
of IN I-OC
relapse NN I-OC
at IN O
4 CD O
years NNS O
were VBD O
0.25 CD O
for IN O
the DT O
12.0 CD O
Gy NNP O
group NN O
and CC O
0.00 CD O
for IN O
the DT O
15.75 CD O
Gy NNP O
group NN O
( ( O
P NNP O
= NNP O
.008 NNP O
) ) O
. . O

The DT O
actuarial JJ B-OC
probabilities NNS I-OC
of IN I-OC
survival NN I-OC
and CC I-OC
relapse-free JJ I-OC
survival NN I-OC
at IN O
4 CD O
years NNS O
were VBD O
0.60 CD O
and CC O
0.58 CD O
among IN O
the DT O
patients NNS O
who WP O
received VBD O
12.0 CD O
Gy NNP O
compared VBN O
with IN O
0.66 CD O
and CC O
0.66 CD O
for IN O
those DT O
who WP O
received VBD O
15.75 CD O
Gy NNP O
. . O

The DT O
4-year JJ B-OC
probabilities NNS I-OC
of IN I-OC
transplant-related JJ I-OC
mortality NN I-OC
were VBD O
0.24 CD O
and CC O
0.34 CD O
respectively RB O
( ( O
P NNP O
= NNP O
.13 NNP O
) ) O
while IN O
the DT O
probability NN B-OC
of IN I-OC
moderate JJ I-OC
to TO I-OC
severe VB I-OC
acute JJ I-OC
graft-versus-host JJ I-OC
disease NN I-OC
was VBD O
0.33 CD O
for IN O
the DT O
12.0 CD O
Gy NNP O
group NN O
and CC O
0.44 CD O
for IN O
the DT O
15.75 CD O
Gy NNP O
group NN O
( ( O
P NNP O
= NNP O
.15 NNP O
) ) O
. . O

The DT O
lower JJR O
relapse NN B-OC
probability NN I-OC
in IN O
the DT O
patients NNS B-POPU
receiving VBG I-POPU
the DT I-POPU
higher JJR I-POPU
dose NN I-POPU
of IN I-POPU
total JJ I-POPU
body NN I-POPU
irradiation NN I-POPU
did VBD O
not RB O
result VB O
in IN O
improved JJ B-OC
survival NN I-OC
because IN O
mortality NN O
from IN O
causes VBZ O
other JJ O
than IN O
relapse NN O
was VBD O
increased VBN O
. . O

-DOCSTART- -X- O O

Final JJ O
analysis NN O
of IN O
the DT O
UKLG NNP O
LY02 NNP O
trial NN O
comparing VBG O
6-8 JJ O
cycles NNS O
of IN O
CHOP NNP B-INTV
with IN O
3 CD O
cycles NNS O
of IN B-INTV
CHOP NNP I-INTV
followed VBN I-INTV
by IN I-INTV
a DT I-INTV
BEAM NNP I-INTV
autograft NN I-INTV
in IN O
patients NNS B-POPU
< JJ I-POPU
65 CD I-POPU
years NNS I-POPU
with IN I-POPU
poor JJ I-POPU
prognosis NN I-POPU
histologically RB I-POPU
aggressive JJ I-POPU
NHL NNP I-POPU
. . O

This DT O
trial NN O
involved VBD O
457 CD B-POPU
patients NNS I-POPU
and CC O
sought VBD O
to TO O
assess VB O
the DT O
value NN O
of IN O
early JJ O
intensification NN O
with IN O
autologous JJ O
transplantation NN O
in IN O
patients NNS B-POPU
with IN I-POPU
poor JJ I-POPU
prognosis NN I-POPU
histologically RB I-POPU
aggressive JJ I-POPU
non-Hodgkin JJ I-POPU
lymphoma NN I-POPU
( ( I-POPU
NHL NNP I-POPU
) ) I-POPU
showing VBG I-POPU
a DT I-POPU
response NN I-POPU
to TO I-POPU
initial JJ I-POPU
CHOP NNP I-POPU
( ( I-POPU
cyclophosphamide NN I-POPU
, , B-INTV
doxorubicin NN I-INTV
, , I-INTV
vincristine NN I-INTV
, , I-INTV
prednisolone NN I-INTV
) ) I-INTV
chemotherapy NN I-INTV
. . O

Randomization NN O
was VBD O
made VBN O
at IN O
the DT O
time NN O
of IN O
diagnosis NN O
with IN O
223 CD O
assigned VBD O
to TO O
continuing VBG O
CHOP NNP B-INTV
and CC O
234 CD O
to TO O
3 CD O
cycles NNS O
of IN O
CHOP NNP B-INTV
followed VBN I-INTV
by IN I-INTV
a DT I-INTV
BEAM NNP I-INTV
( ( I-INTV
carmustine NN I-INTV
, , I-INTV
etoposide RB I-INTV
, , I-INTV
cytarabine NN I-INTV
, , I-INTV
melphalan NN I-INTV
) ) I-INTV
autograft NN I-INTV
. . O

Analysis NN O
was VBD O
on IN O
an DT O
intention NN O
to TO O
treat VB O
basis NN O
. . O

After IN O
the DT O
initial JJ O
three CD O
cycles NNS O
of IN O
CHOP NNP B-INTV
19 CD O
% NN O
of IN O
the DT O
whole JJ O
group NN O
were VBD O
in IN O
complete JJ B-OC
response NN I-OC
( ( I-OC
CR NNP I-OC
) ) I-OC
and CC O
53 CD O
% NN O
in IN O
partial JJ B-OC
remission NN I-OC
( ( I-OC
PR NNP I-OC
) ) I-OC
. . O

At IN O
the DT O
end NN O
of IN O
treatment NN O
86 CD O
% NN O
of IN O
patients NNS O
in IN O
the DT O
CHOP NNP B-INTV
arm NN O
had VBD O
responded VBN O
with IN O
58 CD O
% NN O
in IN O
CR NNP O
. . O

In IN O
the DT O
high-dose JJ O
therapy NN O
arm NN O
the DT B-OC
overall JJ I-OC
response NN I-OC
rate NN I-OC
was VBD O
83 CD O
% NN O
with IN O
64 CD O
% NN O
in IN O
CR NNP O
( ( O
difference NN O
between IN O
arms NNS O
not RB O
significant JJ O
) ) O
. . O

The DT B-OC
progression-free JJ I-OC
survival NN I-OC
( ( I-OC
PFS NNP I-OC
) ) I-OC
and CC I-OC
overall JJ I-OC
survival NN I-OC
at IN I-OC
5 CD I-OC
years NNS I-OC
for IN O
the DT O
continuing VBG O
CHOP NNP O
arm NN O
were VBD O
38 CD O
% NN O
and CC O
50 CD O
% NN O
respectively RB O
, , O
and CC O
for IN O
the DT O
autograft NN O
arm NN O
were VBD O
44 CD O
% NN O
and CC O
50 CD O
% NN O
( ( O
differences NNS O
not RB O
significant JJ O
) ) O
. . O

Of IN O
the DT O
patients NNS O
who WP O
attained VBD O
CR NNP O
and CC O
subsequently RB O
relapsed VBN B-OC
, , O
there EX O
were VBD O
no DT O
long-term JJ B-OC
survivors NNS I-OC
in IN O
the DT O
autograft NN O
recipients NNS O
compared VBN O
to TO O
46 CD O
% NN O
of IN O
the DT O
continuing VBG O
CHOP NNP B-INTV
recipients NNS O
( ( O
P NNP O
= NNP O
0.0008 CD O
) ) O
. . O

In IN O
conclusion NN O
, , O
no DT O
survival JJ O
benefit NN O
was VBD O
demonstrated VBN O
for IN O
an DT O
early JJ O
autograft NN O
in IN O
first JJ O
response NN O
. . O

-DOCSTART- -X- O O

[ JJ B-OC
Therapy NNP I-OC
with IN O
alpha-interferon NN B-INTV
in IN O
non-Hodgkin NN B-POPU
's POS I-POPU
lymphoma NN I-POPU
with IN I-POPU
a DT I-POPU
low JJ I-POPU
grade NN I-POPU
of IN I-POPU
malignancy NN I-POPU
( ( O
correct JJ O
title NN O
supplied VBD O
from IN O
Table NNP O
of IN O
Contents NNP O
) ) O
] NN O
. . O

-DOCSTART- -X- O O

Clofarabine NNP B-INTV
± NNP I-INTV
fludarabine NN I-INTV
with IN O
once RB O
daily JJ O
i.v NN O
. . O

busulfan NN B-INTV
as IN O
pretransplant JJ O
conditioning NN O
therapy NN O
for IN B-POPU
advanced JJ I-POPU
myeloid NN I-POPU
leukemia NN I-POPU
and CC I-POPU
MDS NNP I-POPU
. . O

Although IN O
a DT O
combination NN O
of IN B-INTV
i.v NN I-INTV
. . O

busulfan NN B-INTV
( ( I-INTV
Bu NNP I-INTV
) ) I-INTV
and CC I-INTV
fludarabine NN I-INTV
( ( I-INTV
Flu NNP I-INTV
) ) I-INTV
is VBZ O
a DT O
safe JJ O
, , O
reduced-toxicity JJ O
conditioning NN O
program NN O
for IN O
acute JJ O
myelogenous JJ O
leukemia/myelodysplastic JJ O
syndromes NNS O
( ( O
AML/MDS NNP O
) ) O
, , O
recurrent JJ O
leukemia NN O
posttransplantation NN O
remains VBZ O
a DT O
problem NN O
. . O

To TO O
enhance VB O
the DT O
conditioning NN O
regimen NN O
's POS O
antileukemic JJ O
effect NN O
, , O
we PRP O
decided VBD O
to TO O
supplant VB B-INTV
Flu NNP I-INTV
with IN I-INTV
clofarabine NN I-INTV
( ( I-INTV
Clo NNP I-INTV
) ) I-INTV
, , O
and CC O
assayed VBD O
the DT O
interactions NNS O
of IN O
these DT O
nucleoside JJ O
analogs NNS O
alone RB O
and CC O
in IN O
combination NN O
with IN O
Bu NNP O
in IN O
Bu-resistant NNP O
human NN O
cell NN O
lines NNS O
in IN O
vitro NN O
. . O

We PRP O
found VBD O
pronounced VBD O
synergy NN O
between IN O
each DT O
nucleoside NN O
and CC O
the DT O
alkylator NN O
but CC O
even RB O
more RBR O
enhanced JJ O
cytotoxic NN O
synergy NN O
when WRB O
the DT O
nucleoside JJ O
analogs NNS O
were VBD O
combined VBN O
prior RB O
to TO O
exposing VBG O
the DT O
cells NNS O
to TO O
Bu NNP O
. . O

We PRP O
then RB O
designed VBD O
a DT O
4-arm JJ O
clinical JJ O
trial NN O
in IN B-POPU
patients NNS I-POPU
with IN I-POPU
myeloid JJ I-POPU
leukemia NN I-POPU
undergoing VBG I-POPU
allogeneic JJ I-POPU
stem NN I-POPU
cell NN I-POPU
transplantation NN I-POPU
( ( I-POPU
allo-SCT JJ I-POPU
) ) I-POPU
. . O

Patients NNS O
were VBD O
adaptively RB O
randomized VBN O
as IN O
follows VBZ O
: : O
Arm JJ O
I-Clo NN B-INTV
: : I-INTV
Flu CD I-INTV
10:30 CD O
mg/m NN O
( ( O
2 CD O
) ) O
, , O
Arm NNP O
II-20:20 NNP O
mg/m NN O
( ( O
2 CD O
) ) O
, , O
Arm NNP O
III-30:10 NNP O
mg/m NN O
( ( O
2 CD O
) ) O
, , O
and CC O
Arm NNP O
IV-single-agent NNP B-INTV
Clo NNP I-INTV
at IN O
40 CD O
mg/m NN O
( ( O
2 CD O
) ) O
. . O

The DT O
nucleoside JJ O
analog NN O
( ( O
s PRP O
) ) O
were/was NN O
infused VBN O
over IN O
1 CD O
hour NN O
once RB O
daily JJ O
for IN O
4 CD O
days NNS O
, , O
followed VBD O
on IN O
each DT O
day NN O
by IN O
Bu NNP O
, , O
infused VBD O
over IN O
3 CD O
hours NNS O
to TO O
a DT O
pharmacokinetically RB O
targeted VBN O
daily JJ O
area NN O
under IN O
the DT O
curve NN O
( ( O
AUC NNP O
) ) O
of IN O
6000 CD O
μMol-min JJ O
± JJ O
10 CD B-POPU
% NN I-POPU
. . O

Fifty-one CD B-POPU
patients NNS I-POPU
have VBP I-POPU
been VBN I-POPU
enrolled VBN I-POPU
with IN O
a DT O
minimum JJ O
follow-up JJ O
exceeding VBG O
100 CD O
days NNS B-POPU
. . O

There EX B-POPU
were VBD I-POPU
32 CD I-POPU
males NNS I-POPU
and CC I-POPU
19 CD I-POPU
females NNS I-POPU
, , I-POPU
with IN I-POPU
a DT I-POPU
median JJ I-POPU
age NN I-POPU
of IN I-POPU
45 CD I-POPU
years NNS I-POPU
( ( I-POPU
range NN I-POPU
: : I-POPU
6-59 JJ I-POPU
) ) I-POPU
. . O

Nine JJ B-POPU
patients NNS I-POPU
had VBD I-POPU
chronic JJ I-POPU
myeloid NN I-POPU
leukemia NN I-POPU
( ( I-POPU
CML NNP I-POPU
) ) I-POPU
( ( I-POPU
BC NNP I-POPU
: : I-POPU
2 CD I-POPU
, , I-POPU
second JJ I-POPU
AP NNP I-POPU
: : I-POPU
3 CD I-POPU
, , I-POPU
and CC I-POPU
tyrosine-kinase JJ I-POPU
inhibitor NN I-POPU
refractory NN I-POPU
first RB I-POPU
chronic JJ I-POPU
phase NN I-POPU
[ NNP I-POPU
CP NNP I-POPU
] NN I-POPU
: : I-POPU
4 CD I-POPU
) ) I-POPU
. . O

Forty-two JJ B-POPU
patients NNS I-POPU
had VBD I-POPU
AML NNP I-POPU
: : I-POPU
14 CD I-POPU
were VBD I-POPU
induction NN I-POPU
failures NNS I-POPU
, , I-POPU
8 CD I-POPU
in IN I-POPU
first JJ I-POPU
chemotherapy-refractory JJ I-POPU
relapse NN I-POPU
, , I-POPU
7 CD I-POPU
in IN I-POPU
untreated JJ I-POPU
relapse NN I-POPU
, , I-POPU
3 CD I-POPU
in IN I-POPU
second JJ I-POPU
or CC I-POPU
subsequent JJ I-POPU
relapse NN I-POPU
, , I-POPU
4 CD I-POPU
were VBD I-POPU
in IN I-POPU
second JJ I-POPU
complete JJ I-POPU
remission NN I-POPU
( ( I-POPU
CR NNP I-POPU
) ) I-POPU
, , I-POPU
and CC I-POPU
3 CD I-POPU
in IN I-POPU
second JJ I-POPU
CR NNP I-POPU
without IN I-POPU
platelet NN I-POPU
recovery NN I-POPU
( ( I-POPU
CRp NNP I-POPU
) ) I-POPU
, , I-POPU
2 CD I-POPU
were VBD I-POPU
in IN I-POPU
high-risk JJ I-POPU
CR1 NNP I-POPU
. . O

Finally NNP B-POPU
, , I-POPU
1 CD I-POPU
patient NN I-POPU
was VBD I-POPU
in IN I-POPU
first JJ I-POPU
CRp NNP I-POPU
. . O

Graft-versus-host NNP O
disease NN O
( ( O
GVHD NNP O
) ) O
prophylaxis NN O
was VBD O
tacrolimus JJ O
and CC O
mini-methorexate JJ O
( ( O
MTX NNP O
) ) O
, , O
and CC O
those DT O
who WP O
had VBD O
an DT O
unrelated JJ O
or CC O
1 CD O
antigen-mismatched JJ O
donor NN O
received VBD O
low-dose JJ O
rabbit-ATG NN O
( ( O
Thymoglobulin™ NNP O
) ) O
. . O

All DT O
patients NNS O
engrafted VBN B-POPU
. . O

Forty-one CD B-POPU
patients NNS I-POPU
had VBD I-POPU
active JJ I-POPU
leukemia NN I-POPU
at IN I-POPU
the DT I-POPU
time NN I-POPU
of IN I-POPU
transplant NN I-POPU
, , I-POPU
and CC I-POPU
35 CD I-POPU
achieved VBN I-POPU
CR NNP O
( ( B-POPU
85 CD I-POPU
% NN I-POPU
) ) I-POPU
. . O

Twenty CD O
of IN O
the DT O
42 CD O
AML NNP O
patients NNS O
and CC O
5 CD O
of IN O
9 CD O
CML NNP O
patients NNS O
are VBP O
alive JJ O
with IN B-OC
a DT I-OC
projected JJ I-OC
median JJ I-OC
overall JJ I-OC
survival NN I-OC
( ( O
OS NNP O
) ) O
of IN O
23 CD O
months NNS B-OC
. . O

Marrow NNP B-OC
and CC I-OC
blood NN I-OC
( ( I-OC
T NNP I-OC
cell NN I-OC
) ) I-OC
chimerism NN O
studies NNS O
at IN O
day NN O
+100 NNP O
revealed VBD O
that IN O
both DT O
in IN O
the DT O
lower-dose JJ O
Clo NNP O
groups NNS O
( ( O
groups NNS O
1+2 CD O
) ) O
and CC O
the DT O
higher-dose JJ O
Clo NNP O
groups NNS O
( ( O
groups NNS O
3+4 CD O
) ) O
, , O
the DT O
patients NNS O
had VBD B-OC
a DT I-OC
median NN I-OC
of IN I-OC
100 CD I-OC
% NN I-OC
donor NN I-OC
( ( I-OC
T NNP I-OC
cell NN I-OC
) ) I-OC
-derived VBD I-OC
DNA NNP O
. . O

There EX B-OC
has VBZ I-OC
been VBN I-OC
no DT I-OC
secondary JJ I-OC
graft NN I-OC
failure NN I-OC
. . O

In IN O
the DT O
first JJ O
100 CD O
days NNS O
, , O
1 CD O
patient NN B-OC
died VBD I-OC
of IN I-OC
pneumonia NN I-OC
, , O
and CC O
1 CD B-OC
of IN I-OC
liver NN I-OC
GVHD NNP O
. . O

We PRP O
conclude VBP O
that IN O
( ( O
1 CD O
) ) O
Clo NNP O
± NNP O
Flu NNP O
with IN O
i.v NN O
. . O

Bu NNP B-OC
as IN I-OC
pretransplant JJ I-OC
conditioning NN I-OC
is VBZ I-OC
safe JJ B-POPU
in IN I-POPU
high-risk JJ I-POPU
myeloid JJ I-POPU
leukemia NN I-POPU
patients NNS I-POPU
; : I-POPU
( ( O
2 CD O
) ) O
clofarabine NN B-OC
is VBZ I-OC
sufficiently RB I-OC
immunosuppressive JJ I-OC
to TO O
support VB O
allo-SCT NN O
in IN O
myeloid JJ O
leukemia NN O
; : O
and CC O
( ( O
3 CD O
) ) O
the DT O
median JJ O
OS NNP O
of IN O
23 CD O
months NNS O
in IN O
this DT O
high-risk JJ O
patient NN O
population NN O
is VBZ O
encouraging VBG O
. . O

Additional JJ O
studies NNS O
to TO O
evaluate VB B-OC
the DT I-OC
antileukemic JJ I-OC
efficacy NN B-INTV
of IN I-INTV
Clo NNP I-INTV
± NNP O
Flu NNP B-INTV
with IN I-INTV
i.v NN I-INTV
. . O

Bu NNP B-OC
as IN I-OC
pretransplant JJ I-OC
conditioning NN I-OC
therapy NN I-OC
are VBP I-OC
warranted VBN I-OC
. . O

-DOCSTART- -X- O O

Physical JJ O
activity NN O
for IN O
patients NNS B-POPU
undergoing VBG I-POPU
an DT I-POPU
allogeneic JJ I-POPU
hematopoietic JJ I-POPU
stem NN I-POPU
cell NN I-POPU
transplantation NN I-POPU
: : I-POPU
benefits NNS O
of IN O
a DT O
moderate JJ B-INTV
exercise NN I-INTV
intervention NN I-INTV
. . O

UNLABELLED IN O
An DT O
allogeneic JJ B-INTV
hematopoietic JJ I-INTV
stem NN I-INTV
cell NN I-INTV
transplantation NN I-INTV
( ( O
HSCT NNP O
) ) O
can MD O
have VB O
profound VBN O
and CC O
lasting JJ O
adverse JJ O
effects NNS O
on IN O
a DT O
patient NN O
's POS O
physical JJ O
and CC O
psychological JJ O
well-being NN O
. . O

So RB O
far RB O
, , O
only RB O
few JJ O
studies NNS O
have VBP O
investigated VBN O
the DT O
effectiveness NN B-OC
of IN O
physical JJ O
activity NN O
over IN O
the DT O
entire JJ O
inpatient NN O
phase NN O
of IN O
an DT O
allogeneic JJ O
HSCT NNP O
. . O

PURPOSE NNP O
We PRP O
performed VBD O
a DT O
randomized VBN O
controlled VBN O
study NN O
to TO O
examine VB O
the DT O
influence NN O
of IN O
a DT O
controlled JJ O
moderate JJ B-INTV
exercise NN I-INTV
program NN I-INTV
starting VBG O
parallel JJ O
to TO O
chemotherapeutic JJ O
conditioning NN O
and CC O
total JJ O
body NN O
irradiation NN O
on IN O
the DT O
patient NN O
's POS O
physical JJ O
and CC O
psychological JJ O
constitution NN O
. . O

PATIENTS NNP O
AND CC O
METHODS NNP O
Forty-seven NNP B-POPU
patients NNS I-POPU
undergoing VBG I-POPU
an DT I-POPU
allogeneic JJ I-POPU
HSCT NNP I-POPU
were VBD O
randomly RB O
assigned VBN O
to TO O
an DT O
exercise NN B-INTV
group NN I-INTV
( ( I-INTV
EG NNP I-INTV
) ) I-INTV
or CC O
a DT O
control NN B-INTV
group NN I-INTV
( ( I-INTV
CG NNP I-INTV
) ) I-INTV
. . O

While IN O
the DT O
EG NNP O
took VBD O
part NN O
in IN O
an DT O
endurance NN O
and CC O
activity NN O
of IN O
daily JJ O
living-training JJ O
twice NN O
a DT O
day NN O
, , O
the DT O
CG NNP O
received VBD O
the DT O
clinic NN O
's POS O
standard JJ O
physiotherapy NN O
program NN O
once RB O
a DT O
day NN O
. . O

RESULTS NNP O
Significant NNP B-OC
differences VBZ I-OC
and/or JJ O
trends NNS O
in IN O
favor NN O
of IN O
the DT O
EG NNP O
were VBD O
observed VBN O
regarding VBG O
the DT O
primary JJ O
endpoint NN O
endurance NN B-OC
performance NN I-OC
( ( O
P=0.002 NNP O
) ) O
, , O
muscular JJ B-OC
strength NN I-OC
( ( O
P=0.022 NNP O
) ) O
, , O
fatigue NN B-OC
( ( O
P=0.046 NNP O
) ) O
, , O
and CC O
emotional JJ B-OC
state NN I-OC
( ( O
P=0.028 NNP O
) ) O
without IN O
posing VBG O
an DT O
additional JJ O
risk NN O
for IN O
the DT O
individual NN O
. . O

CONCLUSION VB O
The DT O
results NNS O
show VBP O
that IN O
the DT O
training NN O
program NN O
is VBZ O
feasible JJ O
and CC O
seems VBZ O
to TO O
have VB O
positive JJ O
influences NNS O
on IN O
physical JJ B-OC
performance NN I-OC
and CC I-OC
quality NN I-OC
of IN I-OC
life NN I-OC
in IN O
patients NNS B-POPU
undergoing VBG I-POPU
an DT I-POPU
allogeneic JJ I-POPU
HSCT NNP I-POPU
. . O

However RB O
, , O
further JJ O
studies NNS O
are VBP O
necessary JJ O
to TO O
confirm VB O
these DT O
results NNS O
. . O

-DOCSTART- -X- O O

Antifungal NNP O
prophylaxis NN O
during IN O
remission NN B-POPU
induction NN I-POPU
therapy NN I-POPU
for IN I-POPU
acute JJ I-POPU
leukemia NN I-POPU
fluconazole JJ O
versus NN B-INTV
intravenous JJ I-INTV
amphotericin NN I-INTV
B NNP I-INTV
. . O

BACKGROUND NNP O
Fungal NNP O
infection NN O
is VBZ O
a DT O
frequent JJ O
and CC O
often RB O
fatal JJ O
complication NN O
in IN O
patients NNS B-POPU
undergoing JJ I-POPU
remission NN I-POPU
induction NN I-POPU
therapy NN I-POPU
for IN I-POPU
acute JJ I-POPU
leukemia NN I-POPU
. . O

Although IN O
candidiasis NN O
is VBZ O
the DT O
most RBS O
common JJ O
infection NN O
, , O
mold JJ O
infections NNS O
are VBP O
increasing VBG O
in IN O
frequency NN O
. . O

Fluconazole NNP B-INTV
( ( I-INTV
FLU NNP I-INTV
) ) I-INTV
is VBZ O
a DT O
new JJ O
antifungal JJ O
agent NN O
that WDT O
has VBZ O
been VBN O
used VBN O
successfully RB O
to TO O
treat VB O
Candida NNP O
infections NNS O
and CC O
has VBZ O
modest JJ O
activity NN O
against IN O
aspergillosis NN O
in IN O
animal JJ O
models NNS O
. . O

Subtherapeutic JJ O
doses NNS O
of IN O
amphotericin NN B-INTV
B NNP I-INTV
( ( I-INTV
AMB NNP I-INTV
) ) I-INTV
have VBP O
been VBN O
considered VBN O
effective JJ O
as IN O
prophylaxis NN O
in IN O
these DT O
patients NNS O
. . O

This DT O
study NN O
was VBD O
designed VBN O
to TO O
compare VB O
the DT O
efficacy NN B-OC
and CC I-OC
toxicity NN I-OC
of IN O
these DT O
agents NNS O
as IN O
antifungal JJ O
prophylaxis NN O
. . O

METHODS NNP O
Adults NNP B-POPU
with IN I-POPU
acute JJ I-POPU
leukemia NN I-POPU
undergoing VBG I-POPU
remission NN I-POPU
induction NN I-POPU
chemotherapy NN I-POPU
randomly NN O
were VBD O
assigned VBN O
to TO O
receive VB B-INTV
antifungal JJ I-INTV
prophylaxis NN I-INTV
with IN I-INTV
AMB NNP I-INTV
( ( I-INTV
0.5 CD I-INTV
mg/kg NN I-INTV
three CD I-INTV
times NNS I-INTV
weekly JJ I-INTV
) ) I-INTV
or CC I-INTV
FLU NNP I-INTV
( ( I-INTV
400 CD I-INTV
mg NNS I-INTV
daily RB I-INTV
) ) I-INTV
. . O

Trimethoprim-sulfamethoxazole NN B-INTV
was VBD I-INTV
administered VBN I-INTV
as IN I-INTV
an DT I-INTV
antibacterial JJ I-INTV
prophylaxis NN I-INTV
. . O

Prophylaxis NNP B-INTV
was VBD I-INTV
continued VBN I-INTV
until IN I-INTV
the DT I-INTV
patient NN I-INTV
achieved VBD I-INTV
complete JJ I-INTV
remission NN I-INTV
or CC I-INTV
was VBD I-INTV
treated VBN I-INTV
for IN I-INTV
8 CD I-INTV
weeks NNS I-INTV
without IN I-INTV
antileukemic JJ I-INTV
response NN I-INTV
. . O

Prophylaxis NNP O
was VBD O
discontinued VBN O
if IN O
the DT O
patient NN O
experienced VBD O
a DT O
possible JJ O
or CC O
proven JJ O
fungal JJ O
infection NN O
or CC O
a DT O
serious JJ O
toxicity NN O
. . O

RESULTS NNP O
Overall NNP O
, , O
58 CD O
% NN O
of IN O
the DT O
36 CD B-POPU
patients NNS I-POPU
assigned VBN O
to TO O
AMB NNP B-INTV
successfully RB O
completed VBD O
prophylaxis NNS O
compared VBN O
with IN O
80 CD O
% NN O
of IN O
the DT O
41 CD B-POPU
patients NNS I-POPU
assigned VBN O
to TO O
FLU NNP B-INTV
( ( O
< NNP O
0.05 CD O
) ) O
. . O

Proven NNP B-OC
, , I-OC
probable JJ I-OC
, , I-OC
or CC I-OC
possible JJ I-OC
fungal JJ I-OC
infections NNS I-OC
occurred VBD O
in IN O
31 CD O
% NN O
and CC O
17 CD O
% NN O
of IN O
the DT O
patients NNS O
, , O
respectively RB O
. . O

The DT O
risk NN O
of IN O
discontinuing VBG O
prophylaxis NN O
due JJ O
to TO O
fungal JJ B-OC
infection NN I-OC
or CC O
toxicity NN B-OC
increased VBN O
with IN O
time NN O
in IN O
the DT O
study NN O
and CC O
was VBD O
significantly RB O
greater JJR O
for IN O
AMB NNP O
( ( O
P NNP O
= NNP O
0.02 CD O
) ) O
. . O

CONCLUSIONS NN O
At IN O
the DT O
dose NN O
used VBN O
in IN O
this DT O
study NN O
, , O
AMB NNP B-INTV
was VBD O
no DT O
more RBR O
effective JJ B-OC
and CC O
was VBD O
more JJR O
toxic JJ B-OC
than IN O
FLU NNP B-INTV
for IN O
prophylaxis NN O
of IN O
fungal JJ B-OC
infections NNS I-OC
in IN O
patients NNS B-POPU
undergoing JJ I-POPU
remission NN I-POPU
induction NN I-POPU
chemotherapy NN I-POPU
for IN I-POPU
acute JJ I-POPU
leukemia NN I-POPU
. . O

-DOCSTART- -X- O O

How WRB O
to TO O
establish VB O
equivalence NN O
when WRB O
data NNS O
are VBP O
censored VBN O
: : O
a DT O
randomized JJ B-POPU
trial NN I-POPU
of IN I-POPU
treatments NNS I-POPU
for IN I-POPU
B NNP I-POPU
non-Hodgkin JJ I-POPU
lymphoma NN I-POPU
. . O

Interest NN O
in IN O
equivalence NN O
trials NNS O
has VBZ O
been VBN O
increasing VBG O
for IN O
many JJ O
years NNS O
, , O
though IN O
the DT O
methodology NN O
which WDT O
has VBZ O
been VBN O
developed VBN O
for IN O
such JJ O
trials NNS O
is VBZ O
mainly RB O
for IN O
uncensored JJ O
data NNS O
. . O

In IN O
cancer NN O
research NN O
we PRP O
are VBP O
more RBR O
often RB O
concerned VBN O
with IN O
survival NN B-OC
. . O

In IN O
an DT O
efficacy NN O
trial NN O
, , O
the DT O
null JJ O
hypothesis NN O
specifies NNS O
equality NN O
of IN O
the DT O
two CD O
survival JJ O
distributions NNS O
, , O
but CC O
in IN O
an DT O
equivalence NN O
trial NN O
, , O
a DT O
null JJ O
hypothesis NN O
of IN O
inequivalence NN O
H0 NNP O
has VBZ O
to TO O
be VB O
tested VBN O
. . O

The DT O
usual JJ O
logrank NN B-INTV
test NN I-INTV
has VBZ O
to TO O
be VB O
modified VBN O
to TO O
test VB O
whether IN O
the DT O
true JJ O
value NN O
r NN O
of IN O
the DT O
ratio NN O
of IN O
hazard NN O
rates NNS O
in IN O
two CD O
treatment NN O
groups NNS O
is VBZ O
at IN O
least JJS O
equal JJ O
to TO O
a DT O
limit NN O
value NN O
r0 NN O
. . O

If IN O
prognostic JJ O
factors NNS O
have VBP O
to TO O
be VB O
taken VBN O
into IN O
account NN O
, , O
the DT O
Cox NNP O
model NN O
provides VBZ O
tests NNS O
of IN O
Ho NNP O
, , O
and CC O
a DT O
useful JJ O
confidence NN O
interval NN O
for IN O
the DT O
adjusted JJ O
relative JJ O
derived VBN O
from IN O
the DT O
regression NN O
parameter NN O
for IN O
the DT O
treatment NN O
indicator NN O
. . O

An DT O
equivalence NN O
trial NN O
of IN O
maintenance NN B-INTV
therapy NN I-INTV
was VBD O
carried VBN O
out RP O
in IN O
children NNS B-POPU
with IN I-POPU
B NNP I-POPU
non-Hodgkin JJ I-POPU
lymphoma NN I-POPU
, , O
and CC O
serves VBZ O
as IN O
an DT O
illustration NN O
. . O

-DOCSTART- -X- O O

Adjuvant NNP O
cyclophosphamide NN B-INTV
, , I-INTV
doxorubicin NN I-INTV
, , I-INTV
vincristine NN I-INTV
, , I-INTV
and CC I-INTV
prednisone NN I-INTV
chemotherapy NN I-INTV
after IN O
radiation NN O
therapy NN O
in IN O
stage NN B-POPU
I PRP I-POPU
low-grade JJ I-POPU
and CC I-POPU
intermediate-grade JJ I-POPU
non-Hodgkin JJ I-POPU
lymphoma NN I-POPU
. . O

Results NNS O
of IN O
a DT O
prospective JJ O
randomized NN O
study NN O
. . O

BACKGROUND NNP O
In IN O
a DT O
prospective JJ O
randomized NN O
manner NN O
, , O
this DT O
study NN O
evaluated VBD O
the DT O
effect NN O
of IN O
adjuvant JJ B-INTV
chemotherapy NN I-INTV
( ( I-INTV
cyclophosphamide NN I-INTV
, , I-INTV
doxorubicin NN I-INTV
, , I-INTV
vincristine NN I-INTV
, , I-INTV
and CC I-INTV
prednisone NN I-INTV
; : I-INTV
CHOP NNP I-INTV
) ) I-INTV
in IN O
patients NNS B-POPU
with IN I-POPU
Stage NNP I-POPU
I PRP I-POPU
non-Hodgkin JJ I-POPU
lymphoma NN I-POPU
( ( I-POPU
NHL NNP I-POPU
) ) I-POPU
who WP I-POPU
have VBP I-POPU
achieved VBN I-POPU
a DT I-POPU
complete JJ I-POPU
response NN I-POPU
( ( I-POPU
CR NNP I-POPU
) ) I-POPU
after IN I-POPU
radiation NN I-POPU
therapy NN I-POPU
( ( I-POPU
RT NNP I-POPU
) ) I-POPU
. . O

METHODS NNP O
Forty-four JJ B-POPU
patients NNS I-POPU
with IN I-POPU
clinical JJ I-POPU
or CC I-POPU
pathologic JJ I-POPU
Stage NN I-POPU
I PRP I-POPU
intermediate-grade VBP I-POPU
or CC I-POPU
low-grade JJ I-POPU
NHL NNP I-POPU
were VBD O
randomized VBN O
to TO O
receive VB B-INTV
regional JJ I-INTV
RT NNP I-INTV
alone RB I-INTV
( ( I-INTV
median JJ I-INTV
dose NN I-INTV
, , I-INTV
40 CD I-INTV
Gy NNP I-INTV
) ) I-INTV
or CC I-INTV
regional JJ I-INTV
RT NNP I-INTV
followed VBN I-INTV
by IN I-INTV
six CD I-INTV
cycles NNS I-INTV
of IN I-INTV
CHOP NNP I-INTV
chemotherapy NN I-INTV
. . O

There EX O
were VBD O
no DT O
differences NNS O
in IN O
clinical JJ O
and CC O
pathologic JJ O
characteristics NNS B-OC
between IN O
the DT O
two CD O
treatment NN O
groups NNS O
. . O

RESULTS VB O
The DT O
median JJ B-OC
follow-up NN I-OC
was VBD O
7 CD O
years NNS O
( ( O
range NN O
, , O
2-10 JJ O
years NNS O
) ) O
. . O

The DT O
actuarial JJ B-OC
relapse-free JJ I-OC
survival NN I-OC
( ( I-OC
RFS NNP I-OC
) ) I-OC
rate NN I-OC
for IN O
the DT O
RT NNP O
plus CC O
CHOP NNP O
group NN O
at IN O
7 CD O
years NNS O
was VBD O
83 CD O
% NN O
compared VBN O
with IN O
47 CD O
% NN O
( ( O
P NNP O
< NNP O
0.03 CD O
) ) O
for IN O
the DT O
RT-alone NNP O
group NN O
. . O

The DT O
overall JJ B-OC
survival NN I-OC
( ( I-OC
OS NNP I-OC
) ) I-OC
for IN O
the DT O
two CD O
groups NNS O
was VBD O
88 CD O
% NN O
and CC O
66 CD O
% NN O
, , O
respectively RB O
( ( O
P NNP O
= NNP O
0.2 CD O
) ) O
. . O

In IN O
patients NNS O
with IN O
intermediate-grade JJ O
NHL NNP O
, , O
the DT O
7-year JJ B-OC
actuarial JJ I-OC
RFS NNP I-OC
for IN O
RT NNP O
and CC O
CHOP NNP O
was VBD O
86 CD O
% NN O
compared VBN O
with IN O
20 CD O
% NN O
for IN O
RT NNP O
alone RB O
( ( O
P NNP O
= NNP O
0.004 CD O
) ) O
. . O

The DT O
corresponding JJ B-OC
actuarial JJ I-OC
survival NN I-OC
rates NNS I-OC
were VBD O
92 CD O
% NN O
and CC O
47 CD O
% NN O
, , O
respectively RB O
( ( O
P NNP O
= NNP O
0.08 CD O
) ) O
. . O

In IN O
patients NNS O
with IN O
low-grade JJ O
histologic JJ O
findings NNS O
, , O
the DT O
addition NN O
of IN O
adjuvant JJ O
CHOP NNP B-INTV
did VBD O
not RB O
improve VB O
RFS NNP B-OC
( ( O
P NNP O
= NNP O
0.6 CD O
) ) O
or CC O
OS NNP O
. . O

All DT O
relapses VBZ O
in IN O
this DT O
study NN O
were VBD O
at IN O
sites NNS O
remote VBP O
from IN O
the DT O
initially RB O
involved JJ O
areas NNS O
, , O
and CC O
in IN O
5 CD O
of IN O
11 CD O
patients NNS O
( ( O
45 CD O
% NN O
) ) O
, , O
there EX O
were VBD O
recurrences NNS O
5 CD O
years NNS O
or CC O
longer JJR O
after IN O
initial JJ O
treatment NN O
. . O

CONCLUSIONS VB O
This DT O
study NN O
showed VBD O
that IN O
adjuvant JJ O
CHOP NNP B-INTV
chemotherapy NN I-INTV
significantly RB O
improves VBZ O
RFS NNP O
in IN O
patients NNS O
with IN O
Stage NNP O
I PRP O
intermediate-grade VBP O
NHL NNP O
who WP O
achieve VBP O
a DT O
CR NNP O
after IN O
regional-field JJ O
RT NNP O
. . O

The DT O
chemotherapeutic JJ O
regimen NNS O
favorably RB O
affected VBD O
their PRP$ O
probability NN B-OC
of IN O
survival NN B-OC
. . O

-DOCSTART- -X- O O

Prognostic JJ O
value NN O
of IN O
clinical JJ O
, , O
laboratory NN O
, , O
and CC O
histological JJ O
characteristics NNS O
in IN O
multiple JJ O
myeloma NN O
: : O
improved JJ O
definition NN O
of IN O
risk NN O
groups NNS O
. . O

Follow-up NNP O
data NN O
of IN O
320 CD B-POPU
multiple JJ I-POPU
myeloma NN I-POPU
( ( I-POPU
MM NNP I-POPU
) ) I-POPU
patients NNS I-POPU
entering VBG I-POPU
the DT I-POPU
German JJ I-POPU
Myeloma NNP I-POPU
Treatment NNP I-POPU
Group NNP I-POPU
( ( I-POPU
GMTG NNP I-POPU
) ) I-POPU
trial NN I-POPU
MM01 NNP I-POPU
were VBD O
analysed VBN O
for IN O
factors NNS O
predicting VBG O
overall JJ B-OC
( ( I-OC
OAS NNP I-OC
) ) I-OC
and CC I-OC
tumour $ I-OC
related VBN I-OC
survival NN I-OC
( ( I-OC
TRS NNP I-OC
) ) I-OC
. . O

Response NN O
to TO O
primary JJ B-INTV
induction NN I-INTV
chemotherapy NN I-INTV
was VBD O
relevant JJ O
for IN O
prognosis NN O
if IN O
a DT O
limit NN O
of IN O
25 CD O
% NN O
tumour NN O
cell NN O
mass NN O
( ( O
TCM NNP O
) ) O
reduction NN O
was VBD O
used VBN O
to TO O
separate JJ O
responders NNS O
from IN O
non-responders NNS O
. . O

Furthermore NNP O
, , O
TCM NNP B-OC
, , I-OC
histological JJ I-OC
grading NN I-OC
of IN I-OC
myeloma NN I-OC
cells NNS I-OC
, , I-OC
degree NN I-OC
of IN I-OC
bone NN I-OC
marrow NN I-OC
infiltration NN I-OC
, , I-OC
haemoglobin NN I-OC
, , I-OC
platelet NN I-OC
counts NNS I-OC
, , I-OC
calcium NN I-OC
, , I-OC
creatinine NN I-OC
, , I-OC
albumin NN I-OC
, , I-OC
beta NN I-OC
2M CD I-OC
, , I-OC
and CC I-OC
Bence NNP I-OC
Jones NNP I-OC
proteinuria NNS I-OC
correlated VBD O
to TO O
both DT O
OAS NNP O
and CC O
TRS NNP O
. . O

Age NNP O
was VBD O
relevant JJ O
for IN O
OAS NNP O
only RB O
. . O

The DT O
multivariate NN O
analysis NN O
revealed VBD O
histological JJ B-OC
grading NN I-OC
, , I-OC
TCM NNP I-OC
and CC I-OC
platelets NNS I-OC
as IN O
the DT O
most RBS O
reliable JJ O
prognostic JJ O
factors NNS O
. . O

Based VBN O
on IN O
these DT O
data NNS O
the DT O
Durie/Salmon NNP O
classification NN O
could MD O
be VB O
improved VBN O
by IN O
defining VBG O
poor JJ B-POPU
prognosis NN I-POPU
patients NNS I-POPU
( ( I-POPU
50 CD I-POPU
% NN I-POPU
TRS NNP I-POPU
: : I-POPU
16 CD I-POPU
months NNS I-POPU
) ) I-POPU
characterised VBN I-POPU
by IN I-POPU
pretreatment JJ I-POPU
platelets NNS I-POPU
of IN I-POPU
< NN I-POPU
or CC I-POPU
= $ I-POPU
150,000 CD I-POPU
and/or JJ O
poorly RB O
differentiated VBN O
myeloma NN O
cell NN O
morphology NN O
. . O

Patients NNS B-POPU
lacking VBG I-POPU
both DT I-POPU
risk NN I-POPU
factors NNS I-POPU
displayed VBD O
50 CD O
% NN O
survival JJ B-OC
times NNS I-OC
of IN O
46 CD O
months NNS O
in IN O
stage NN O
III NNP O
and CC O
88 CD O
months NNS O
in IN O
stage NN O
II NNP O
. . O

-DOCSTART- -X- O O

Measurement NN O
of IN O
health-related JJ B-OC
quality NN I-OC
of IN I-OC
life NN I-OC
in IN O
multiple JJ B-POPU
myeloma NN I-POPU
. . O

Nordic NNP O
Myeloma NNP O
Study NNP O
Group NNP O
. . O

When WRB O
a DT O
randomized VBN O
trial NN O
( ( O
NMSG NNP O
4/90 CD O
) ) O
comparing VBG O
treatment NN O
with IN O
melphalan/prednisone NN B-INTV
to TO O
melphalan/ VB B-INTV
prednisone NN I-INTV
+ NNP I-INTV
interferon VBZ I-INTV
alpha-2b NN I-INTV
in IN O
newly RB B-POPU
diagnosed VBN I-POPU
multiple JJ I-POPU
myeloma NN I-POPU
was VBD O
initiated VBN O
in IN O
1990 CD O
, , O
a DT O
quality-of-life JJ B-OC
assessment NN I-OC
was VBD O
integrated VBN O
into IN O
the DT O
study NN O
. . O

We PRP O
used VBD O
the DT O
questionnaire NN O
( ( O
QLQ-C30 NNP O
) ) O
developed VBN O
by IN O
the DT O
European JJ O
Organization NNP O
of IN O
Research NNP O
and CC O
Treatment NNP O
of IN O
Cancer NNP O
( ( O
EORTC NNP O
) ) O
Study NNP O
Group NNP O
on IN O
Quality NNP B-OC
of IN I-OC
Life NNP I-OC
. . O

The DT O
QLQ-C30 JJ O
incorporates NNS O
five CD O
functional JJ O
scales NNS O
, , O
three CD O
symptom NN O
scales NNS O
, , O
a DT O
global JJ O
health NN O
and CC O
quality-of JJ B-OC
life NN I-OC
scale NN I-OC
and CC O
some DT O
single JJ O
symptom NN O
measures NNS O
. . O

The DT O
questionnaire NN O
was VBD O
completed VBN O
prior JJ O
to TO O
treatment NN O
and CC O
after IN O
1 CD O
, , O
6 CD O
, , O
12 CD O
, , O
24 CD O
, , O
36 CD O
and CC O
48 CD O
months NNS O
. . O

524 CD B-POPU
( ( I-POPU
90.2 CD I-POPU
% NN I-POPU
) ) I-POPU
of IN I-POPU
581 CD I-POPU
patients NNS I-POPU
enrolled VBN I-POPU
in IN I-POPU
the DT I-POPU
NMSG NNP I-POPU
4/90 CD I-POPU
completed VBD I-POPU
the DT I-POPU
first JJ I-POPU
questionnaire NN I-POPU
, , I-POPU
and CC I-POPU
484 CD I-POPU
( ( I-POPU
83.3 CD I-POPU
% NN I-POPU
) ) I-POPU
completed VBD I-POPU
all DT I-POPU
questionnaires NNS I-POPU
given VBN I-POPU
to TO I-POPU
them PRP I-POPU
. . O

All DT O
but CC O
one CD O
of IN O
the DT O
scales NNS O
met VBD O
the DT O
minimum JJ O
criteria NNS O
of IN O
reliability NN O
( ( O
Cronbach NNP O
's POS O
alpha NN O
> NNP O
/ NNP O
0.70 CD O
) ) O
. . O

Validity NNP O
was VBD O
shown VBN O
by IN O
( ( O
1 CD O
) ) O
the DT O
ability NN O
of IN O
the DT O
scales NNS O
to TO O
discriminate VB O
clearly RB O
between IN O
patients NNS O
differing VBG O
in IN O
clinical JJ O
status NN O
as IN O
defined VBN O
by IN O
pretreatment NN O
W.H.O NNP O
. . O

performance NN O
index NN O
and CC O
Durie NNP O
& CC O
Salmon NNP O
stage NN O
, , O
and CC O
( ( O
2 CD O
) ) O
the DT O
sensitivity NN O
to TO O
changes NNS O
in IN O
objective JJ O
disease NN O
status NN O
( ( O
response NN O
and CC O
relapse NN O
) ) O
. . O

This DT O
is VBZ O
the DT O
first JJ O
report NN O
of IN O
the DT O
measurement NN O
of IN O
health-related JJ B-OC
quality NN I-OC
of IN I-OC
life NN I-OC
in IN O
a DT O
prospective JJ O
clinical JJ O
trial NN O
in IN O
multiple JJ O
myeloma NN O
. . O

The DT B-OC
results NNS I-OC
demonstrate VBP I-OC
that IN I-OC
the DT I-OC
QLQ-C30 NNP I-OC
is VBZ I-OC
a DT I-OC
reliable JJ I-OC
and CC I-OC
valid JJ I-OC
instrument NN I-OC
for IN I-OC
the DT I-OC
measurement NN I-OC
of IN I-OC
quality NN I-OC
of IN I-OC
life NN I-OC
in IN I-OC
these DT I-OC
patients NNS I-OC
. . O

The DT O
data NN O
will MD O
be VB O
used VBN O
for IN O
a DT O
cost-utility JJ O
analysis NN O
of IN O
the DT O
results NNS O
of IN O
the DT O
NMSG NNP O
4/90 CD O
trial NN O
. . O

-DOCSTART- -X- O O

Pharmacokinetics NNS B-OC
of IN O
adriamycin NN B-INTV
and CC O
adriamycin NN B-INTV
-- : I-INTV
DNA NN I-INTV
complex NN I-INTV
in IN O
L1210 NNP B-POPU
mice NN I-POPU
and CC I-POPU
men NNS I-POPU
. . O

-DOCSTART- -X- O O

Marginal NNP O
zone NN O
B NNP O
cell NN O
lymphoma NN O
of IN O
the DT O
parotid JJ O
glands NNS O
: : O
results NNS O
of IN O
a DT O
randomised JJ O
trial NN O
comparing VBG O
radiotherapy NN B-INTV
to TO O
combined VBN B-INTV
therapy NN I-INTV
. . O

39 CD B-POPU
patients NNS I-POPU
with IN I-POPU
marginal JJ I-POPU
zone NN I-POPU
B NNP I-POPU
cell NN I-POPU
lymphoma NN I-POPU
( ( I-POPU
MZBCL NNP I-POPU
) ) I-POPU
of IN I-POPU
the DT I-POPU
parotid NN I-POPU
glands NNS I-POPU
( ( I-POPU
stages NNS I-POPU
I PRP I-POPU
or CC I-POPU
II NNP I-POPU
) ) I-POPU
were VBD I-POPU
studied VBN I-POPU
. . O

They PRP O
were VBD O
randomized VBN O
to TO O
be VB O
treated VBN O
with IN O
either DT O
radiotherapy NN B-INTV
alone RB I-INTV
( ( O
extended JJ O
fields NNS O
, , O
4500 CD O
cGy NN O
) ) O
or CC O
radiotherapy NN B-INTV
( ( I-INTV
the DT I-INTV
same JJ I-INTV
schedule NN I-INTV
) ) I-INTV
plus CC I-INTV
adjuvant JJ I-INTV
chemotherapy NN I-INTV
( ( I-INTV
cyclophosphamide NN I-INTV
, , I-INTV
vincristine NN I-INTV
and CC I-INTV
prednisone NN I-INTV
) ) I-INTV
. . O

The DT O
end NN B-OC
points NNS I-OC
were VBD O
survival JJ B-OC
and CC I-OC
time NN I-OC
to TO I-OC
treatment NN I-OC
failure NN I-OC
( ( I-OC
TTF NNP I-OC
) ) I-OC
. . O

Patients NNPS O
who WP O
received VBD O
radiotherapy VB B-INTV
alone RB O
had VBD O
a DT O
complete JJ B-OC
remission NN I-OC
rate NN I-OC
of IN O
100 CD O
% NN O
, , O
the DT O
TTF NNP B-OC
was VBD O
90 CD O
% NN O
at IN O
5 CD O
years NNS O
and CC O
overall JJ B-OC
survival NN I-OC
at IN O
5 CD O
years NNS O
was VBD O
90 CD O
% NN O
with IN O
no DT O
statistical JJ O
difference NN O
when WRB O
compared VBN O
with IN O
patients NNS O
who WP O
received VBD O
combined JJ B-INTV
therapy NN I-INTV
[ NN O
100 CD O
, , O
80 CD O
and CC O
95 CD O
% NN O
, , O
respectively RB O
( ( O
P NNP O
= NNP O
0.5 CD O
) ) O
] NN O
. . O

Although IN O
adjuvant JJ B-INTV
chemotherapy NN I-INTV
was VBD O
well RB O
tolerated VBN B-OC
, , O
the DT O
use NN O
of IN O
this DT O
therapeutic JJ O
approach NN O
in IN O
patients NNS O
with IN O
early JJ O
stage NN O
MZBCL NNP O
did VBD O
not RB O
offer VB O
any DT O
advantage NN O
over IN O
radiotherapy NN O
alone RB O
as IN O
the DT O
initial JJ O
treatment NN O
. . O

Until IN O
now RB O
, , O
radiotherapy NN B-INTV
was VBD O
considered VBN O
the DT O
treatment NN O
of IN O
choice NN O
in IN O
this DT O
clinical JJ O
setting NN O
of IN O
patients NNS O
. . O

-DOCSTART- -X- O O

Dose-response JJ O
relationship NN O
of IN O
complementary JJ B-INTV
radiotherapy NN I-INTV
following VBG O
four CD O
cycles NNS O
of IN O
combination NN B-INTV
chemotherapy NN I-INTV
in IN O
intermediate-stage JJ O
Hodgkin NNP B-POPU
's POS I-POPU
disease NN I-POPU
. . O

PURPOSE NNP O
To TO O
determine VB O
the DT O
appropriate JJ O
irradiation NN O
dose NN O
after IN O
four CD O
cycles NNS O
of IN O
modern JJ B-INTV
combination NN I-INTV
chemotherapy NN B-POPU
in IN I-POPU
nonbulky JJ I-POPU
involved JJ I-POPU
field NN I-POPU
( ( I-POPU
IF/BF NNP I-POPU
) ) I-POPU
and CC I-POPU
noninvolved VBN I-POPU
extended-field NN I-POPU
( ( I-POPU
EF/IF NNP I-POPU
) ) I-POPU
sites VBZ I-POPU
in IN I-POPU
patients NNS I-POPU
with IN I-POPU
intermediate-stage JJ I-POPU
Hodgkin NNP I-POPU
's POS I-POPU
disease NN I-POPU
( ( I-POPU
HD NNP I-POPU
) ) I-POPU
. . O

MATERIALS NNP O
AND CC O
METHODS NNP O
HD NNP B-POPU
patients NNS I-POPU
in IN I-POPU
stage NN I-POPU
I PRP I-POPU
to TO I-POPU
IIIA NNP I-POPU
with IN I-POPU
a DT I-POPU
large JJ I-POPU
mediastinal JJ I-POPU
mass NN I-POPU
, , I-POPU
E NNP I-POPU
stage NN I-POPU
, , I-POPU
or CC I-POPU
massive JJ I-POPU
spleen JJ I-POPU
involvement NN I-POPU
were VBD O
treated VBN O
with IN O
two CD O
double JJ O
cycles NNS B-INTV
of IN I-INTV
alternating VBG I-INTV
cyclophosphamide NN I-INTV
, , I-INTV
vincristine NN I-INTV
, , I-INTV
procarbazine NN I-INTV
, , I-INTV
and CC I-INTV
prednisone NN I-INTV
( ( I-INTV
COPP NNP I-INTV
) ) I-INTV
plus CC I-INTV
doxorubicin JJ I-INTV
, , I-INTV
bleomycin NN I-INTV
, , I-INTV
vinblastine NN I-INTV
, , I-INTV
and CC I-INTV
dacarbazine NN I-INTV
( ( I-INTV
ABVD NNP I-INTV
) ) I-INTV
followed VBN I-INTV
by IN I-INTV
EF NNP I-INTV
irradiation NN I-INTV
in IN O
two CD O
successive JJ O
trials NNS O
( ( O
HD1 NNP O
and CC O
HD5 NNP O
) ) O
. . O

In IN O
the DT O
HD1 NNP O
trial NN O
( ( O
1983 CD O
to TO O
1988 CD O
) ) O
, , O
146 CD B-POPU
patients NNS I-POPU
who WP I-POPU
responded VBD I-POPU
to TO I-POPU
chemotherapy VB I-POPU
were VBD I-POPU
randomized VBN I-POPU
to TO I-POPU
receive VB I-POPU
20 CD I-POPU
Gy NNP I-POPU
( ( I-POPU
70 CD I-POPU
patients NNS I-POPU
) ) I-POPU
or CC I-POPU
40 CD I-POPU
Gy NNP I-POPU
( ( I-POPU
76 CD I-POPU
patients NNS I-POPU
) ) I-POPU
of IN I-POPU
EF NNP I-POPU
irradiation NN I-POPU
in IN I-POPU
all DT I-POPU
fields NNS I-POPU
outside IN I-POPU
bulky JJ I-POPU
disease NN I-POPU
sites NNS I-POPU
. . O

A DT B-POPU
cohort NN I-POPU
of IN I-POPU
111 CD I-POPU
patients NNS I-POPU
who WP I-POPU
fulfilled VBD I-POPU
the DT I-POPU
same JJ I-POPU
inclusion NN I-POPU
criteria NNS I-POPU
in IN I-POPU
the DT I-POPU
subsequent JJ I-POPU
trial NN I-POPU
HD5 NNP I-POPU
( ( I-POPU
1988 CD I-POPU
to TO I-POPU
1993 CD I-POPU
) ) I-POPU
were VBD I-POPU
treated VBN I-POPU
with IN I-POPU
30 CD I-POPU
Gy NNP I-POPU
. . O

Bulky NNP O
disease NN O
always RB O
received VBD O
40 CD O
Gy NNP O
. . O

RESULTS NNP O
Freedom-from-treatment-failure NNP B-OC
( ( I-OC
FFTF NNP I-OC
) ) I-OC
and CC I-OC
survival NN I-OC
( ( I-OC
SV NNP I-OC
) ) I-OC
curves VBZ I-OC
showed VBD O
no DT O
differences NNS O
between IN O
the DT O
20- JJ O
, , O
30- JJ O
, , O
and CC O
40-Gy JJ O
groups NNS O
. . O

However RB O
, , O
acute JJ B-OC
toxicities NNS I-OC
were VBD O
more RBR O
frequent JJ O
in IN O
the DT O
40-Gy JJ O
arm NN O
. . O

Analysis NN B-OC
of IN I-OC
relapse NN I-OC
patterns NNS I-OC
showed VBD O
that IN O
18 CD O
of IN O
26 CD O
relapsing VBG O
patients NNS O
either CC O
failed VBD O
to TO O
respond VB O
in IN O
initial JJ O
bulky NN O
sites NNS O
( ( O
n JJ O
= NNP O
5 CD O
) ) O
or CC O
had VBD O
an DT O
extranodal JJ O
relapse NN O
( ( O
n JJ O
= NNP O
9 CD O
) ) O
or CC O
both DT O
( ( O
n JJ O
= NNP O
4 CD O
) ) O
. . O

After IN O
5 CD O
years NNS O
, , O
the DT O
cumulative JJ O
risk NN B-OC
for IN I-OC
relapse NN I-OC
in IN O
bulky NN O
sites NNS O
is VBZ O
10 CD O
% NN O
, , O
despite IN O
40 CD O
Gy NNP O
of IN O
radiation NN B-INTV
. . O

CONCLUSION NNP O
Our PRP$ O
results NNS O
strongly RB O
suggest VBP O
that IN O
there EX O
is VBZ O
no DT O
relevant JJ O
radiotherapy NN B-INTV
dose JJ B-OC
effect NN I-OC
in IN O
the DT O
range NN O
between IN O
20 CD O
Gy NNP O
and CC O
40 CD O
Gy NNP O
in IN O
IF/BF NNP O
and CC O
EF/IF NNP O
after IN O
4 CD O
months NNS O
of IN O
modern JJ B-POPU
polychemotherapy NN I-POPU
in IN I-POPU
patients NNS I-POPU
with IN I-POPU
intermediate-stage JJ I-POPU
HD NNP I-POPU
. . O

Relapse NNP O
patterns VBZ O
indicate VB O
that IN O
patients NNS O
destined VBD O
to TO O
relapse VB O
need VB O
more JJR O
systemic JJ O
, , O
rather RB O
than IN O
local JJ O
, , O
treatment NN O
. . O

Based VBN O
on IN O
our PRP$ O
data NNS O
, , O
we PRP O
conclude VBP O
that IN O
20 CD O
Gy NNP O
is VBZ O
sufficient JJ O
in IN O
EF/IF NNP O
of IN O
intermediate-stage JJ O
HD NNP O
following VBG O
four CD O
cycles NNS O
of IN O
modern JJ O
polychemotherapy NN B-INTV
. . O

-DOCSTART- -X- O O

Circulating VBG B-INTV
blood NN I-INTV
B NNP I-INTV
cells NNS I-INTV
in IN O
multiple JJ B-POPU
myeloma NN I-POPU
: : I-POPU
analysis NN O
and CC O
relationship NN O
to TO O
circulating VBG O
clonal JJ O
cells NNS O
and CC O
clinical JJ O
parameters NNS O
in IN O
a DT O
cohort NN O
of IN O
patients NNS B-POPU
entered VBN I-POPU
on IN I-POPU
the DT I-POPU
Eastern NNP I-POPU
Cooperative NNP I-POPU
Oncology NNP I-POPU
Group NNP I-POPU
phase VBD I-POPU
III NNP I-POPU
E9486 NNP I-POPU
clinical JJ I-POPU
trial NN I-POPU
. . O

Recent JJ O
analyses NNS O
of IN O
circulating VBG O
blood NN O
B NNP O
cells NNS O
in IN O
myeloma NN O
have VBP O
generated VBN O
controversy NN O
concerning VBG O
the DT O
exact JJ O
levels NNS O
of IN O
these DT O
cells NNS O
and CC O
whether IN O
they PRP O
may MD O
represent VB O
circulating VBG O
clonal JJ O
tumor NN O
B NNP O
cells NNS O
. . O

Previous JJ O
reports NNS O
suggested VBD O
that IN O
CD19+ NNP B-OC
B NNP I-OC
cells NNS I-OC
are VBP O
markedly RB O
increased VBN O
in IN O
myeloma NN B-POPU
patients NNS I-POPU
and CC O
that IN O
this DT O
population NN O
shares NNS O
clonotypic VBD O
rearrangements NNS O
with IN O
the DT O
malignant JJ O
plasma NN O
cell NN O
. . O

We PRP O
studied VBD O
the DT O
numbers NNS O
of IN O
CD19+ NNP B-POPU
B NNP I-POPU
cells NNS I-POPU
by IN I-POPU
flow JJ I-POPU
cytometry NN I-POPU
in IN I-POPU
previously RB I-POPU
untreated JJ I-POPU
newly RB I-POPU
diagnosed VBN I-POPU
myeloma NN I-POPU
patients NNS I-POPU
in IN I-POPU
Eastern NNP I-POPU
Cooperative NNP I-POPU
Oncology NNP I-POPU
Group NNP I-POPU
( ( I-POPU
ECOG NNP I-POPU
) ) I-POPU
phase NN I-POPU
III NNP I-POPU
trial NN I-POPU
E9486 NNP I-POPU
. . O

There EX B-POPU
were VBD I-POPU
628 CD I-POPU
patients NNS I-POPU
who WP I-POPU
were VBD I-POPU
eligible JJ I-POPU
for IN I-POPU
the DT I-POPU
clinical JJ I-POPU
protocol NN I-POPU
E9486 NNP I-POPU
, , I-POPU
but CC I-POPU
of IN I-POPU
these DT I-POPU
521 CD I-POPU
were VBD I-POPU
also RB I-POPU
entered VBN I-POPU
on IN I-POPU
the DT I-POPU
companion NN I-POPU
laboratory NN I-POPU
study NN I-POPU
( ( I-POPU
E9487 NNP I-POPU
) ) I-POPU
and CC I-POPU
had VBD I-POPU
CD19 NNP I-POPU
data NNS I-POPU
. . O

In IN O
comparison NN O
with IN O
normal JJ O
controls NNS O
, , O
the DT O
myeloma NN O
patients NNS O
exhibited VBD O
a DT O
marked JJ O
heterogeneity NN O
in IN O
the DT O
number NN O
of IN O
circulating VBG O
CD19+ NNP B-OC
B NNP I-OC
cells NNS I-OC
as IN O
detected VBN O
by IN O
flow JJ B-INTV
cytometry NN I-INTV
. . O

Approximately RB O
20 CD O
% NN O
of IN O
patients NNS O
had VBD O
significantly RB O
increased VBN O
levels NNS B-OC
of IN I-OC
circulating VBG I-OC
CD19+ NNP I-OC
B NNP I-OC
cells NNS I-OC
. . O

However RB O
, , O
the DT O
total JJ B-OC
CD19+ NNP I-OC
blood NN I-OC
population NN I-OC
from IN O
myeloma NN O
was VBD O
not RB O
significantly RB O
different JJ O
from IN O
the DT O
median NN O
of IN O
age-matched JJ O
, , O
normal JJ O
controls NNS O
. . O

Analysis NN O
of IN O
CD19+ NNP B-OC
blood NN I-OC
cells NNS I-OC
in IN O
relationship NN O
to TO O
circulating VBG O
clonal JJ O
cells NNS O
was VBD O
done VBN O
in IN O
13 CD O
myeloma NN O
patients NNS O
using VBG O
a DT O
clonotypic NN O
, , O
quantitative JJ O
allele-specific JJ O
oligonucleotide-polymerase NN O
chain NN O
reaction NN O
( ( O
PCR NNP O
) ) O
assay VBP O
. . O

No DT O
correlation NN O
was VBD O
found VBN O
between IN O
the DT O
numbers NNS O
of IN O
CD19+ NNP B-OC
B NNP I-OC
cells NNS I-OC
( ( O
range NN O
, , O
5 CD O
% NN O
to TO O
51 CD O
% NN O
) ) O
and CC O
PCR NNP B-INTV
estimates NNS O
of IN O
the DT O
number NN O
of IN O
clonal JJ O
cells NNS O
in IN O
the DT O
peripheral JJ O
blood NN O
( ( O
range NN O
, , O
.009 CD O
% NN O
to TO O
3.6 CD O
% NN O
) ) O
. . O

Low JJ O
CD19+ NNP B-OC
B-cell NNP I-OC
level NN I-OC
( ( O
< JJ O
125 CD O
microL NN O
) ) O
was VBD O
associated VBN O
with IN O
clinical JJ B-OC
stage NN I-OC
III NNP I-OC
( ( O
P NNP O
= NNP O
.033 NNP O
) ) O
. . O

A DT O
significant JJ O
relationship NN O
exists VBZ O
between IN O
higher JJR O
levels NNS O
( ( O
> CD O
or CC O
= VB O
125/microL CD O
) ) O
of IN O
CD19 NNP B-OC
cells NNS I-OC
and CC O
longer JJR B-OC
overall JJ I-OC
survival NN I-OC
( ( O
P NNP O
< NNP O
.0001 NNP O
) ) O
. . O

In IN O
addition NN O
, , O
high JJ O
CD19 NNP B-OC
levels NNS I-OC
also RB O
predicted VBD O
a DT O
clinical JJ O
response NN O
and CC O
longer JJR O
event-free JJ B-OC
survival NN I-OC
. . O

There EX O
was VBD O
a DT O
strong JJ O
inverse NN O
association NN O
between IN O
the DT O
level NN O
of IN O
CD19 NNP B-INTV
values NNS I-INTV
at IN O
diagnosis NN O
and CC O
infections NNS O
within IN O
the DT O
first JJ O
2 CD O
months NNS O
of IN O
diagnosis NN O
. . O

Importantly RB O
, , O
the DT O
number NN B-OC
of IN I-OC
deaths NNS I-OC
related VBN I-OC
to TO I-OC
infections NNS I-OC
was VBD O
significantly RB O
greater JJR O
in IN O
the DT O
low JJ O
versus NN O
high JJ O
CD19 NNP O
group NN O
( ( O
P NNP O
< NNP O
.0202 NNP O
) ) O
. . O

Also RB O
, , O
CD19 NNP O
is VBZ O
an DT O
independent JJ O
prognostic JJ O
factor NN O
in IN O
addition NN O
to TO O
plasma VB O
cell NN O
labeling VBG O
indices NNS O
, , O
beta2-microglobulin NN O
, , O
hemoglobin NN O
, , O
and CC O
plasmablastic JJ O
morphology NN O
. . O

Patients NNS O
with IN O
infections NNS O
were VBD O
more RBR O
likely JJ O
to TO O
have VB O
low JJ O
levels NNS B-OC
of IN I-OC
CD19+ NNP I-OC
cells NNS I-OC
. . O

In IN O
summary JJ O
, , O
higher JJR O
CD19+ NNP B-OC
cell NN I-OC
levels NNS I-OC
are VBP O
a DT O
favorable JJ O
prognostic JJ O
sign NN O
with IN O
no DT O
apparent JJ O
relationship NN O
to TO O
circulating VBG O
tumor NN O
cells NNS O
. . O

In IN O
addition NN O
, , O
this DT O
analysis NN O
strongly RB O
suggests VBZ O
that IN O
low JJ O
peripheral JJ O
blood NN B-OC
levels NNS I-OC
of IN I-OC
CD19+ NNP I-OC
cells NNS O
are VBP O
an DT O
adverse JJ O
prognostic JJ O
sign NN O
in IN O
myeloma NN O
. . O

The DT O
CD19+ NNP B-INTV
cell NN B-OC
levels NNS O
in IN O
myeloma NN O
patients NNS B-POPU
is VBZ O
an DT O
important JJ O
parameter NN O
in IN O
the DT O
overall JJ O
assessment NN O
of IN O
these DT O
patients NNS B-POPU
. . O

-DOCSTART- -X- O O

Association NNP O
of IN O
PML-RAR NNP O
alpha JJ O
fusion NN O
mRNA NN O
type NN O
with IN O
pretreatment JJ O
hematologic JJ B-OC
characteristics NNS I-OC
but CC O
not RB O
treatment NN O
outcome NN O
in IN O
acute JJ B-POPU
promyelocytic JJ I-POPU
leukemia NN I-POPU
: : I-POPU
an DT O
intergroup NN O
molecular NN O
study NN O
. . O

In IN O
each DT O
case NN O
of IN O
acute JJ B-POPU
promyelocytic JJ I-POPU
leukemia NN I-POPU
( ( I-POPU
APL NNP I-POPU
) ) I-POPU
one CD O
of IN O
three CD O
PML-RAR JJ O
alpha NN O
mRNA NN O
types NNS O
is VBZ O
produced VBN O
, , O
depending VBG O
on IN O
the DT O
break/fusion NN O
site NN O
in IN O
the DT O
PML NNP O
gene NN O
that WDT O
is VBZ O
linked VBN O
to TO O
a DT O
common JJ O
RAR NNP O
alpha JJ O
gene NN O
segment NN O
: : O
a DT O
short JJ O
( ( O
S NNP O
) ) O
-form NN O
type NN O
, , O
PML NNP O
exon VBZ O
3 CD O
RAR NNP O
alpha NN O
exon VBZ O
3 CD O
; : O
a DT O
long JJ O
( ( O
L NNP O
) ) O
-form NN O
type NN O
, , O
PML NNP O
exon VBZ O
6 CD O
RAR NNP O
alpha NN O
exon VBZ O
3 CD O
; : O
or CC O
a DT O
variable JJ O
( ( O
V NNP O
) ) O
-form NN O
type NN O
, , O
variably RB O
deleted VBD O
PML NNP O
exon VBD O
6 CD O
RAR NNP O
alpha NN O
exon VBD O
3 CD O
. . O

We PRP O
evaluated VBD O
whether IN O
PML-RAR NNP O
alpha NN O
mRNA NN O
type NN O
is VBZ O
associated VBN O
with IN O
distinct JJ O
pretreatment JJ O
clinical JJ O
characteristics NNS O
and CC O
therapeutic JJ O
outcome NN O
in IN O
previously RB B-POPU
untreated VBN I-POPU
adult NN I-POPU
APL NNP I-POPU
patients NNS I-POPU
registered VBD I-POPU
to TO I-POPU
protocol VB I-POPU
INT NNP I-POPU
0129 CD I-POPU
by IN I-POPU
the DT I-POPU
Eastern NNP I-POPU
Cooperative NNP I-POPU
Oncology NNP I-POPU
Group NNP I-POPU
, , I-POPU
the DT I-POPU
Southwest NNP I-POPU
Oncology NNP I-POPU
Group NNP I-POPU
, , I-POPU
and CC I-POPU
the DT I-POPU
Cancer NNP I-POPU
and CC I-POPU
Leukemia NNP I-POPU
Group NNP I-POPU
B NNP I-POPU
. . O

Of IN B-POPU
279 CD I-POPU
clinically RB I-POPU
eligible JJ I-POPU
cases NNS I-POPU
, , I-POPU
230 CD I-POPU
were VBD I-POPU
molecularly RB I-POPU
evaluable JJ I-POPU
, , O
and CC O
of IN O
these DT O
, , O
111 CD O
were VBD O
randomized VBN O
to TO O
receive VB B-INTV
remission NN I-INTV
induction NN I-INTV
therapy NN I-INTV
with IN I-INTV
all-trans NNS I-INTV
retinoic JJ I-INTV
acid NN I-INTV
( ( I-INTV
ATRA NNP I-INTV
) ) I-INTV
and CC O
119 CD O
with IN O
conventional JJ B-INTV
chemotherapy NN I-INTV
. . O

Nine NNP O
cases NNS O
not RB O
excluded VBN O
by IN O
central JJ O
pathology NN O
review NN O
were VBD O
PML-RAR NNP B-OC
alpha JJ I-OC
negative JJ I-OC
, , O
and CC O
notably RB O
, , O
none NN O
of IN O
five CD O
of IN O
these DT O
cases NNS O
treated VBD O
with IN O
ATRA NNP O
achieved VBD O
complete JJ B-OC
remission NN I-OC
( ( O
CR NNP O
) ) O
. . O

Among IN O
221 CD O
PML-RAR JJ O
alpha-positive JJ O
cases NNS O
, , O
there EX O
were VBD O
82 CD O
S-form JJ O
cases NNS O
( ( O
37 CD O
% NN O
) ) O
, , O
121 CD O
L-form JJ O
cases NNS O
( ( O
55 CD O
% NN O
) ) O
, , O
and CC O
18 CD O
V-form JJ O
cases NNS O
( ( O
8 CD O
% NN O
) ) O
. . O

Before IN O
any DT O
antileukemic JJ O
therapy NN O
, , O
the DT O
S-form NNP O
type NN O
, , O
compared VBN O
with IN O
the DT O
L-form NNP O
type NN O
, , O
was VBD O
associated VBN O
with IN O
higher JJR O
values NNS O
for IN O
the DT O
white JJ B-OC
blood NN I-OC
cell NN I-OC
( ( I-OC
WBC NNP I-OC
) ) I-OC
count NN I-OC
( ( O
median JJ O
2,500/microL CD O
v NN O
1,600/microL CD O
; : O
P NNP O
= NNP O
.009 NNP O
) ) O
, , O
the DT O
percentage NN O
of IN O
blood NN B-OC
blasts NNS I-OC
plus CC I-OC
promyelocytes NNS I-OC
( ( O
median JJ O
29 CD O
% NN O
v JJ O
8.5 CD O
% NN O
; : O
P NNP O
= NNP O
.03 NNP O
) ) O
, , O
and CC O
the DT O
absolute JJ B-OC
blood NN I-OC
blasts NNS I-OC
plus CC I-OC
promyelocytes NNS I-OC
( ( O
884/microL CD O
v RB O
126/microL CD O
; : O
P NNP O
= NNP O
.019 NNP O
) ) O
. . O

Also RB O
, , O
an DT O
increased JJ O
percentage NN O
of IN O
S-form NNP O
versus IN O
L-form NNP O
cases NNS O
had VBD O
the DT O
M3 NNP B-OC
variant NN I-OC
phenotype NN I-OC
, , O
24 CD O
% NN O
v JJ O
12 CD O
% NN O
( ( O
P NNP O
= NNP O
.036 NNP O
) ) O
. . O

There EX O
were VBD O
no DT O
differences NNS O
between IN O
S-form NNP O
and CC O
L-form NNP O
cases NNS O
in IN O
either DT O
CR NNP B-OC
rate NN I-OC
( ( O
79 CD O
% NN O
v JJ O
69 CD O
% NN O
; : O
P NNP O
= NNP O
.14 NNP O
) ) O
or CC O
disease JJ B-OC
free JJ I-OC
survival NN I-OC
distribution NN I-OC
( ( O
multivariate JJ O
analysis NN O
adjusting VBG O
for IN O
the DT O
association NN O
of IN O
S-form NNP O
type NN O
and CC O
higher JJR O
WBC NNP O
count NN O
; : O
P NNP O
= NNP O
.40 NNP O
) ) O
. . O

We PRP O
conclude VBP O
that IN O
the DT O
S-form NNP O
type NN O
is VBZ O
associated VBN O
with IN O
previously-identified JJ O
adverse JJ O
risk NN O
WBC NNP O
parameters NNS O
but CC O
that IN O
the DT O
identification NN O
of IN O
the DT O
S-form NNP O
or CC O
L-form NNP O
type NN O
of IN O
PML-RAR NNP O
alpha NN O
mRNA NN O
, , O
per IN O
se FW O
, , O
does VBZ O
not RB O
predict VB O
clinical JJ O
outcome NN O
or CC O
add VB O
to TO O
the DT O
value NN O
of IN O
an DT O
increased VBN O
WBC NNP O
count NN O
as IN O
a DT O
negative JJ O
prognostic JJ O
indicator NN O
in IN O
APL NNP B-POPU
patients NNS I-POPU
. . O

-DOCSTART- -X- O O

Long-term JJ O
follow-up NN O
of IN O
three CD O
randomized JJ O
trials NNS O
comparing VBG O
idarubicin NN B-INTV
and CC I-INTV
daunorubicin NN I-INTV
as IN O
induction NN O
therapies NNS O
for IN O
patients NNS B-POPU
with IN I-POPU
untreated JJ I-POPU
acute NN I-POPU
myeloid NN I-POPU
leukemia NN I-POPU
. . O

BACKGROUND NNP O
Most NNP O
clinical JJ O
trials NNS O
for IN O
acute NN O
leukemia NN O
have VBP O
reported VBN O
results NNS O
after IN O
2-3 JJ O
years NNS O
of IN O
follow-up NN O
. . O

Comparisons NNS O
between IN O
the DT O
original JJ O
data NNS O
and CC O
longer-term JJ O
follow-up JJ O
data NNS O
may MD O
be VB O
of IN O
interest NN O
, , O
particularly RB O
with IN O
regard NN O
to TO O
promising VBG O
new JJ O
therapies NNS O
. . O

METHODS NNP O
In IN B-POPU
1996 CD I-POPU
, , I-POPU
survival NN I-POPU
data NNS I-POPU
were VBD I-POPU
updated VBN I-POPU
from IN I-POPU
three CD I-POPU
prospective JJ I-POPU
, , I-POPU
randomized JJ I-POPU
comparisons NNS I-POPU
of IN I-POPU
idarubicin NN I-POPU
and CC I-POPU
daunorubicin NN I-POPU
that WDT I-POPU
began VBD I-POPU
in IN I-POPU
1984 CD I-POPU
and CC I-POPU
1985 CD I-POPU
. . O

These DT B-POPU
were VBD I-POPU
trials NNS I-POPU
of IN I-POPU
the DT I-POPU
Memorial NNP I-POPU
Sloan-Kettering NNP I-POPU
Cancer NNP I-POPU
Center NNP I-POPU
( ( I-POPU
MSKCC NNP I-POPU
) ) I-POPU
, , I-POPU
the DT I-POPU
U.S. NNP I-POPU
Multicenter NNP I-POPU
Study NNP I-POPU
Group NNP I-POPU
, , I-POPU
and CC I-POPU
the DT I-POPU
Southeastern NNP I-POPU
Cancer NNP I-POPU
Study NNP I-POPU
Group NNP I-POPU
( ( I-POPU
SEG NNP I-POPU
) ) I-POPU
. . O

The DT O
original JJ O
results NNS O
of IN O
these DT O
trials NNS O
were VBD O
reported VBN O
in IN O
1991 CD O
and CC O
1992 CD O
. . O

RESULTS VB O
The DT O
original JJ O
results NNS O
of IN O
the DT O
SEG NNP O
trial NN O
demonstrated VBD O
no DT O
significant JJ B-OC
difference NN I-OC
between IN I-OC
idarubicin NN I-OC
and CC I-OC
daunorubicin NN I-OC
. . O

The DT O
updated JJ O
survival NN B-OC
analysis NN I-OC
showed VBD O
similar JJ O
results NNS O
. . O

The DT O
MSKCC NNP O
trial NN O
revealed VBD O
a DT O
significant JJ O
advantage NN B-OC
of IN I-OC
idarubicin NNS I-OC
compared VBN O
with IN O
daunorubicin NN O
in IN O
both CC O
the DT O
original JJ O
and CC O
the DT O
updated JJ O
analyses NNS O
. . O

The DT O
U.S. NNP O
Multicenter NNP O
trial NN O
found VBD O
a DT O
significant JJ O
difference NN O
favoring VBG O
idarubicin NN O
in IN O
the DT O
original JJ O
analysis NN O
, , O
but CC O
the DT O
difference NN O
was VBD O
not RB O
significant JJ O
in IN O
the DT O
updated JJ O
analysis NN O
. . O

CONCLUSIONS VB O
It PRP O
is VBZ O
essential JJ O
that IN O
the DT O
median JJ O
length NN O
of IN O
follow-up JJ O
be VB O
clearly RB O
stated VBN O
in IN O
any DT O
clinical JJ O
trial NN O
. . O

When WRB O
the DT O
results NNS O
obtained VBD O
with IN O
a DT O
particularly RB O
promising JJ O
new JJ O
drug NN O
or CC O
procedure NN O
are VBP O
presented VBN O
early RB O
in IN O
the DT O
course NN O
of IN O
study NN O
( ( O
within IN O
1-2 CD O
years NNS O
) ) O
, , O
the DT O
investigators NNS O
should MD O
strongly RB O
consider VB O
a DT O
repeat NN O
evaluation NN O
after IN O
an DT O
additional JJ O
3-5 CD O
years NNS O
of IN O
follow-up NN O
. . O

-DOCSTART- -X- O O

Improved VBN O
survival NN O
with IN O
early JJ B-INTV
intensification NN I-INTV
: : I-INTV
combined VBN O
results NNS O
from IN O
the DT O
Medical NNP O
Research NNP O
Council NNP O
childhood VBD O
ALL DT O
randomised VBN B-POPU
trials NNS I-POPU
, , O
UKALL NNP O
X NNP O
and CC O
UKALL NNP O
XI NNP O
. . O

Medical NNP O
Research NNP O
Council NNP O
Working NNP O
Party NNP O
on IN O
Childhood NNP O
Leukaemia NNP O
. . O

The DT O
Medical NNP O
Research NNP O
Council NNP O
( ( O
MRC NNP O
) ) O
United NNP O
Kingdom NNP O
trial NN O
for IN O
childhood NN B-POPU
acute NN I-POPU
lymphoblastic JJ I-POPU
leukaemia NN I-POPU
( ( I-POPU
UKALL NNP I-POPU
X NNP I-POPU
) ) I-POPU
randomised VBD I-POPU
patients NNS I-POPU
aged VBN I-POPU
0-14 CD I-POPU
years NNS I-POPU
inclusive JJ I-POPU
with IN I-POPU
an DT I-POPU
initial JJ I-POPU
white JJ I-POPU
blood NN I-POPU
count NN I-POPU
of IN I-POPU
less JJR I-POPU
than IN I-POPU
100 CD I-POPU
x JJ I-POPU
10 CD I-POPU
( ( I-POPU
9 CD I-POPU
) ) I-POPU
/l NN I-POPU
to TO I-POPU
receive VB I-POPU
an DT I-POPU
early JJ I-POPU
intensification NN I-POPU
block NN I-POPU
, , I-POPU
a DT I-POPU
late JJ I-POPU
intensification NN I-POPU
block NN I-POPU
, , I-POPU
both DT I-POPU
, , I-POPU
or CC I-POPU
neither RB I-POPU
. . O

The DT O
next JJ O
trial NN O
, , O
UKALL NNP B-POPU
XI NNP I-POPU
, , I-POPU
for IN I-POPU
children NNS I-POPU
aged VBN I-POPU
1-14 CD I-POPU
years NNS I-POPU
, , O
randomised VBD O
between IN O
different JJ B-INTV
central JJ I-INTV
nervous JJ I-INTV
system NN I-INTV
( ( I-INTV
CNS NNP I-INTV
) ) I-INTV
directed VBD I-INTV
therapies NNS I-INTV
. . O

At IN O
the DT O
beginning NN O
of IN O
the DT O
trial NN O
, , O
all DT B-POPU
patients NNS I-POPU
were VBD I-POPU
also RB I-POPU
randomised VBN I-POPU
between IN I-POPU
late JJ I-POPU
intensification NN I-POPU
alone RB I-POPU
and CC I-POPU
both DT I-POPU
early JJ I-POPU
plus NN I-POPU
late JJ I-POPU
blocks NNS I-POPU
. . O

The DT O
effects NNS O
of IN O
both DT O
the DT O
early JJ O
and CC O
the DT O
late JJ O
block NN O
in IN O
UKALL NNP O
X NNP O
alone RB O
have VBP O
been VBN O
reported VBN O
previously RB O
. . O

This DT O
paper NN O
examines VBZ O
the DT O
effect NN O
of IN O
the DT O
addition NN O
of IN O
the DT O
early JJ O
intensification NN O
block NN O
to TO O
treatment NN O
which WDT O
included VBD O
late JJ O
intensification NN O
, , O
combining VBG O
the DT O
data NN O
from IN O
UKALL NNP O
X NNP O
and CC O
the DT O
first JJ O
part NN O
of IN O
UKALL NNP O
XI NNP O
. . O

Early JJ O
intensification NN O
was VBD O
associated VBN O
with IN O
fewer JJR O
bone NN B-OC
marrow NN I-OC
relapses NNS I-OC
and CC O
a DT O
reduction NN O
in IN O
the DT O
odds NNS O
of IN O
death NN B-OC
of IN O
0.63 CD O
( ( O
95 CD O
% NN O
confidence NN O
interval NN O
: : O
0.46-0.87 JJ O
) ) O
. . O

Survival NN B-OC
was VBD O
significantly RB O
improved VBN O
with IN O
an DT O
increase NN O
at IN O
5 CD O
years NNS O
of IN O
8 CD O
% NN O
, , O
from IN O
79 CD O
to TO O
87 CD O
% NN O
. . O

Following VBG O
this DT O
demonstration NN O
that WDT O
early JJ O
intensification NN O
improves VBZ O
survival NN O
, , O
the DT O
effect NN O
of IN O
a DT O
third JJ O
intensification NN O
block NN O
is VBZ O
under IN O
investigation NN O
. . O

-DOCSTART- -X- O O

A DT O
double JJ O
blind NN O
randomized VBD O
study NN O
of IN O
oral JJ O
clodronate NN B-INTV
in IN O
the DT O
treatment NN O
of IN O
bone NN B-POPU
metastases NNS I-POPU
from IN I-POPU
tumors NNS I-POPU
poorly RB I-POPU
responsive VBP I-POPU
to TO I-POPU
chemotherapy VB I-POPU
. . O

Bisphosphonates NNS B-INTV
are VBP O
used VBN O
in IN O
oncology NN O
as IN O
a DT O
means NN O
of IN O
decreasing VBG O
complications NNS O
due JJ O
to TO O
bone VB B-POPU
metastases NNS I-POPU
, , O
in IN O
association NN O
with IN O
anticancer NN O
treatment NN O
, , O
especially RB O
in IN O
patients NNS O
with IN O
breast NN O
cancer NN O
, , O
prostate NN O
cancer NN O
and CC O
myeloma NN O
. . O

Little JJ O
is VBZ O
known VBN O
about IN O
the DT O
effects NNS O
of IN O
bisphosphonates NNS B-INTV
on IN O
bone NN O
metastases NNS O
from IN O
other JJ O
tumors NNS O
and CC O
in IN O
particular JJ O
from IN O
tumors NNS O
for IN O
which WDT O
no DT O
effective JJ O
treatment NN O
is VBZ O
available JJ O
. . O

We PRP O
conducted VBD O
a DT O
randomized VBN O
, , O
double-blind JJ O
placebo-controlled JJ B-INTV
trial NN O
of IN O
oral JJ B-INTV
clodronate NN I-INTV
in IN O
patients NNS B-POPU
with IN I-POPU
bone NN I-POPU
metastases NNS I-POPU
from IN I-POPU
tumors NNS I-POPU
poorly RB I-POPU
responsive VBP I-POPU
to TO I-POPU
chemotherapy VB I-POPU
, , O
with IN O
the DT O
aims NNS O
of IN O
evaluating VBG O
the DT O
effects NNS B-OC
of IN I-OC
this DT I-OC
drug NN I-OC
on IN I-OC
symptoms NNS I-OC
control NN I-OC
and CC I-OC
bone NN I-OC
metastases NNS I-OC
evolution NN I-OC
. . O

Sixty-six JJ B-POPU
patients NNS I-POPU
with IN I-POPU
poorly JJ I-POPU
responsive JJ I-POPU
tumors NNS I-POPU
such JJ I-POPU
as IN I-POPU
non-small JJ I-POPU
cell NN I-POPU
lung NN I-POPU
cancer NN I-POPU
( ( I-POPU
NSCLC NNP I-POPU
) ) I-POPU
, , I-POPU
bladder NN I-POPU
cancer NN I-POPU
, , I-POPU
gastrointestinal JJ I-POPU
cancers NNS I-POPU
, , I-POPU
kidney NN I-POPU
cancer NN I-POPU
, , I-POPU
melanoma NN I-POPU
and CC I-POPU
metastatic JJ I-POPU
carcinoma NN I-POPU
of IN I-POPU
unknown JJ I-POPU
origin NN I-POPU
entered VBD I-POPU
the DT I-POPU
study NN I-POPU
. . O

Patients NNS B-POPU
were VBD I-POPU
randomized VBN I-POPU
to TO I-POPU
receive VB I-POPU
either DT I-POPU
clodronate NN I-POPU
1,600 CD I-POPU
mg/day NN I-POPU
for IN I-POPU
one CD I-POPU
year NN I-POPU
or CC I-POPU
identical JJ I-POPU
placebo-containing JJ I-POPU
tablets NNS I-POPU
. . O

Various JJ B-INTV
parameters NNS I-INTV
such JJ I-INTV
as IN I-INTV
Karnofsky NNP I-INTV
performance NN I-INTV
status NN I-INTV
, , I-INTV
pain NN I-INTV
score NN I-INTV
( ( I-INTV
measured VBN I-INTV
by IN I-INTV
a DT I-INTV
visual-analogue JJ I-INTV
scale NN I-INTV
) ) I-INTV
and CC I-INTV
analgesic JJ I-INTV
requirement NN I-INTV
were VBD I-INTV
recorded VBN I-INTV
at IN I-INTV
monthly JJ I-INTV
intervals NNS I-INTV
. . O

Of IN B-POPU
the DT I-POPU
66 CD I-POPU
patients NNS I-POPU
enrolled VBD I-POPU
, , I-POPU
9 CD I-POPU
were VBD I-POPU
observed VBN I-POPU
for IN I-POPU
one CD I-POPU
month NN I-POPU
or CC I-POPU
less JJR I-POPU
; : I-POPU
7 CD I-POPU
were VBD I-POPU
followed VBN I-POPU
for IN I-POPU
two CD I-POPU
months NNS I-POPU
; : I-POPU
only RB I-POPU
50 CD I-POPU
patients NNS I-POPU
were VBD I-POPU
followed VBN I-POPU
for IN I-POPU
more JJR I-POPU
than IN I-POPU
2 CD I-POPU
months NNS I-POPU
and CC I-POPU
could MD I-POPU
be VB I-POPU
adequately RB I-POPU
evaluated VBN I-POPU
. . O

At IN O
3 CD O
months NNS O
both DT O
clodronate NN B-INTV
and CC O
placebo-treated JJ B-INTV
patients NNS O
had VBD O
a DT O
decrease NN B-OC
in IN I-OC
Karnofsky NNP I-OC
performance NN I-OC
status NN I-OC
, , O
with IN O
the DT O
decrease NN O
being VBG O
more RBR O
evident JJ O
in IN O
the DT O
placebo NN O
group NN O
. . O

Mean NNP B-OC
pain NN I-OC
scores NNS I-OC
showed VBD O
an DT O
increase NN B-OC
of IN I-OC
pain NN I-OC
in IN O
patients NNS O
receiving VBG O
placebo NN B-INTV
and CC O
a DT O
decrease NN O
of IN O
pain NN O
in IN O
patients NNS O
receiving VBG O
clodronate NN B-INTV
, , O
although IN O
the DT O
difference NN O
failed VBD O
to TO O
be VB O
statistically RB O
significant JJ O
. . O

Analgesics NNPS B-OC
requirement NN I-OC
increased VBN O
in IN O
both DT O
groups NNS O
, , O
but CC O
significantly RB O
more RBR O
in IN O
patients NNS O
receiving VBG O
placebo NN B-INTV
( ( O
p JJ O
= NNP O
0.042 CD O
) ) O
, , O
in IN O
whom WP O
increase NN O
in IN O
opioid JJ O
requirements NNS O
was VBD O
particularly RB O
evident JJ O
. . O

Toxicity NNP B-OC
was VBD I-OC
low JJ I-OC
, , O
with IN O
occasional JJ B-OC
gastroenteric JJ I-OC
discomfort NN I-OC
in IN O
both DT O
groups NNS O
. . O

The DT O
main JJ O
problem NN O
of IN O
this DT O
study NN O
was VBD O
the DT O
difficulty NN O
in IN O
recruiting VBG O
an DT O
adequate JJ O
number NN O
of IN O
patients NNS O
and CC O
following VBG O
them PRP O
for IN O
a DT O
sufficient JJ O
period NN O
of IN O
time NN O
: : O
general JJ O
conditions NNS O
rapidly RB O
deteriorated VBD O
in IN O
many JJ O
patients NNS O
, , O
and CC O
approximately RB O
25 CD O
% NN O
of IN O
the DT O
66 CD O
enrolled NNS O
were VBD O
not RB O
considered VBN O
evaluable JJ O
; : O
few JJ O
patients NNS O
survived VBD O
for IN O
the DT O
length NN O
of IN O
the DT O
study NN O
, , O
one CD O
year NN O
. . O

This DT O
might MD O
partly RB O
account VB O
for IN O
the DT O
lack NN O
of IN O
significance NN O
of IN O
some DT O
of IN O
the DT O
parameters NNS O
under IN O
study NN O
. . O

With IN O
these DT O
limits NNS O
, , O
oral JJ O
clodronate NN O
demonstrated VBD O
some DT O
efficacy NN O
in IN O
symptom NN O
control NN O
and CC O
in IN O
reducing VBG O
the DT O
need NN O
for IN O
analgesics NNS O
. . O

-DOCSTART- -X- O O

Combined VBN B-INTV
modality NN I-INTV
therapy NN I-INTV
in IN O
advanced JJ O
Hodgkin NNP O
's POS O
disease NN O
: : O
a DT B-POPU
report NN I-POPU
on IN I-POPU
218 CD I-POPU
patients NNS I-POPU
with IN I-POPU
a DT I-POPU
median JJ I-POPU
follow-up NN I-POPU
of IN I-POPU
eight CD I-POPU
years NNS I-POPU
. . O

BACKGROUND NNP O
AND CC O
OBJECTIVE NNP O
This DT O
study NN O
was VBD O
designed VBN O
to TO O
evaluate VB O
the DT O
efficacy NN B-OC
and CC I-OC
toxicity NN I-OC
of IN O
monthly JJ O
alternating VBG O
ABVD/MOPP NNP B-INTV
compared VBN I-INTV
to TO I-INTV
ABVD/OPP NNP I-INTV
regimens NNS O
in IN O
patients NNS B-POPU
with IN I-POPU
advanced JJ I-POPU
stage NN I-POPU
Hodgkin NNP I-POPU
's POS I-POPU
disease NN I-POPU
( ( I-POPU
HD NNP I-POPU
) ) I-POPU
, , I-POPU
as RB I-POPU
well RB I-POPU
as IN I-POPU
in IN I-POPU
early JJ I-POPU
stage NN I-POPU
patients NNS I-POPU
with IN I-POPU
systemic JJ I-POPU
symptoms NNS I-POPU
and/or VBP I-POPU
bulky JJ I-POPU
disease NN I-POPU
. . O

DESIGN NNP O
AND NNP O
METHODS NNP O
218 CD B-POPU
patients NNS I-POPU
with IN I-POPU
previously RB I-POPU
untreated VBN I-POPU
HD NNP I-POPU
entered VBD I-POPU
this DT I-POPU
study NN I-POPU
: : I-POPU
106 CD I-POPU
patients NNS I-POPU
in IN I-POPU
arm NN I-POPU
A NNP I-POPU
( ( I-POPU
ABVD/MOPP NNP I-POPU
) ) I-POPU
and CC I-POPU
112 CD I-POPU
in IN I-POPU
arm NN I-POPU
B NNP I-POPU
( ( I-POPU
ABVD/OPP NNP I-POPU
) ) I-POPU
. . O

Patients NNPS O
received VBD O
eight CD O
courses NNS O
of IN O
one CD O
of IN O
the DT O
two CD O
regimens NNS O
after IN O
stratification NN O
according VBG O
to TO O
the DT O
stage NN O
. . O

Patients NNS O
in IN O
complete JJ O
remission NN O
( ( O
CR NNP O
) ) O
received VBD O
20 CD O
Gy NNP O
to TO O
the DT O
involved JJ O
field NN O
and CC O
40 CD O
Gy NNP O
to TO O
the DT O
spleen NN O
. . O

The DT O
actuarial JJ B-OC
survival NN I-OC
curves NNS I-OC
were VBD O
performed VBN O
according VBG O
to TO O
Kaplan NNP O
and CC O
Meier NNP O
. . O

RESULTS NNP O
No NNP O
statistically RB O
significant JJ O
differences NNS O
were VBD O
observed VBN O
between IN O
the DT O
two CD O
arms NNS O
in IN O
terms NNS O
of IN O
CR NNP B-OC
rate NN I-OC
and CC I-OC
toxicity NN I-OC
. . O

However RB O
, , O
analysis NN O
of IN O
total JJ B-OC
relapses NNS I-OC
revealed VBD O
that IN O
patients NNS O
treated VBN O
with IN O
ABVD/OPP NNP B-INTV
had VBD O
a DT O
significantly RB O
higher JJR O
likelihood NN O
of IN O
achieving VBG O
a DT O
second JJ B-OC
CR NNP I-OC
compared VBN O
to TO O
patients NNS B-POPU
who WP I-POPU
entered VBD I-POPU
the DT I-POPU
ABVD/MOPP NNP I-POPU
arm NN I-POPU
. . O

INTERPRETATION NNP O
AND CC O
CONCLUSIONS NNP O
Both NNP O
schemes NNS O
of IN O
chemotherapy NN O
followed VBN O
by IN O
radiotherapy NN O
produce VBP O
high JJ O
percentages NNS O
of IN O
CR NNP B-OC
, , I-OC
low JJ I-OC
risk NN I-OC
of IN I-OC
relapse NN I-OC
and CC I-OC
an DT I-OC
acceptable JJ I-OC
toxicity NN I-OC
. . O

-DOCSTART- -X- O O

Recombinant JJ B-INTV
human JJ I-INTV
granulocyte NN I-INTV
and CC I-INTV
granulocyte-macrophage JJ I-INTV
colony-stimulating JJ I-INTV
factor NN I-INTV
( ( I-INTV
G-CSF NNP I-INTV
and CC I-INTV
GM-CSF NNP I-INTV
) ) I-INTV
administered VBD O
following VBG O
cytotoxic NN B-INTV
chemotherapy NNS I-INTV
have VBP O
a DT O
similar JJ O
ability NN O
to TO O
mobilize VB O
peripheral JJ O
blood NN O
stem NN O
cells NNS O
. . O

The DT O
availability NN O
of IN O
hematopoietic JJ O
growth NN O
factors NNS O
has VBZ O
greatly RB O
facilitated VBN O
the DT O
mobilization NN B-OC
and CC I-OC
collection NN I-OC
of IN I-OC
peripheral JJ I-OC
blood NN I-OC
stem NN I-OC
cells NNS I-OC
( ( I-OC
PBSC NNP I-OC
) ) I-OC
. . O

It PRP O
was VBD O
the DT O
aim NN O
of IN O
this DT O
double-blind NN O
study NN O
to TO O
compare VB O
the DT O
PBSC-mobilizing NNP O
efficacy NN O
of IN O
recombinant JJ B-INTV
human JJ I-INTV
G-CSF NNP I-INTV
and CC O
GM-CSF NNP B-INTV
when WRB O
administered VBN O
post-chemotherapy NN B-INTV
. . O

Twenty-six JJ B-POPU
patients NNS I-POPU
with IN I-POPU
relapsed JJ I-POPU
Hodgkin NNP I-POPU
's POS I-POPU
disease NN I-POPU
were VBD O
included VBN O
in IN O
the DT O
study NN O
. . O

Their PRP$ B-POPU
median JJ I-POPU
age NN I-POPU
was VBD I-POPU
31 CD I-POPU
years NNS I-POPU
( ( I-POPU
range NN I-POPU
, , I-POPU
22-59 JJ I-POPU
) ) I-POPU
and CC I-POPU
14 CD I-POPU
patients NNS I-POPU
were VBD I-POPU
males NNS I-POPU
and CC I-POPU
12 CD I-POPU
were VBD I-POPU
females NNS I-POPU
. . O

Patients NNS B-POPU
were VBD I-POPU
pretreated VBN I-POPU
with IN I-POPU
a DT I-POPU
median NN I-POPU
of IN I-POPU
eight CD I-POPU
cycles NNS I-POPU
of IN I-POPU
cytotoxic NN I-POPU
chemotherapy NN I-POPU
, , I-POPU
while IN I-POPU
18 CD I-POPU
patients NNS I-POPU
had VBD I-POPU
undergone JJ I-POPU
extended JJ I-POPU
field NN I-POPU
irradiation NN I-POPU
. . O

The DT O
patients NNS O
received VBD O
dexamethasone RB B-INTV
24 CD I-INTV
mg JJ I-INTV
days NNS I-INTV
1-7 CD I-INTV
, , I-INTV
melphalan FW I-INTV
30 CD I-INTV
mg/m2 NNS I-INTV
day NN I-INTV
3 CD I-INTV
, , I-INTV
BCNU NNP I-INTV
60 CD I-INTV
mg/m2 NN I-INTV
day NN I-INTV
3 CD I-INTV
, , I-INTV
etoposide RB I-INTV
75 CD I-INTV
mg/m2 JJ I-INTV
days NNS I-INTV
4-7 CD I-INTV
, , I-INTV
Ara-C NNP I-INTV
100 CD I-INTV
mg/m2 NN I-INTV
twice RB I-INTV
daily JJ I-INTV
days NNS I-INTV
4-7 JJ I-INTV
( ( I-INTV
Dexa-BEAM NNP I-INTV
) ) I-INTV
. . O

Twelve CD O
patients NNS O
were VBD O
randomized VBN O
to TO O
receive VB B-INTV
5/microg/kg/day CD I-INTV
G-CSF NNP I-INTV
and CC O
14 CD O
patients NNS O
to TO O
receive VB O
5 CD B-INTV
microg/kg/day JJ I-INTV
GM-CSF NNP I-INTV
, , O
both DT O
administered VBN O
subcutaneously RB O
starting VBG O
on IN O
day NN O
1 CD O
after IN O
the DT O
end NN O
of IN O
Dexa-BEAM NNP B-INTV
. . O

Primary JJ O
endpoints NNS O
of IN O
the DT O
study NN O
were VBD O
the DT O
number NN B-OC
of IN I-OC
CD34+ NNP I-OC
cells NNS I-OC
harvested VBD I-OC
per IN I-OC
kg NN I-OC
body NN I-OC
weight VBD I-OC
on IN I-OC
the DT I-OC
occasion NN I-OC
of IN I-OC
six CD I-OC
consecutive JJ I-OC
leukaphereses NNS I-OC
and CC O
the DT O
time NN B-OC
needed VBN I-OC
for IN I-OC
hematological JJ I-OC
reconstitution NN I-OC
following VBG I-OC
autografting VBG I-OC
. . O

Twenty-one CD O
patients NNS O
completed VBN O
PBSC NNP O
collection NN O
, , O
and CC O
six CD O
patients NNS O
of IN O
the DT O
G-CSF NNP O
group NN O
and CC O
nine CD O
of IN O
the DT O
GM-CSF NNP O
group NN O
were VBD O
autografted VBN O
. . O

No DT O
difference NN O
was VBD O
observed VBN O
with IN O
respect NN O
to TO O
the DT O
median JJ B-OC
yield NN I-OC
of IN I-OC
CFU-GM NNP I-OC
and CC I-OC
CD34+ NNP I-OC
cells NNS I-OC
: : I-OC
32.5 CD O
x $ O
10 CD O
( ( O
4 CD O
) ) O
/kg NN O
vs $ O
31.3 CD O
x $ O
10 CD O
( ( O
4 CD O
) ) O
/kg CD O
CFU-GM NNP O
, , O
and CC O
7.6 CD O
x NNS O
10 CD O
( ( O
6 CD O
) ) O
/kg NN O
vs $ O
5.6 CD O
x $ O
10 CD O
( ( O
6 CD O
) ) O
/kg NN O
CD34+ NNP O
cells NNS O
, , O
for IN O
G-CSF NNP B-INTV
and CC B-OC
GM-CSF NNP B-INTV
, , O
respectively RB O
( ( O
U NNP O
test NN O
, , O
P= NNP O
0.837 CD O
and CC O
0.696 CD O
) ) O
. . O

High-dose JJ O
chemotherapy NN O
consisted VBN O
of IN O
cyclophosphamide NN B-INTV
1.7 CD O
g/m2 JJ O
days NNS O
1-4 CD O
, , O
BCNU NNP B-INTV
150 CD O
mg/m2 NN O
days NNS O
1-4 CD O
, , O
etoposide RB B-INTV
400 CD O
mg/m2 JJ O
days NNS O
1-4 JJ O
. . O

All DT O
patients NNS O
transplanted VBN O
with IN O
more JJR O
than IN O
5 CD O
x JJ O
10 CD O
( ( O
6 CD O
) ) O
CD34+ NNP O
cells/kg NN O
had VBD O
a DT O
rapid JJ O
platelet NN B-OC
recovery NN I-OC
( ( O
20 CD O
x RB O
10 CD O
( ( O
9 CD O
) ) O
/l NN O
) ) O
between IN O
6 CD O
and CC O
11 CD O
days NNS O
and CC O
neutrophil JJ B-OC
recovery NN I-OC
( ( O
0.5 CD O
x RB O
10 CD O
( ( O
9 CD O
) ) O
/1 NN O
) ) O
between IN O
9 CD O
and CC O
16 CD O
days NNS O
, , O
while IN O
patients NNS O
transplanted VBN O
with IN O
less JJR O
than IN O
5 CD O
x JJ O
10 CD O
( ( O
6 CD O
) ) O
/kg NN O
had VBD O
a DT O
delayed VBN B-OC
reconstitution NN I-OC
, , O
regardless RB O
of IN O
the DT O
kind NN O
of IN O
growth NN O
factor NN O
used VBN O
for IN O
PBSC NNP O
mobilization NN O
. . O

In IN O
conclusion NN O
, , O
our PRP$ O
data NNS O
indicate VBP O
that IN O
in IN O
patients NNS B-POPU
with IN I-POPU
Hodgkin NNP I-POPU
's POS I-POPU
disease NN I-POPU
G-CSF NNP O
and CC O
GM-CSF NNP O
given VBN O
after IN O
salvage NN O
chemotherapy NN O
appear VBP O
to TO O
be VB O
not RB O
different JJ O
in IN O
their PRP$ O
ability NN B-OC
to TO I-OC
mobilize VB I-OC
PBSC NNP I-OC
resulting VBG O
in IN O
a DT O
similar JJ O
time NN B-OC
needed VBN I-OC
for IN I-OC
hematological JJ I-OC
reconstitution NN I-OC
when WRB O
autografted VBD O
following VBG O
high-dose JJ O
therapy NN O
. . O

-DOCSTART- -X- O O

Marginal JJ O
benefit/disadvantage NN B-OC
of IN O
granulocyte JJ B-POPU
colony-stimulating JJ I-POPU
factor NN I-POPU
therapy NN I-POPU
after IN I-POPU
autologous JJ I-POPU
blood NN I-POPU
stem NN I-POPU
cell NN I-POPU
transplantation NN I-POPU
in IN I-POPU
children NNS I-POPU
: : I-POPU
results NNS O
of IN O
a DT O
prospective JJ O
randomized VBN O
trial NN O
. . O

The DT O
Japanese JJ B-POPU
Cooperative NNP I-POPU
Study NNP I-POPU
Group NNP I-POPU
of IN I-POPU
PBSCT NNP I-POPU
. . O

In IN O
this DT O
prospective JJ O
trial NN O
, , O
a DT O
total NN O
of IN O
74 CD B-POPU
children NNS I-POPU
who WP I-POPU
were VBD I-POPU
scheduled VBN I-POPU
to TO I-POPU
undergo VB I-POPU
high-dose JJ I-POPU
chemotherapy NN I-POPU
followed VBN I-POPU
by IN I-POPU
autologous JJ I-POPU
peripheral JJ I-POPU
blood NN I-POPU
stem NN I-POPU
cell NN I-POPU
transplantation NN I-POPU
( ( I-POPU
PBSCT NNP I-POPU
) ) I-POPU
were VBD O
prospectively RB O
randomized VBN O
at IN O
diagnosis NN O
to TO O
evaluate VB O
the DT O
effectiveness NN B-OC
of IN O
exogenous JJ O
granulocyte JJ B-INTV
colony-stimulating JJ I-INTV
factor NN I-INTV
( ( O
G-CSF NNP O
) ) O
treatment NN O
in IN O
accelerating VBG O
hematopoietic JJ B-OC
recovery NN I-OC
after IN O
PBSCT NNP O
. . O

The DT B-POPU
diagnosis NN I-POPU
included VBD I-POPU
acute JJ I-POPU
lymphoblastic JJ I-POPU
leukemia NN I-POPU
( ( I-POPU
ALL DT I-POPU
) ) I-POPU
( ( I-POPU
n JJ I-POPU
= NNP I-POPU
27 CD I-POPU
) ) I-POPU
, , I-POPU
neuroblastoma FW I-POPU
( ( I-POPU
n JJ I-POPU
= NNP I-POPU
29 CD I-POPU
) ) I-POPU
, , I-POPU
and CC I-POPU
miscellaneous JJ I-POPU
solid JJ I-POPU
tumors NNS I-POPU
( ( I-POPU
n JJ I-POPU
= NNP I-POPU
18 CD I-POPU
) ) I-POPU
. . O

Eligibility NNP B-POPU
criteria NNS I-POPU
included VBD I-POPU
( ( I-POPU
1 CD I-POPU
) ) I-POPU
primary NN I-POPU
PBSCT NNP I-POPU
, , I-POPU
( ( I-POPU
2 CD I-POPU
) ) I-POPU
chemotherapy-responsive JJ I-POPU
disease NN I-POPU
, , I-POPU
and CC I-POPU
( ( I-POPU
3 CD I-POPU
) ) I-POPU
collected VBN I-POPU
cell NN I-POPU
number NN I-POPU
> $ I-POPU
1 CD I-POPU
x $ I-POPU
10 CD I-POPU
( ( I-POPU
5 CD I-POPU
) ) I-POPU
colony-forming NN I-POPU
unit-granulocyte-macrophage JJ I-POPU
( ( I-POPU
CFU-GM NNP I-POPU
) ) I-POPU
/kg NN I-POPU
and CC I-POPU
> $ I-POPU
1 CD I-POPU
x $ I-POPU
10 CD I-POPU
( ( I-POPU
6 CD I-POPU
) ) I-POPU
CD34 NNP I-POPU
( ( I-POPU
+ NNP I-POPU
) ) I-POPU
cells/kg VBP I-POPU
patient NN I-POPU
's POS I-POPU
body NN I-POPU
weight NN I-POPU
. . O

After IN O
applying VBG O
the DT O
above NN O
criteria NN O
, , O
11 CD B-POPU
patients NNS I-POPU
were VBD I-POPU
excluded VBN I-POPU
due JJ I-POPU
to TO I-POPU
disease VB I-POPU
progression NN I-POPU
before IN I-POPU
PBSCT NNP I-POPU
( ( I-POPU
n JJ I-POPU
= NNP I-POPU
6 CD I-POPU
) ) I-POPU
or CC I-POPU
a DT I-POPU
low JJ I-POPU
number NN I-POPU
of IN I-POPU
harvested JJ I-POPU
cells NNS I-POPU
( ( I-POPU
n JJ I-POPU
= NNP I-POPU
5 CD I-POPU
) ) I-POPU
, , I-POPU
leaving VBG I-POPU
63 CD I-POPU
patients NNS I-POPU
for IN I-POPU
analysis NN I-POPU
; : I-POPU
32 CD I-POPU
patients NNS I-POPU
in IN O
the DT O
treatment NN O
group NN O
( ( O
300 CD O
microg/m2 NN O
of IN O
G-CSF NNP B-INTV
intravenously RB O
over IN O
1 CD O
hour NN O
from IN O
day NN O
1 CD O
of IN O
PBSCT NNP B-INTV
) ) I-INTV
and CC O
31 CD O
in IN O
the DT O
control NN B-INTV
group NN I-INTV
without IN O
treatment NN O
. . O

Two CD O
distinct JJ O
disease-oriented JJ O
high-dose JJ B-INTV
regimens NNS I-INTV
without IN I-INTV
total JJ I-INTV
body NN I-INTV
irradiation NN I-INTV
consisted VBD I-INTV
of IN I-INTV
the DT I-INTV
MCVAC NNP I-INTV
regimen NNS I-INTV
using VBG I-INTV
ranimustine NN I-INTV
( ( I-INTV
MCNU NNP I-INTV
, , I-INTV
450 CD I-INTV
mg/m2 NN I-INTV
) ) I-INTV
, , I-INTV
cytosine JJ I-INTV
arabinoside NN I-INTV
( ( I-INTV
16 CD I-INTV
g/m2 NN I-INTV
) ) I-INTV
, , I-INTV
etoposide RB I-INTV
( ( I-INTV
1.6 CD I-INTV
g/m2 NN I-INTV
) ) I-INTV
, , I-INTV
and CC I-INTV
cyclophosphamide NN I-INTV
( ( O
100 CD O
mg/kg NN O
) ) O
for IN O
patients NNS O
with IN O
ALL NNP O
, , O
and CC O
the DT O
Hi-MEC NNP B-INTV
regimen NNS I-INTV
using VBG I-INTV
melphalan NN I-INTV
( ( O
180 CD O
mg/m2 NN O
) ) O
, , O
etoposide RB B-INTV
( ( O
1.6 CD O
g/m2 NN O
) ) O
, , O
and CC O
carboplatinum NN B-INTV
( ( O
1.6 CD O
g/m2 NN O
) ) O
for IN O
those DT O
with IN O
solid JJ O
tumors NNS O
. . O

Five CD B-POPU
patients NNS I-POPU
( ( I-POPU
two CD I-POPU
in IN I-POPU
the DT I-POPU
treatment NN I-POPU
group NN I-POPU
and CC I-POPU
three CD I-POPU
in IN I-POPU
the DT I-POPU
control NN I-POPU
group NN I-POPU
) ) I-POPU
were VBD I-POPU
subsequently RB I-POPU
removed VBN I-POPU
due JJ I-POPU
to TO I-POPU
protocol VB I-POPU
violations NNS I-POPU
. . O

All DT O
patients NNS O
survived VBD B-OC
PBSCT NNP B-POPU
. . O

The DT O
median JJ B-OC
numbers NNS I-OC
of IN I-OC
transfused JJ I-OC
mononuclear JJ I-OC
cells NNS I-OC
( ( I-OC
MNC NNP I-OC
) ) I-OC
, , I-OC
CD34 NNP I-OC
( ( I-OC
+ NNP I-OC
) ) I-OC
cells NNS I-OC
, , I-OC
and CC I-OC
CFU-GM NNP I-OC
were VBD O
, , O
respectively RB O
, , O
4.5 CD O
( ( O
range NN O
, , O
1 CD O
to TO O
19 CD O
) ) O
x NN O
10 CD O
( ( O
8 CD O
) ) O
/kg NN O
, , O
8.0 CD O
( ( O
1.1 CD O
to TO O
25 CD O
) ) O
x NN O
10 CD O
( ( O
6 CD O
) ) O
/kg NN O
, , O
and CC O
3.7 CD O
( ( O
1.2 CD O
to TO O
23 CD O
) ) O
x NN O
10 CD O
( ( O
5 CD O
) ) O
/kg NN O
in IN O
the DT O
treatment NN O
group NN O
( ( O
n JJ O
= NNP O
30 CD O
) ) O
and CC O
2.9 CD O
( ( O
0.8 CD O
to TO O
21 CD O
) ) O
x NN O
10 CD O
( ( O
8 CD O
) ) O
/kg NN O
, , O
6.3 CD O
( ( O
1.1 CD O
to TO O
34 CD O
) ) O
x NN O
10 CD O
( ( O
6 CD O
) ) O
/kg NN O
, , O
and CC O
5.5 CD O
( ( O
1.3 CD O
to TO O
37 CD O
) ) O
x NN O
10 CD O
( ( O
5 CD O
) ) O
/kg NN O
, , O
respectively RB O
, , O
in IN O
the DT O
control NN O
group NN O
( ( O
n JJ O
= NNP O
28 CD O
) ) O
, , O
with IN O
no DT O
significant JJ O
difference NN O
. . O

After IN O
PBSCT NNP O
, , O
the DT O
time NN B-OC
to TO I-OC
achieve VB I-OC
an DT I-OC
absolute JJ I-OC
neutrophil NN I-OC
count NN I-OC
( ( I-OC
ANC NNP I-OC
) ) I-OC
of IN I-OC
> $ I-OC
0.5 CD I-OC
x $ I-OC
10 CD I-OC
( ( I-OC
9 CD I-OC
) ) I-OC
/L NN I-OC
in IN O
the DT O
treatment NN O
group NN O
was VBD O
less JJR O
than IN O
that DT O
in IN O
the DT O
control NN O
group NN O
( ( O
median JJ O
, , O
11 CD O
v NN O
12 CD O
days NNS O
; : O
the DT O
log-rank JJ O
test NN O
, , O
P NNP O
=.046 NNP O
) ) O
, , O
although IN O
the DT O
last JJ O
day NN O
of IN O
red JJ O
blood NN O
cell NN O
( ( O
RBC NNP O
) ) O
transfusion NN O
( ( O
day NN O
11 CD O
v NN O
day NN O
10 CD O
) ) O
and CC O
the DT O
duration NN B-OC
of IN I-OC
febrile JJ I-OC
days NNS I-OC
( ( O
> JJ O
38 CD O
degrees NNS O
C NNP O
) ) O
after IN O
PBSCT NNP O
( ( O
4 CD O
v RB O
4 CD O
days NNS O
) ) O
were VBD O
identical JJ O
in IN O
both DT O
groups NNS O
. . O

However RB O
, , O
platelet JJ B-OC
recovery NN I-OC
to TO I-OC
> VB I-OC
20 CD I-OC
x JJ I-OC
10 CD I-OC
( ( I-OC
9 CD I-OC
) ) I-OC
/L NN I-OC
was VBD O
significantly RB O
longer RBR O
in IN O
treatment NN O
group NN O
than IN O
control NN O
group NN O
( ( O
26 CD O
v RB O
16 CD O
days NNS O
; : O
P NNP O
=.009 NNP O
) ) O
and CC O
> $ O
50 CD O
x $ O
10 CD O
( ( O
9 CD O
) ) O
/L NN O
tended VBD O
to TO O
take VB O
longer JJR O
in IN O
the DT O
treatment NN O
group NN O
( ( O
29 CD O
v RB O
26 CD O
days NNS O
; : O
P NNP O
=.126 NNP O
) ) O
, , O
with IN O
significantly RB O
more JJR O
platelet JJ B-OC
transfusion-dependent JJ I-OC
days NNS I-OC
( ( O
27 CD O
v RB O
13 CD O
days NNS O
; : O
t-test JJ O
, , O
P NNP O
=.037 NNP O
) ) O
. . O

When WRB O
patients NNS O
were VBD O
divided VBN O
into IN O
two CD O
different JJ O
disease NN O
cohorts NNS O
, , O
ALL DT O
patients NNS O
showed VBD O
no DT O
difference NN O
in IN O
engraftment JJ B-OC
kinetics NNS I-OC
between IN O
the DT O
G-CSF NNP O
treatment NN O
and CC O
control NN O
groups NNS O
, , O
while IN O
differences NNS O
were VBD O
seen VBN O
in IN O
those DT O
with IN O
solid JJ O
tumors NNS O
. . O

We PRP O
concluded VBD O
that IN O
the DT O
marginal JJ O
clinical JJ O
benefit NN O
of IN O
1 CD O
day NN O
earlier RBR O
recovery NN B-OC
of IN I-OC
granulocytes NNS I-OC
could MD O
be VB O
offset VBN O
by IN O
the DT O
delayed JJ O
recovery NN B-OC
of IN I-OC
platelets NNS I-OC
. . O

We PRP O
recommend VBP O
that IN O
the DT O
routine JJ O
application NN O
of IN O
costly JJ O
G-CSF NNP B-POPU
therapy NN I-POPU
in IN I-POPU
children NNS I-POPU
undergoing VBG I-POPU
PBSCT NNP I-POPU
should MD O
be VB O
seriously RB O
reconsidered VBN O
. . O

-DOCSTART- -X- O O

BEACOPP NNP O
, , O
a DT O
new JJ O
dose-escalated JJ B-INTV
and CC I-INTV
accelerated JJ I-INTV
regimen NNS I-INTV
, , O
is VBZ O
at IN O
least JJS O
as RB O
effective JJ O
as IN O
COPP/ABVD NNP B-INTV
in IN O
patients NNS B-POPU
with IN I-POPU
advanced-stage JJ I-POPU
Hodgkin NNP I-POPU
's POS I-POPU
lymphoma NN I-POPU
: : I-POPU
interim JJ O
report NN O
from IN O
a DT O
trial NN O
of IN O
the DT O
German JJ B-POPU
Hodgkin NNP O
's POS O
Lymphoma NNP O
Study NNP O
Group NNP O
. . O

PURPOSE NNP O
The DT O
HD9 NNP O
trial NN O
aims NNS O
to TO O
evaluate VB O
whether IN O
moderate JJ O
dose JJ O
escalation NN O
and/or IN O
acceleration NN O
of IN O
standard JJ B-INTV
polychemotherapy NN I-INTV
is VBZ O
beneficial JJ O
for IN O
advanced-stage JJ B-POPU
Hodgkin NNP I-POPU
's POS I-POPU
disease NN I-POPU
( ( I-POPU
HD NNP I-POPU
) ) I-POPU
. . O

Two CD O
variants NNS O
of IN O
a DT O
novel JJ B-INTV
bleomycin NN I-INTV
, , I-INTV
etoposide RB I-INTV
, , I-INTV
doxorubicin NN I-INTV
, , I-INTV
cyclophosphamide NN I-INTV
, , I-INTV
vincristine NN I-INTV
, , I-INTV
procarbazine NN I-INTV
, , I-INTV
and CC I-INTV
prednisone NN I-INTV
( ( I-INTV
BEACOPP NNP I-INTV
) ) I-INTV
scheme NN I-INTV
( ( I-INTV
standard JJ I-INTV
and CC I-INTV
escalated VBD I-INTV
dose NN I-INTV
) ) I-INTV
are VBP O
compared VBN O
with IN O
cyclophosphamide NN B-INTV
, , I-INTV
vincristine NN I-INTV
, , I-INTV
procarbazine NN I-INTV
, , I-INTV
and CC I-INTV
prednisone NN I-INTV
( ( I-INTV
COPP NNP I-INTV
) ) I-INTV
/doxorubicin NN I-INTV
, , I-INTV
bleomycin NN I-INTV
, , I-INTV
vinblastine NN I-INTV
, , I-INTV
and CC I-INTV
dacarbazine NN I-INTV
( ( I-INTV
ABVD NNP I-INTV
) ) I-INTV
. . O

PATIENTS NNP O
AND CC O
METHODS NNP O
The DT B-POPU
randomized VBN I-POPU
, , I-POPU
three-arm JJ I-POPU
trial NN I-POPU
recruited VBD I-POPU
patients NNS I-POPU
in IN I-POPU
stages NNS I-POPU
IIB NNP I-POPU
and CC I-POPU
IIIA NNP I-POPU
with IN I-POPU
risk NN I-POPU
factors NNS I-POPU
and CC I-POPU
stages NNS I-POPU
IIIB NNP I-POPU
and CC I-POPU
IV NNP I-POPU
. . O

BEACOPP NNP O
in IN O
baseline NN O
dose NN O
contains VBZ O
all DT O
drug NN O
dosages NNS O
of IN O
COPP/ABVD NNP B-INTV
( ( O
except IN O
vincristine NN O
and CC O
procarbazine NN O
) ) O
rearranged VBD O
in IN O
a DT O
shorter NN O
, , O
3-week JJ O
cycle NN O
. . O

Escalated VBN O
BEACOPP NNP O
uses VBZ O
higher JJR O
doses NNS O
of IN O
cyclophosphamide NN B-INTV
, , I-INTV
doxorubicin NN I-INTV
, , I-INTV
and CC I-INTV
etoposide RB I-INTV
with IN I-INTV
granulocyte JJ I-INTV
colony-stimulating JJ I-INTV
factor NN I-INTV
( ( I-INTV
G-CSF NNP I-INTV
) ) I-INTV
support NN O
. . O

After IN O
eight CD O
chemotherapy NN B-INTV
cycles NNS O
, , O
initial JJ O
bulky NN O
and CC O
residual JJ O
disease NN O
is VBZ O
irradiated VBN O
. . O

The DT O
trial NN O
is VBZ O
monitored VBN O
and CC O
analyzed VBN O
by IN O
means NNS O
of IN O
a DT O
sequential JJ O
strategy NN O
. . O

RESULTS NNP O
An DT O
interim JJ O
analysis NN O
with IN O
505 CD B-POPU
assessable JJ I-POPU
patients NNS I-POPU
and CC O
a DT O
median JJ O
follow-up NN O
of IN O
23 CD O
months NNS O
showed VBD O
a DT O
significant JJ O
inferiority NN O
( ( O
according VBG O
to TO O
sequential JJ O
monitoring NN O
strategy NN O
) ) O
of IN O
the DT O
COPP/ABVD NNP B-INTV
regimen NNS O
in IN O
progression NN B-OC
rate NN I-OC
and CC I-OC
freedom NN I-OC
from IN I-OC
treatment NN I-OC
failure NN I-OC
( ( I-OC
FFTF NNP I-OC
) ) I-OC
compared VBN O
with IN O
the DT O
pooled JJ O
results NNS O
of IN O
both DT O
BEACOPP NNP B-INTV
variants NNS O
. . O

The DT O
24-month JJ B-OC
FFTF NNP I-OC
rate NN I-OC
was VBD O
75 CD O
% NN O
for IN O
COPP/ABVD NNP O
and CC O
84 CD O
% NN O
for IN O
BEACOPP NNP B-INTV
pooled VBD O
( ( O
P NNP O
= NNP O
.034 NNP O
) ) O
. . O

There EX O
was VBD O
12 CD O
% NN O
progressive JJ B-OC
disease NN I-OC
with IN O
COPP/ABVD NNP O
and CC O
6 CD O
% NN O
with IN O
BEACOPP NNP B-INTV
pooled VBD O
. . O

Differences NNS B-OC
in IN I-OC
survival NN I-OC
were VBD O
not RB O
significant JJ O
in IN O
sequential JJ O
analysis NN O
. . O

The DT O
acute JJ B-OC
toxicity NN I-OC
of IN I-OC
baseline NN I-OC
BEACOPP NNP B-INTV
resembled VBD O
that IN O
of IN O
COPP/ABVD NNP B-INTV
; : I-INTV
escalated VBD O
BEACOPP NNP B-INTV
showed VBD O
increased VBN O
but CC O
manageable JJ O
hematologic JJ O
toxicity NN O
. . O

CONCLUSION NNP O
Combined VBD O
with IN O
local JJ O
irradiation NN O
, , O
BEACOPP NNP B-INTV
in IN O
one CD O
or CC O
both DT O
variants NNS O
shows VBZ O
superior JJ O
disease NN O
control NN O
compared VBN O
with IN O
COPP/ABVD NNP B-INTV
, , O
with IN O
acceptable JJ O
acute JJ O
toxicity NN O
. . O

Further JJ O
follow-up NN O
is VBZ O
required VBN O
to TO O
assess VB O
the DT O
effect NN O
of IN O
dosage NN O
and CC O
the DT O
effect NN O
on IN O
survival NN O
and CC O
late JJ O
toxicities NNS O
. . O

-DOCSTART- -X- O O

Study NNP O
of IN O
cytosine NN B-INTV
arabinoside NN I-INTV
( ( I-INTV
NSC-63878 NNP I-INTV
) ) I-INTV
synchronization NN I-INTV
plus CC I-INTV
vincristine NN I-INTV
( ( I-INTV
NSC-67574 NNP I-INTV
) ) I-INTV
, , I-INTV
prednisone NN I-INTV
( ( I-INTV
NSC-10023 NNP I-INTV
) ) I-INTV
, , I-INTV
and CC I-INTV
L-asparaginase NNP I-INTV
( ( I-INTV
NSC-109229 NNP I-INTV
) ) I-INTV
for IN O
remission NN O
induction NN O
in IN O
advanced JJ B-POPU
acute NN I-POPU
leukemia NN I-POPU
in IN I-POPU
children NNS I-POPU
. . O

Cytosine NNP B-INTV
arabinoside NN I-INTV
( ( I-INTV
CA NNP I-INTV
) ) I-INTV
was VBD O
utilized VBN O
in IN O
efforts NNS O
to TO O
synchronize VB O
leukemic JJ O
cells NNS O
in IN O
DNA NNP O
synthesis NN O
for IN O
treatment NN O
with IN O
vincristine NN B-INTV
, , I-INTV
prednisone NN I-INTV
, , I-INTV
and CC I-INTV
L-asparaginase NNP I-INTV
in IN O
children NNS B-POPU
with IN I-POPU
acute JJ I-POPU
leukemia NN I-POPU
in IN I-POPU
relapse NN I-POPU
. . O

The DT O
results NNS O
did VBD O
not RB O
indicate VB O
any DT O
therapeutic JJ B-OC
advantage NN I-OC
for IN O
patients NNS O
treated VBN O
with IN O
this DT O
combination NN O
compared VBN O
to TO O
those DT O
treated VBN O
without IN O
any DT O
attempt NN O
at IN O
CA NNP B-INTV
synchronization NN I-INTV
. . O

-DOCSTART- -X- O O

The DT O
prophylactic JJ B-OC
effect NN I-OC
of IN O
itraconazole JJ B-INTV
capsules NNS O
and CC O
fluconazole JJ B-INTV
capsules NNS O
for IN O
systemic JJ O
fungal JJ O
infections NNS O
in IN O
patients NNS B-POPU
with IN I-POPU
acute JJ I-POPU
myeloid NN I-POPU
leukemia NN I-POPU
and CC I-POPU
myelodysplastic JJ I-POPU
syndromes NNS I-POPU
: : I-POPU
a DT O
Japanese JJ B-POPU
multicenter NN O
randomized VBN O
, , O
controlled VBN O
study NN O
. . O

We PRP O
performed VBD O
a DT O
randomized VBN O
, , O
controlled VBN O
study NN O
comparing VBG O
the DT O
prophylactic JJ B-OC
effects NNS I-OC
of IN O
capsule NN O
forms NNS O
of IN O
fluconazole NN B-INTV
( ( O
n JJ O
= NNP O
110 CD O
) ) O
and CC O
itraconazole JJ B-INTV
( ( O
n JJ O
= NNP O
108 CD O
) ) O
in IN O
patients NNS B-POPU
with IN I-POPU
acute JJ I-POPU
myeloid NN I-POPU
leukemia NN I-POPU
( ( I-POPU
AML NNP I-POPU
) ) I-POPU
or CC I-POPU
myelodysplastic JJ I-POPU
syndromes NNS I-POPU
( ( I-POPU
MDS NNP I-POPU
) ) I-POPU
during IN I-POPU
and CC I-POPU
after IN I-POPU
chemotherapy NN I-POPU
. . O

There EX O
were VBD O
4 CD O
cases NNS O
with IN O
possible JJ O
systemic JJ O
fungal JJ O
infection NN O
in IN O
the DT O
itraconazole NN B-INTV
group NN O
, , O
and CC O
there EX O
were VBD O
8 CD O
possible JJ O
and CC O
3 CD O
probable JJ O
cases NNS O
in IN O
the DT O
fluconazole JJ B-INTV
group NN O
. . O

Adverse JJ B-OC
events NNS I-OC
did VBD O
not RB O
significantly RB O
differ VB O
in IN O
the DT O
2 CD O
groups NNS O
. . O

In IN O
patients NNS O
with IN O
MDS NNP O
or CC O
in IN O
the DT O
remission-induction JJ O
phase NN O
of IN O
chemotherapy NN O
, , O
the DT O
numbers NNS O
of IN O
cases NNS B-OC
with IN I-OC
probable JJ I-OC
or CC I-OC
possible JJ I-OC
infections NNS I-OC
were VBD O
lower JJR O
in IN O
the DT O
itraconazole NN B-INTV
group NN O
than IN O
in IN O
the DT O
fluconazole NN B-INTV
group NN O
, , O
whereas IN O
no DT O
difference NN O
was VBD O
seen VBN O
in IN O
patients NNS O
with IN O
AML NNP O
or CC O
in IN O
the DT O
consolidation NN O
phase NN O
of IN O
therapy NN O
. . O

In IN O
patients NNS O
with IN O
neutrophil JJ O
counts NNS O
of IN O
> $ O
0.1 CD O
x $ O
10 CD O
( ( O
9 CD O
) ) O
/L NN O
lasting VBG O
for IN O
more JJR O
than IN O
4 CD O
weeks NNS O
, , O
the DT O
frequency NN B-OC
of IN I-OC
infection NN I-OC
in IN O
the DT O
fluconazole JJ B-INTV
group NN O
( ( O
5 CD O
of IN O
9 CD O
patients NNS O
) ) O
was VBD O
significantly RB O
higher JJR O
than IN O
in IN O
the DT O
itraconazole JJ B-INTV
group NN O
( ( O
0 CD O
of IN O
7 CD O
patients NNS O
; : O
P NNP O
= NNP O
.03 NNP O
) ) O
. . O

Our PRP$ O
results NNS O
suggest VBP O
that IN O
both DT O
drugs NNS O
were VBD O
well RB O
tolerated VBN O
in IN O
patients NNS B-POPU
with IN I-POPU
AML NNP I-POPU
or CC I-POPU
MDS NNP I-POPU
who WP I-POPU
received VBD I-POPU
chemotherapy NN I-POPU
and CC O
that IN O
the DT O
efficacy NN B-OC
of IN O
itraconazole NN B-INTV
for IN O
prophylaxis NN O
against IN O
systemic JJ O
fungal JJ O
disease NN O
is VBZ O
not RB O
inferior JJ O
to TO O
that DT O
of IN O
fluconazole NN B-INTV
. . O

-DOCSTART- -X- O O

Amonafide NN B-INTV
: : I-INTV
An DT O
active JJ O
agent NN O
in IN O
the DT O
treatment NN O
of IN O
previously RB B-POPU
untreated VBN I-POPU
advanced JJ I-POPU
breast NN I-POPU
cancer NN I-POPU
-- : I-POPU
a DT I-POPU
cancer NN O
and CC O
leukemia NN O
group NN O
B NNP O
study NN O
( ( O
CALGB NNP O
8642 CD O
) ) O
. . O

Amonafide NNP B-INTV
is VBZ O
a DT O
new JJ O
imide JJ O
derivative NN O
of IN O
naphthalic JJ O
acid NN O
. . O

The DT O
drug NN O
had VBD O
demonstrated VBN O
significant JJ O
activity NN O
in IN O
preclinical JJ O
studies NNS O
and CC O
some DT O
activity NN O
in IN O
Phase NNP O
I PRP O
trials NNS O
. . O

The DT O
drug NN O
is VBZ O
extensively RB O
metabolized VBN O
and CC O
detected VBN O
in IN O
plasma NN O
and CC O
urine NN O
. . O

Its PRP$ O
toxicity NN O
has VBZ O
previously RB O
been VBN O
correlated VBN O
to TO O
the DT O
formation NN O
of IN O
an DT O
active JJ O
metabolite NN O
, , O
N-acetyl-amonafide NNP O
. . O

Amonafide NNP B-INTV
was VBD O
chosen VBN O
for IN O
inclusion NN O
in IN O
the DT O
Cancer NNP O
and CC O
Leukemia NNP O
Group NNP O
B NNP O
( ( O
CALGB NNP O
) ) O
master NN O
metastatic JJ O
breast NN O
cancer NN O
protocol NN O
. . O

CALGB NNP O
8642 CD O
randomizes VBZ O
previously RB B-POPU
untreated VBN I-POPU
metastatic JJ I-POPU
breast NN I-POPU
cancer NN I-POPU
patients NNS I-POPU
either CC O
to TO O
one CD O
of IN O
several JJ O
Phase NNP O
II NNP O
agents NNS O
given VBN O
for IN O
up IN O
to TO O
four CD O
cycles NNS O
and CC O
then RB O
followed VBN O
by IN O
standard JJ O
cyclophosphamide-doxorubicin-5-fluorouracil NN B-INTV
, , O
or CC O
to TO O
immediate VB O
treatment NN O
with IN O
standard JJ O
cyclophosphamide-doxorubicin-5-fluorouracil NN B-INTV
. . O

The DT O
end NN O
point NN O
of IN O
CALGB NNP O
8642 CD O
is VBZ O
to TO O
assess VB B-OC
the DT I-OC
difference NN I-OC
in IN I-OC
survival NN I-OC
, , I-OC
toxicity NN I-OC
, , I-OC
and CC I-OC
overall JJ I-OC
response NN I-OC
when WRB O
limited JJ O
exposure NN O
to TO O
Phase NNP O
II NNP O
agents NNS O
precedes VBZ O
standard JJ O
chemotherapy NN O
. . O

This DT O
report NN O
deals VBZ O
only RB O
with IN O
amonafide RB B-INTV
as IN O
a DT O
Phase NNP O
II NNP O
agent NN O
. . O

Comparisons NNS O
with IN O
the DT O
cyclophosphamide-doxorubicin-5-fluorouracil JJ B-INTV
arm NN O
will MD O
not RB O
be VB O
addressed VBN O
. . O

Patients NNS B-POPU
had VBD I-POPU
to TO I-POPU
have VB I-POPU
histologically RB I-POPU
documented VBN I-POPU
measurable JJ I-POPU
breast NN I-POPU
cancer NN I-POPU
and CC I-POPU
a DT I-POPU
performance NN I-POPU
status NN I-POPU
of IN I-POPU
0-1 NNP I-POPU
. . O

Patients NNS B-POPU
could MD I-POPU
not RB I-POPU
have VB I-POPU
had VBN I-POPU
prior JJ I-POPU
chemotherapy NN I-POPU
for IN I-POPU
metastatic JJ I-POPU
disease NN I-POPU
. . O

Prior NNP B-POPU
adjuvant JJ I-POPU
chemotherapy NN I-POPU
was VBD I-POPU
permitted VBN I-POPU
. . O

Patients NNS B-POPU
could MD I-POPU
not RB I-POPU
have VB I-POPU
visceral JJ I-POPU
crisis NN I-POPU
. . O

Amonafide NNP B-INTV
was VBD O
given VBN O
at IN O
300 CD O
mg/m2/day JJ O
i.v NN O
. . O

for IN O
5 CD O
days NNS O
, , O
and CC O
repeated VBD O
at IN O
21-day JJ O
intervals NNS O
for IN O
a DT O
maximum NN O
of IN O
four CD O
cycles NNS O
. . O

Escalation NN O
and CC O
reduction NN O
in IN O
dose NN O
was VBD O
mandated VBN O
dependent NN O
on IN O
hematotoxicity NN O
or CC O
lack NN O
thereof NN O
. . O

Toxicity NN B-OC
was VBD O
primarily RB O
hematological JJ B-OC
and CC O
bimodal NN O
: : O
32 CD O
% NN O
had VBD O
grade VBN O
3 CD O
or CC O
4 CD O
leukopenia NN B-OC
and CC O
24 CD O
% NN O
had VBD O
grade VBN O
3 CD O
or CC O
4 CD O
thrombocytopenia NN B-OC
; : I-OC
22 CD O
% NN O
had VBD O
no DT O
leukopenia NN B-OC
and CC O
44 CD O
% NN O
had VBD O
no DT O
thrombocytopenia NN B-OC
. . O

The DT O
response NN B-OC
rate NN I-OC
was VBD O
18 CD O
% NN O
, , O
including VBG O
one CD O
complete JJ O
response NN O
. . O

When WRB O
response NN O
was VBD O
analyzed VBN O
by IN O
hematological JJ B-OC
toxicity NN I-OC
, , O
there EX O
was VBD O
a DT O
35.7 CD O
% NN O
response NN O
if IN O
patients NNS O
had VBD O
leukopenia VBN B-OC
grade NN O
3/4 CD O
( ( O
versus IN O
8.3 CD O
% NN O
, , O
P NNP O
= NNP O
0.08 CD O
) ) O
. . O

There EX O
was VBD O
a DT O
50 CD O
% NN O
response NN O
if IN O
patients NNS O
had VBD O
thrombocytopenia VBN B-OC
grade NN O
3/4 CD O
( ( O
versus IN O
7.1 CD O
% NN O
, , O
P NNP O
= NNP O
< NNP O
0.01 CD O
) ) O
. . O

We PRP O
conclude VBP O
that DT O
amonafide NN B-INTV
is VBZ O
somewhat RB O
active JJ O
in IN O
previously RB O
untreated VBN O
breast NN O
cancer NN O
patients NNS O
. . O

There EX O
may MD O
be VB O
a DT O
steep JJ O
dose-response NN O
curve NN O
, , O
based VBN O
on IN O
the DT O
significant JJ O
correlation NN O
between IN O
myelosuppression NN O
and CC O
response NN O
. . O

Rates NNS B-OC
of IN I-OC
responses NNS I-OC
in IN O
patients NNS O
adequately RB O
dosed VBN O
( ( O
i.e. FW O
, , O
with IN O
significant JJ O
hematotoxicity NN B-OC
) ) I-OC
with IN O
amonafide NN B-INTV
ranged VBD O
from IN O
35 CD O
to TO O
50 CD O
% NN O
. . O

Further JJ O
studies NNS O
will MD O
incorporate VB O
individualized JJ O
dosing NN O
based VBN O
on IN O
pretreatment NN O
acetylator NN O
phenotyping NN O
. . O

